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ABSTRACT
With the advent of patient-centered care, individuals with Afib are asked to participate in the
shared decision-making (SDM) process. Choosing therapies in thromboembolic risk reduction is
complex, involves trade-offs along with considering risks and benefits of therapeutics. Afib
affects between 2.7 million and 6.1 million American adults (January et al., 2014), and with the
growing elderly population that number is expected to double by 2030 (Colilla et al., 2013). In
2016 Medicare required a SDM process for individuals considering left atrial appendage for
stroke prevention. There have been no studies reported examining individual characteristics and
participating in SDM in individuals with Afib. The purpose of this study was to explore and
investigate relationships between individual characteristics such as demographics, clinical
features, decisional self-efficacy (DSE) decisional conflict (DC), and control preference (CP) on
perceived participation in SDM in individuals with Afib. This study examined relationships
between constructs of decisional needs (e.g., individual characteristics) as described by the
Ottawa Decisional Support Framework (O'Connor, 2006) and SDM. The sample was drawn from
an online Afib support group (StopAfib.org). The survey tools included demographics,
Decisional Self-Efficacy (DSE) Scale, SURE test, CPS Scale, FRAIL scale, SDM Q9, and
Satisfaction with Decision Instrument. IRB approval was through Molloy College. Greater
participation in SDM were reported in participants: 75 years or older (p = .023), men (p = .002),
individuals reporting permanent Afib (p = .049), CHA2DS2-VASc score of =/>3 (p = .043),
individuals receiving an educational packet or DA (p < .01), greater DSES (p < .01), and
individuals with less DC (p < .01). Greater DSES (p < .01) and receiving a decisional aid (p
= .029) were the most predictive variables for participating in SDM (p < .01). This study
provided insight into clinical characteristics as potential facilitators and barriers in SDM in
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individuals with Afib. The results of this study have broad implications for providing
individualized care through the development of comprehensive needs assessment to facilitate
SDM.
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CHAPTER ONE: INTRODUCTION
Background
Public policy and medical ethics increasingly emphasize the importance of moving from
a practitioner-centered to a patient-centered model of health care (Barry & Edgman-Levitan,
2012). The health care system in the United States has strong paternalistic influences in health
care decision making (Wittman-Price, 2006). Paternalism assumes the clinician is the expert in
the decision. This has been an accepted pattern of medical decision making, which may mitigate
the decision based on respect for patients as unique living beings and within the context of their
own social world (Epstein & Street, 2011). Decision-making processes have been studied in
isolation to understand each in detail. The price paid for that depth is a limited understanding of
how individual decision-making skills (i.e., characteristics) are related to other decision-making
skills. These may include socioeconomic status, age, and cognitive abilities (de Bruin et al.,
2007). Additionally, evidence suggests that when patients have made well-informed decisions,
they adhere better to treatment regimens and make more conservative decisions, often deferring
or declining costly interventions (Elwyn et al., 2010). This result may have a positive economic
impact on population health and future generations regarding the sustainability of health care.
Patients’ reports of their experiences with care are increasingly important health care
performance measures; therefore, it is possible that individuals more involved in their decisions,
or whose roles match their preferred role in health care decisions, may have better care
experiences (Kehl et al., 2015).
The focus of the 21st-century health care system is to be patient centered, which occurs
when medical decisions are made with respect to individual patient preferences, are responsive to
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needs, and are guided by patient values (Stacey et al., 2010). Shared decision making (SDM) is
consistent with the goals of ethical clinical practice through its emphasis on evidence-based
medicine, patient-centered care, and informed consent. SDM is described as most relevant for
preference-sensitive decisions, in which there is no “best” treatment option from an evidence
standpoint and patient preferences are central to the choice (Politi et al., 2013).
The concept of clinical “equipoise” exists when a clinician lacks good basis for a choice
between two or more care options or when one is truly uncertain about the overall benefit or
harm offered by the treatment. The assumption that there is not one “better” intervention over
another may place individuals in a state of “uncertainty” (Cook & Sheets, 2011). The expectation
of incorporating SDM is to reduce utilization and cost, as this has been demonstrated when
patients are engaged and empowered to make health care decisions based on their own values
and preferences (Dartmouth-Hitchcock Medical Center, 2012). One of the most notable
diagnoses where the concept of medical SDM has focused in recent years is in the atrial
fibrillation (Afib) population, where the professional societies have incorporated the term of
“Shared Decision Making” into the clinical guideline recommendations (Centers for Medicare &
Medicaid Services, 2016). The focus of SDM in Afib has focused on the use of decisional aids
(DAs), whether presented before, during, or after the clinical encounter. However, there is more
to SDM than presenting patients with decision aids. Individuals bring to the clinical encounter
their individualized “life world,” which reflect how decisions may affect their individualized
“wellness” state as defined by the patient. Therefore, clinicians and researchers have an
obligation to focus on the individual patient. The individual patient presents to a clinical
encounter as “experts” in how Afib and treatment options affect them individually. Therefore,
there should be a deeper exploration of the extent to which individuals participate in SDM, given
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various characteristics such as demographics, decisional self-efficacy, decisional conflict,
decisional control preference, and frailty status.
As predicted by Dr. Eugene Braunwald in 1997, Afib has become the most common
sustained arrhythmia in clinical practice and a major public health concern (Alonso & Bengtson,
2013). Research has demonstrated an increase in morbidity and mortality associated with Afib,
as it contributes to hospitalizations, strokes, and thromboembolic events (Chugh et al., 2014);
hemodynamic abnormalities (January et al., 2014); cognitive impairment (Serpytis et al., 2018);
dementia (Bunch et al., 2010); impaired quality of life; and increased medical costs (Andrade et
al., 2014).
Afib confers approximately a five-fold increased risk of stroke than the general
population (Lip & Lane, 2012), of which at least 90% are caused by thrombi in an anatomical
structure of the left atrium known as the left atrial appendage (O'Neill et al., 2017). The annual
risk for stroke in patients with Afib varies based on the presence of multiple risk factors, most
importantly age; where the risk increases from 1.5% for patients who are 50-59 years of age to
23% for those who are aged 80-89 (Sanders et al., 2018). Both individual burden and public
burden may compromise the health care system in an aging population, so individual
characteristics pertaining to health care decision making require investigation.
In 2010, the Global Burden of Diseases, Injuries, and Risk Factors Study estimated 33.5
million patients with Afib worldwide, which constituted approximately 0.5% of the total world
population (Chugh et al., 2014). In the United States, the diagnosis of Afib is estimated at 0.4%
to 1% of the general population (Sanders et al., 2018), which accounts for an estimated 2.7
million to 6.1 million individuals. Among individuals with European descent, the lifetime risk of
developing Afib after age 40 is 26% for men and 23% for women (January et al., 2014). With the
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population aging, this number is projected to increase to 12.1 million by 2030 and 15.9 million
Americans by the year 2050 (Andrade et al., 2014; Miyasaka et al., 2006). This upward trend of
incidences may be related to the increased ability to identify Afib through surveillance measures
and the effects of improved survival of individuals with coronary artery disease and heart failure
(Alonso & Bengtson, 2013).
Afib imposes an enormous economic burden related to clinical presentation,
complications, loss of productivity (Khaykin & Shamiss, 2012), and hospitalizations (Nisar et
al., 2018). Hospitalizations for Afib has seen an increase of 23% from 2000 to 2010, primarily
among patients older than 65 years (Nisar et al., 2018). In 2010, the cost to manage one patient
with Afib was estimated at $7,015. Two other studies estimated the entire annual system cost
between $20,00 to $40,000 entire annual system cost for all care in individuals with Afib
(Khaykin & Shamiss, 2012). In the United States (based on Afib samples from 2001 and costs
estimated for the year 2005), the economic cost attributed to Afib-related stroke was over $2
billion, and total annual estimated medical expenditure related to Afib was $6.65 billion (Coyne
et al., 2006; Khaykin & Shamiss, 2012). Overall comprehensive costs (including direct and
indirect costs for inpatient, and outpatient/pharmacy) reflects $26 billion (January et al., 2014).
The cost to care for an Afib sequel may be economically unsustainable in an already costcontained health care environment.
Afib is a heart rhythm disorder, which results in uncoordinated atrial activation and,
consequently, ineffective atrial contractions. Afib is classified according to etiology and duration.
In 2014, American Heart Association’s “American College of Cardiology and Heart Rhythm
Society Guidelines” reaffirmed the historical definition of valvular Afib: “the absence of
rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair”
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(January et al., 2014). In a recent update, valvular Afib was defined as: “in the setting of
moderate-to-severe mitral stenosis or in the presence of an artificial mechanical heart valve and
to further classify non-valvular Afib (NVAF) as the absence of moderate-to-severe mitral
stenosis or mechanical heart valve” (January et al., 2019, p. 10). The purpose of the “valvular”
versus “non-valvular” classification is to determine the risk of a thromboembolic event (January
et al., 2014). Whereas the stroke rate of patients with Afib is approximately 5 times the stroke
risk of people without Afib (January et al., 2014), the relative risk is about 15 times in patients
who have Afib and mitral stenosis; therefore, individuals with valvular atrial fibrillation require a
specific pharmacologic strategy (Fauchier et al., 2015). The duration of Afib is classified into
four categories: paroxysmal, persistent, long-standing persistent, and permanent (January et al.,
2014). Management strategies for patients with Afib include rate control, rhythm control, and
prevention of thromboembolic events. This dissertation will focus on individual characteristics
and participation in shared medical decision making with health care provider regarding
thromboembolic stroke prevention. This dissertation will not address Afib rate or rhythm control
in the context of SDM.
Patients differ in their risk for ischemic stroke and risk of major bleeding, making
generic information inadequate (Centers for Medicare & Medicaid Services, 2016).
Thromboembolic risk stratification is paramount in the Afib population and defined as achieving
maximum treatment benefit with the lowest risk of complications for each patient based on their
individual risk for each outcome (Sanders et al., 2018). Commonly used screening tools used to
assist clinicians in assessing an individual’s risk of thromboembolic stroke and risk for bleeding
associated with NVAF have been developed and validated. Common instruments include the
CHADS2 and CHA2DS2-VASc (Figure 1.1) scoring system to assess the risk of
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thromboembolism in the non-valvular afib (NVAF) population and the HAS-BLED Bleeding
Risk Assessment Instrument (Figure 1.1) to ascertain the risk for bleeding (Lane & Lip, 2012 ).
Figure 1.1
Assessment of Stroke (CHA2DS2-VASc) and Bleeding Risk (HAS-BLED) in Atrial Fibrillation
patients. Source. Adapted from Lane & Lip, 2012.

In 2013, a review conducted by the Agency for Healthcare Research and Quality
demonstrated that the CHADS2 and CHA2DS2-VASc scoring system had the best predictive
ability for stroke and the HAS-BLED scoring system had the best predictive ability of bleeding
risk in patients with Afib (Sanders et al., 2018). Both tools are noted in the document from
Centers for Medicare & Medicaid Services (2016), National Coverage Determination, addressing
individualized risk stratification in mandating a SDM methodology with the use of decisional
aids (DAs) for patients considering left atrial appendage closure in stroke prevention treatment in
a NVAF population. The CHA2DS2-VASc tool is categorized as a Class I (level of evidence
“B”) recommendation to be performed in NVAF patients by professional cardiology
organizations. (January et al., 2019).
When using either CHADS2 or CHA2DS2-VASc and HAS-BLED risk assessment tools
in combination with a SDM methodology, patients and caregivers are expected to be informed of
both risks involved with alternative therapies to make an informed medical decision based on
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their personal risk scores. However, incorporating an individual’s personal values and
preferences for treatment allows for individualization consistent with patient-centered care.
Therefore, individualizing their risk for stroke allows individuals to weigh the benefits and risks
from a personally meaningful perspective. A 50-year-old individual may have different meanings
of health and long term goals of care along with effects of quality of life than an 89-year-old with
Afib undergoing therapeutic stroke prevention management. Therefore, although decisions based
on scoring systems provide informative statistics on risks for thromboembolic stroke, they do not
consider the life experiences, social domains, impact on the quality of life, current health status,
and the health goals of individuals.
When faced with decisions in health care, patients are often given a substantial amount of
information that is new, relatively complex, and potentially threatening (Witt et al., 2012). Stroke
prophylaxis with antithrombotic therapy is recognized as having complex considerations.
Patients differ widely in their risks, making generic information about therapies far less useful
than individualized recommendations based on patient-specific risks, individual patient values,
and preferences for health outcomes (Centers for Medicare & Medicaid Services, 2016; Eckman
et al., 2015). Given the availability of multiple comparable options, the decision for stroke
prevention in Afib depends on patient preferences and efforts to promote SDM (O'Neill et al.,
2017). The rationale for involving patients in health care decision making arises from the ethical
imperative of patient autonomy. Law, government policy, and the governing bodies of the
medical profession are moving from paternalism in the direction of informed choice (Towle et
al., 2006). The concept of paternalism has roots in the Hippocratic idea of physician (and today
the nurse or other staff) as the caretaker of the patient’s interest. Accordingly, medical decisions
may fail to involve the patient in the process and may also go against an individual’s wants or
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ignore the perspective of the patient. Paternalism does not see or treat the patient autonomously
(Sandman & Munthe, 2010), which may conflict with the concept of an individual’s preferences
or values.
The President’s Commission of 1982 believed that the effectiveness of health care in
terms of improving patients’ well-being and satisfying their needs would be enhanced by the
support of behavioral research demonstrating promise of increasing professional-patient
communications and SDM (United States et al., 1982). SDM involves an exchange of
information between two vested parties: clinicians discuss the risks and benefits of treatment
options, and patients share their individual values, expectations, and preferences regarding the
presented options. The clinician is the expert on “options” available and the patient is the expert
regarding their individual “health values” (Coylewright & Holmes, 2017). Rejecting the “onesize-fits-all” approach, SDM becomes a tool to translate evidence into practice that is patient
centered (Seaburg et al., 2014). Studies have shown that patients who are “active” participants
who have the skills, ability, and willingness to manage their own health and health care have
better health outcomes at lower costs compared to less active patients (James, 2013). There is a
shared agreement that making patients better informed and more directly responsible for their
health and care management is pivotal to making health care organizations more sustainable at
economic, organizational, and psychological levels (Graffigna et al., 2015).
Many countries have recognized SDM as an ethical imperative because the process
respects patient autonomy and promotes patient engagement (Elwyn et al., 2010). In the pinnacle
report on the Quality of Health care in America, the Institute of Medicine (2001) recognized the
need to incorporate patient-centered care with the aim to focus on the patients’ experience of
illness and health care and on the systems that work or fail to meet the individual patient needs.
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The report describes the importance of encompassing qualities of compassion, empathy, and
responsiveness to the needs, values, and expressed preferences of the individual patient, of which
may change over time (Institute of Medicine, 2001). In 2001, with ongoing pressures to control
health care spending, the Agency for Healthcare Research and Quality announced the use of
cost-effective analysis to compare the costs and the values of different health care interventions
in creating better health. One such initiative was customized patient-centered care to meet
patients’ needs. The intent of this initiative was to support the redesign and evaluation of new
care processes that lead to greater patient empowerment, improved patient provider interaction,
easier navigation through health care systems, and improved access, quality, and outcomes. This
initiative encourages researchers to examine how innovative approaches to care, chronic illness
management, shared clinician-patient decision making, and patient-clinician communication can
improve patient outcomes at reasonable costs (Institute of Medicine, 2001).
In 2007, Washington State became the first state to enact legislation establishing
increased legal protection to physicians who participate in SDM with the use of DAs. To qualify
for this alternative to traditional informed consent, clinicians are required to use a certified DA to
facilitate discussions about treatment options and patients are required to sign an attestation that
they have reviewed the decision aid with the clinician, discussed the alternatives, risks, and
benefits, and decided on a specific course of action (Spatz et al., 2017; Washington State
Legislature, 2007). Clinicians in Washington State who practice SDM are presumed to have
engaged patients in an informed consent process regarding the elective procedure and are
provided with increased protection against potential litigation based on the failure to inform
(Spatz et al., 2017). In Massachusetts, the certification of Accountable Care Organizations and
medical homes must incorporate patient engagement and SDM into health policies (James,
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2013). In 2010, the U.S. Patient Protection and Affordable Care Act encouraged greater use of
SDM in health care where there is not one clearly superior course of treatment (Frosch et al.,
2011; Oshima Lee & Emanuel, 2013) and introduced payment reform, shifting the focus from
incentive fee for service medicine to tying payment to the improvement in population health
outcomes (Frosch & Carman, 2016). The Affordable Care Act aimed to facilitate SDM, primarily
by funding an independent entity that would develop consensus-based standards and certify
patient decision aids for use by federal health programs (Oshima Lee & Emanuel, 2013). The
Affordable Care Act also called for the creation of an SDM Resource Centers where providers
were to be trained in how to use SDM interventions and best practices on implementation would
be shared and disseminated. However, although the new law authorized SDM programs,
Congress subsequently did not appropriate money to fund this provision (Frosch et al., 2011).
In 2016 the Centers for Medicare and Medicaid have mandated that SDM methodologies
be incorporated in the NVAF population undergoing left atrial appendage closure. Additionally,
professional organizations such as the American Heart Association and the American College of
Cardiology and Heart Rhythm Society recognize SDM as a Class 1 (Level of Evidence C)
recommendation, as through expert consensus where the benefits outweigh the risks. SDM in
Afib indicates that anticoagulation therapy should be individualized on the basis of the absolute
risks and relative risks of stroke and bleeding, as well as the patient’s values and preferences
(January et al., 2019). For those high-risk individuals who choose left atrial appendage occlusion
procedures, the use of a DA is mandated for the reimbursement of medical services (Centers for
Medicare & Medicaid Services, 2016).
Policy makers perceive SDM as desirable because of its potential to reduce the overuse of
options that are clearly not associated with benefits for all, enhance the use of options clearly
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associated with benefits for the vast majority, reduce unwarranted health care practice variations,
foster the sustainability of the health care system, and promote the right of patients to be
involved in decisions concerning their health (Légaré et al., 2008; Légaré, Ratté et al., 2010). A
growing body of evidence demonstrates that patients who receive specific, unbiased information
about their treatment options end up receiving lower-intensity services than patients who do not
receive this type of information (Stacey et al., 2011). Outcomes in the use of SDM processes
have demonstrated that patients who receive enhanced decision-making support for valuesensitive conditions (including heart conditions, benign uterine conditions, benign prostatic
hyperplasia, hip pain, knee pain, and back pain) ultimately have overall medical costs that are
5.3% lower than those receiving only the usual support, 12.5% fewer hospital admissions, and
20.9% fewer preference-sensitive heart surgeries (James, 2013; Veroff et al., 2013).
Recently, there has been interest in funding SDM opportunities through governmental
agencies and academic centers. In 2012, sixteen high value health care collaborative centers, one
of which is Dartmouth-Hitchcock Medical Center, received part of a $26 million grant from the
Center for Medicare and Medicaid Innovation to fund a program to engage patients and
implement SDM for patients facing hip, knee, or spine surgery and for patients with chronic
conditions (e.g., diabetes or congestive heart failure). The implementation of SDM incorporation
is expected to result in a $64 million savings over three years, largely due to reduced utilization
and cost that has been shown when patients are engaged and empowered to make health care
decisions based on their own values and preferences. Dartmouth used these funds to train patient
and family “activators” to engage in SDM, with patients and families focusing on preferences
and supplying sensitive care choices (Dartmouth-Hitchcock Medical Center, 2012). Afib has
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been a focus diagnosis for SDM implementation, as it is a high-volume diagnosis with high
economic impact on health care organizations.
Recently, the American Heart Association and the Patient Centers Outcome Research
Institute formed the “Choices to Inform Dialogue and Empower A-Fib Patients” (DECIDE)
Center to test and deliver SDM tools for clinicians and patients. DECIDE should be used by
clinician and patient to assist in determining which treatment options might work best to provide
the desired outcomes for each individual patient. As part of a $5 million grant, the University of
Utah received $2.75 million to test the effectiveness of SDM tool under the DECIDE Program
(Patient-Centered Outcomes Research Institute, 2018). The Mayo Clinic, along with the National
Heart, Lung, and Blood Institute, has undertaken a randomized trial named “Shared Decision
Making for Stroke Prevention in Atrial Fibrillation” (SDM4Afib) to determine the extent to
which the Anticoagulation Choice decision tool promotes SDM. This decisional tool evaluates
knowledge transfer, knowledge of risks, collaborative agreement, patient decision satisfaction,
quality of communication, and patient satisfaction and its impact on anticoagulation use and
adherence versus standard care in patients with NVAF (U.S. National Library of Medicine,
2018). Much of the research focus is on the development of DAs, with the intent to reduce
“decisional conflict,” which is described as a patient’s uncertainty about the course of action to
take when the choices involve risk, loss, regret, or a challenge to personal life values (Légaré et
al., 2010).
Decision aids may facilitate a departure from traditional paternalistic models of medicine,
by encouraging open discussions in which clinicians and patients explore benefits and tradeoffs
together while weighing preferred treatment options with best available evidence (O'Neill et al.,
2017). Numerous DAs have been developed for the NVAF population with the primary intent to
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decrease decisional conflict. DAs can assist in matching treatment choice with patients’ values,
goals, and preferences, and limit unwanted treatment (Blumenthal-Barby et al., 2015). Patients
with “value-sensitive” health decisions frequently experience conflict surrounding medical
decisions (e.g., decisional conflict) and require support. Decisional support involves assessing
factors influencing a patient’s decisional conflict, providing support to address decisional needs,
monitoring progress in decision making, and screening for factors influencing implementation
(Stacey et al., 2008). Although DAs may facilitate discussion around treatment options, these
should be used as an adjunct in the SDM process.
Providing patients with the evidence-based outcomes knowledge about treatment options
is necessary for patients’ involvement in decision making, but this information alone is not
enough (Joseph-Williams et al., 2016). Studies demonstrate that individuals with Afib may
develop cognitive impairment (Kalantarian, 2016; Kilander et al., 1998; Lavy et al., 1980;
O'Connell et al., 1998; Sabatini et al., 2000; Yang et al., 2017), have a two-fold increased risk of
dementia (January et al., 2014), and inadequate health literacy (Aronis et al., 2017; Reading et
al., 2017) that may question the applicability and acceptability of lengthy DAs in the Afib
population.
In making a medical decision, it is important to consider a complex interaction of a
person’s cognitive styles, personality traits, and cognitive and social competencies within a
specific disease-related and environmental context. These factors contribute to shaping
individual health belief models and coping styles. Individual control beliefs and beliefs regarding
self-efficacy are considered highly relevant for a given behavior (Heesen et al., 2013). High
uncertainty and often-risky decisions are frequently made under extraordinary physical and
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emotional stress and time constraints, placing a high cognitive demand on an individual (Pierce
& Hicks, 2001).
Past research has indicated gaps in clinician skill sets such as inadequate assessment of
patient preferences (O'Neill et al., 2017) and taxonomy of key decisional needs such as
knowledge, values clarification, and social support in situations where options need to be
deliberated to benefit or hamper decisional support interventions (Pluye et al., 2017). Patients
with complex care needs often suffer from a combination of multiple chronic conditions, drug
interactions, and social vulnerability, which can lead to the overuse, underuse, or misuse of
health care services (Pluye et al., 2017). Individuals with Afib may be considered as having
complex care needs based on symptomatology, quality of life, medication regimens, frequent
office visits, and hospitalizations. Typically, patients with complex care needs face interactional
issues related to personal uncertainty or disagreements (e.g., decisional conflict) regarding
possible options and unmet decisional needs (e.g., knowledge acquisition, clarification of values
and preferences, support, and resources). Decisional needs include the assessment of decisional
conflict, lack of knowledge and information exchange, values, expectations and preference
clarification, support, and resources. Unmet decisional needs affect the decision quality, which in
turn may affect behavior, lead to negative emotions and impact health care use (i.e., overuse,
underuse, and misuse). Gaps in decisional needs may hamper decisional support interventions as
these unmet needs may affect decisional quality (Pluye et al., 2017). Understanding how various
health-related contexts influence decision behavior is limited by the lack of clinical studies
designed to capture these dynamic processes. Because decision making is a cognitive skill that
changes with experience and over time (Pierce & Hicks, 2001), an investigation into the
individual characteristics and how they affect decision making of individuals with Afib are
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needed to capture this complex process. The decision-making process may include culture,
gender, socioeconomics, ethnicity, physical and emotional stress, cognitive demand, uncertainty,
time constraints (Pierce & Hicks, 2001), illness perception, along with behavioral and cognitive
responses to illness (Borg Xuereb et al., 016). This dissertation explored decisional needs
assessment, including demographic characteristics, decisional self-efficacy of the individual,
decisional conflict assessment, preferred roles in health care decision making, and frailty status
as an impact on participation in SDM.
Contemporary medicine advocates for patient participation in medical decision making
because paternalistic patterns of decision making influence the biomedical sphere. However,
patient engagement in SDM may be compromised by factors that can affect motivation,
willingness, and ability to engage in SDM(James, 2013), prior experiences, knowledge, health
literacy, attitudes and beliefs regarding the role of participation, health status, functional capacity,
and self-efficacy (Carman et al., 2013). As previously mentioned, the ethical imperative is to
respect patient autonomy in decision making. However, existing studies do not provide evidence
that the Afib population do in fact participate in SDM. Investigation into the influence of how
individual characteristics influence perceived participation in SDM is essential to understand a
patient’s preferences, individual abilities, including the role an individual’s wants in decision
making (Elwyn et al., 2017). Therefore, the imperative is for health care providers to assess the
needs of individual patients and understand the role each patient wishes to play in his or her care
(Levinson et al., 2005).
The concept of “patient centered care” is the focus of this dissertation as it pertains to
individualized characteristics and the impact on participating in SDM. Constructs of SDM
pertaining to individual characteristics and decisional needs assessment discussed in this
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dissertation include decisional self-efficacy, decisional conflict, decision control preferences, and
frailty status of an individual on the impact on participating in SDM. Additionally, participants at
all stages of decision making (e.g., time since decision) will be assessed for presence of
decisional conflict over time.
Afib is considered to be a “preference-sensitive” diagnosis, where an individual’s
preferences may influence a decision. With the advent of newer therapies (e.g., direct-oral
anticoagulation medications [DOAC] and left atrial appendage occlusion procedures), research
into SDM in the Afib population has been limited to communication dyads and the development
of DAs (which have not been rigorously tested) at reducing decisional conflict. There is a
growing body of evidence suggesting that engaging patients in health care can lead to better
health outcomes, contribute to improvements in quality and patient safety, and help control
health care costs (Carman et al., 2013). To be consistent with patient-centered care, when
considering a SDM methodology, one must first consider assessment of an individual’s
characteristics which may influence participation in SDM.
Gaps in the Literature
Although there are studies to support the use of SDM methodology to improve patient
outcomes (Légaré et al., 2012), there remain gaps in the literature that warrant further
investigation pertaining to individual characteristics and the extent of participating in SDM.
Important work has already been done in the areas of SDM, but recommendations and important
outcomes measurements remain to be explored with the implementation of SDM in Afib,
including patient knowledge about their options, patient participation in deliberations, decisional
quality, patient satisfaction with the experience, clinical outcomes, and adherence to therapy
(Seaburg et al., 2014). Previous research has indicated gaps in clinician skill sets such as
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inadequate assessment of patient preferences. Therefore, individual characteristics that may
influence a patient’s decision warrant further investigation. To this author’s knowledge, since the
advent of newer therapies such as direct-oral-anticoagulants and left atrial appendage occlusion
procedures, individual decisional needs assessment has not been explored or described as its
relationship to participation in SDM in the Afib population seeking thromboembolic stroke
prevention (TESP). This study provides a guide to a comprehensive needs’ assessment in a
sample of individuals with Afib. The study will explore relationships among demographic
characteristic, decisional self-efficacy, decisional conflict, role preference, and frailty status on
perceptions of participation in SDM in individuals who are currently considering or have decided
regarding thromboembolic stroke prevention within the last three months.
Problem Statement
The decisional processes are complex cognitive, perceptual, and affective activities that
are multidimensional and often inaccessible to direct observation (Pierce & Hicks, 2001). Afib
has been associated with cognitive decline and decreased quality of life (StopAfib.com, 2018).
Furthermore, Afib is independently associated with poorer performance on cognitive function,
which suggests that Afib has effects on memory and new learning (O'Connell et al., 1998).
Previous research suggests that many individuals diagnosed with Afib lack awareness about their
diagnosis and inadequate health literacy may be an important contributing factor (Reading et al.,
2017). Much of the ongoing research in SDM revolves around the development of DAs, none of
which has been rigorously tested in the Afib population and may not be “literate appropriate” in
this population.
Key elements of decision making include knowledge, self-efficacy (Bailey et al., 2016),
and participation in decision making (in which age and poor health influence participation;
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Levinson et al., 2005). In the United States, clinicians are mandated to implement an SDM
model with the use of DAs in the NVAF population, considering left atrial appendage closure as
a treatment strategy for stroke prevention, along with Class 1C recommendations (1 = Strong
Class of Recommendation, C = Level of Evidence by Consensus) to participate in an SDM
methodology by professional organizations. Strategies have focused on the use of DAs; yet, there
has been little effort to understanding individuals’ characteristics and policies have not focused
on preparing patients for SDM (Joseph-Williams, Elwyn, & Edwards, 2014). Additionally,
provisions for patient-centered care should include how patients want to be involved in their care
(Zizzo et al., 2017).
This exploratory and descriptive correlation study explores relationships between
individual characteristics in a sample of individuals with Afib currently or recently (within the
previous three months) considering stroke prevention options and participation in SDM from the
individual’s perception. This study explores individual characteristics, including demographics,
decisional self-efficacy, decisional conflict, role preferences, and the influence of frailty on
perceptions of participating in SDM for thromboembolic stroke prevention.
Purpose
The purpose of the exploratory section is to provide normative data on this sample of
Afib participants, and the descriptive study explores relationships among characteristics such as
demographics, decisional self-efficacy, decisional conflict, role preference style, and frailty on an
individual’s perception of participation in SDM in a sample of individuals with Afib. With a
focus on patient-centered care, the purpose of this project is to give insight into individual
characteristics as it pertains to SDM decisional needs in a sample of individuals with Afib.
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Definition of Terms
For the purpose of this study, several key terms warrant a conceptual understanding of
their meanings.
Control Preferences in Medical DecisionsThe degree of control an individual wants to assume when decisions being about medical
treatment (Degner et al., 1997). According to Degner, Sloan, and Venkatesh (1997),
patients are hypothesized to have differing preferences about keeping control over
treatment decision making, sharing control with their physician or relinquishing control
to their physician.
Decisional Aid An educational tool that helps patients, caregivers, or authorized representatives
understand and communicate their beliefs and preferences related to their treatment
options, and to decide with their health care provider what treatments are best for them
based on their treatment options, scientific evidence, circumstances, beliefs, and
preferences (United States Government Public Law 111-148 111th Congress, 2010).
Decisional ConflictDecisions can lead to decisional conflict: “a state of uncertainty about which course of
action to take when choices among competing actions involve risk, loss, regret, or
challenge to personal life values” (Légaré et al., 2006, p. 374).
Decisional ProcessInteraction of patient and contextual factors that are set in motion by the unique features
of the decision problem (Pierce & Hicks, 2001).
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Decisional Self- EfficacySelf-confidence or beliefs in one’s abilities in decision making, including SDM
(O'Connor, 2002).
EquipoiseEquipoise exists when a clinician has no good basis for a choice between two or more
care options or when one is truly uncertain about the overall benefit or harm offered by
the treatment to his or her patient (Cook & Sheets, 2011). This term is used to describe
situations where the patient’s important outcomes of the treatment options under
discussions are known but where a choice between them depends on personal values and
preferences and there is substantial uncertainty about one or more relevant outcomes
(Agoritsas & Lehman, 2016).
FrailtyFrailty is an increased vulnerability to minor stressors because of age-related decline.
With frailty, this decline is accelerated, and homoeostatic mechanisms start to fail.
Apoptosis, senescence, cellular repair, inflammation, and immune activation have been
implicated as pathways responsible for this decline (Rowe et al., 2014).
Left Atrial AppendageThe left atrial appendage is a small, ear-shaped sac in the muscle wall of the left atrium. It
is unclear what function, if any, the left atrial appendage performs (Cleveland Clinic,
2018).
Non-Valvular Atrial FibrillationPresence of Afib with the absence of moderate to severe mitral stenosis or mechanical
heart valve (January et al., 2019).
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PaternalismThe usurpation of one person’s choice of their own good by another person (Archard,
1990). An intentional overriding of one person’s known preferences or actions by another
person (Rodriguez-Osorio & Dominguez-Cherit, 2008).
Patient EmpowermentPatient empowerment has been described as including dimensions such as personal
control, self-efficacy, and decision-making capacity relating to health and health care
(McAllister, 2016).
Preference Sensitive CareMedical care where clinical evidence does not clearly support one treatment option, such
that the appropriate course of treatment depends on the values of the patient or the
preferences of the patient, caregivers, or authorized representatives regarding benefits,
harms, and scientific evidence for each treatment option. The use of such care should
depend on the informed patient choice among clinically appropriate treatment options
(United States Government Public Law 111-148 111th Congress, 2010).
Recall BiasSystematic error, which may occur when participants recall past events, which can
compromise the generalizability of findings (El-Masri, 2013).
Self-EfficacySelf-efficacy is the belief in one’s capabilities to organize and execute the courses of
action required to produce given attainments. Personal influences may include
motivation, thought processes, affective states, and actions. An individual’s belief may
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influence the courses of actions people choose and how much effort they put forth in
given endeavors (Bandura,1997).
Shared Decision MakingAn approach where clinicians and patients share the best available evidence when faced
with the task of making decisions, and where patients are supported to consider options
that achieve informed preferences (Elwyn et al., 2012; Elwyn et al., 2010). SDM is a
process undertaken between a clinician and a patient with a preference-sensitive
condition that has more than one clinically appropriate intervention or management
strategy (Holmes-Rovner et al., 1996) to help the patient decide among multiple
acceptable health care choices in accordance with his or her preferences and values. A
basic tenet of SDM is that clinicians are the experts in the evidence and the patients are
the experts in what matters most to them (Spatz et al., 2017).
Research Questions
The objective of this study is to provide a normative description of the sample and to
describe relationships between individual characteristics and participation in SDM in a sample of
individuals with Afib currently contemplating or decided on a treatment strategy for stroke
prevention within the last three months. Constructs to be measured are decisional self-efficacy,
decisional conflict, control (role) preferences and frailty, involvement in SDM, and satisfaction
with the decision if it has been made within the last three months.
1. What are the characteristics of the participants in this study (Atrial Fibrillation: Decision
Making in Stroke Prevention; Afib: DMSP)?
2. What is the incidence of participation in shared decision making in a sample of
individuals with Afib?
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3. What is the relationship between sociodemographic characteristics (e.g., age, gender,
educational attainment, partnership status) and decisional self-efficacy, decisional
conflict, control preferences, and shared decision making in an Afib sample?
4. What is the relationship between the type of Afib and decisional self-efficacy, decisional
conflict, control preference, and participation in shared decision making in an Afib
sample?
5. What is the relationship between CHA2DS2-VASc score and participation in shared
decision making in an Afib sample?
6. What is the relationship between receiving an educational packet and/or decisional aid
from a healthcare provider and participation in shared decision making and decisional
conflict in an Afib sample?
7. What is the relationship between time since decision and decisional conflict in an Afib
sample?
8. What is the relationship between decisional self-efficacy and participation in shared
decision making in an Afib sample?
9. What is the relationship between decisional conflict and participation in shared decision
making in an Afib sample?
10. What is the relationship in control preferences style and participation in shared decision
making in an Afib sample?
11. What is the relationship between frailty scores and participation in shared decision
making in an Afib sample?
12. What is the relationship between participation in shared decision making and satisfaction
with decision in an Afib sample?
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13. What is the relationship between consequences of decision and satisfaction with decision
in an Afib sample?
Significance
In the specialty of cardiovascular medicine, Medicare has tied reimbursement with the
implementation of SDM methodologies using DAs in individuals at high risk of thromboembolic
stroke considering left atrial appendage closure. Although SDM is part of an ethical imperative,
individual attributes and characteristics must be considered within the SDM framework and
tailored on individual characteristics as dictated by patient-centered care. Prior research has
demonstrated that patients with Afib may have cognitive impairment, alterations in health
literacy, additional comorbidities, and advancing age, which can all influence an individual’s
acceptance of participation in SDM. Although much of the research on SDM revolves around the
use of DAs to increase knowledge, engage patients, and decrease decisional conflict, a recent
systematic review has not demonstrated these results in the Afib population (Stacey et al., 2017).
To this researcher’s knowledge, there has not been a comprehensive study investigating
individual characteristic in individuals with Afib that may influence participating in SDM.
Knowledge gained from this study may influence a growing epistemology of “decisional needs”
assessment throughout the decision-making process in the Afib population and continue to
develop the ontological science of decision making and personal influencing characteristic
attributes. Although the use of DAs may promote engagement, this checklist component of SDM
should not be used in isolation when patient-centered care is the goal. The argument for this
study is that DAs are supplements and should not be isolated as the end-all in SDM, as an
individual’s characteristics and experiences within one’s “lifeworld” and social context may
influence participation. The Centers for Medicare and Medicaid are poised to extend mandatory-
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SDM to other treatments and tests (Merchant, Dickert, & Howard, 2018), so it is imperative to
understand the individual and population characteristics to provide individualized, patientcentered care.
Conceptual Frameworks
Increased emphasis for patients to be involved in their health-care decisions has led to the
development of decision-making models to aid patients in making informed decisions about
treatment options (Carroll et al., 2013). The Ottawa Decisional Support Framework (ODSF) is
the primary theoretical framework that guides this dissertation.
ODSF is a decision framework for assisting patients with decisions that produce conflict
or decisions that are produced from a new situation such as a medical diagnosis. ODSF is a
leading framework for the study of decision making, which stresses the concept of “decisional
needs” affecting decision quality (informed, values based), which affects behavior (e.g., delay in
decision), health outcomes, emotions (e.g., regret), and the appropriate use of resources. Within
the ODSF, the “needs” assessment is meant to identify what a patient population needs to make
better decisions and what health practitioners need to improve the support they provide to
patients during the decision-making process (Blumenthal-Barby et al., 2015). The ODSF uses
concepts and theories from general psychology, social psychology, decision analysis, Janis and
Mann’s concept of decisional conflict, Fischoff, Slovi and Lictenstein’s Values framework,
Norbeck and Orem’s Social Support Theory, and Bandura’s Self-Efficacy Theory (O'Connor,
2006). Determinants of a decision are factors that influence the decisions and include patients’
and practitioners’ demographic and clinical characteristics, perceptions of the decision (e.g.,
knowledge, expectations, values and decisional conflict, stage of decision making and
predispositions), perceptions of others involved in the decision-making process (perceived
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opinions of others, pressure, support, participation roles), and personal and external resources to
make decisions (Cranney et al., 2002). The ODSF includes the cognitive, rational perspective to
include emotional, social, and environmental dimensions (Figure 1.2). According to the ODSF, a
“good decision” is one that is informed, consistent with personal values, acted on, and in which
participants express satisfaction with decision making (O'Connor et al., 1999).
This framework was chosen because it addresses concepts of interest such as participants’
decisional needs, which include decisional conflict, role in decision making, self-efficacy,
personal and clinical characteristics of the individual, knowledge and expectations, and values.
This original framework extends to include all participants involved in decision making,
including families, couples, and health practitioners (O'Connor, 2006). The ODSF postulates that
improving the quality of decision making may have a favorable impact on patients’ outcomes
(Légaré et al., 2006).
Within the ODSF, Janis and Mann’s Conflict Theory is highlighted, as the theory includes
the concept of “decisional conflict,” which is one characteristic of focus. Janis and Mann’s
Conflict Theory Model of decision making posits that when people think about vital affect-laden
issues, they experience intense thoughts and emotional distress. Decisional conflicts occur when
a person must make an important choice and can involve hesitations, vacillations, feelings of
uncertainty, and signs of acute emotional distress. According to the Conflict Theory Model, five
stages of decision making can be applied to understand the context of advanced illness: appraisal
of the challenge, survey alternatives, weighing the alternatives, deliberations, and adherence to
the decision (Janis & Mann, 1977, p. 172; Waldrop & Meeker, 2012).

43
Figure 1.2
Ottawa Decision Support Framework Source. Adapted from O'Connor, 2006

Decisional conflict develops as patients cope with weighing risks and benefits of
alternative options in the patient decision-making process. The stress associated with this conflict
can lead to increased anxiety. As a result, patient decisions may be based on maladaptive rather
than adaptive forms of coping behavior. Janis and Mann’s Model explains how individuals’
coping skills for decision making may impact post-decisional feelings and could lead to regret
over the decision made. Janis and Mann’s Conflict Theory Model of decision making is that a
certain degree of stress from preconditions (risk, hope, time) affects a person’s decision-making
style, the quality of the decision, and the level of satisfaction or regret with the outcome (Jones et
al., 2018).
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Within Conflict Theory Model, the presence or absence of three antecedent conditions
determines which decisional conflict pattern the subject chooses to follow: (1) awareness of a
serious risk if nothing is done, (2) hope of finding a better alternative, and (3) belief that there is
enough time to learn about and assess the situation and choose the best alternative. Five resulting
patterns to decision making emerge as unconflicted adherence, unconflicted change, defensive
avoidance, hypervigilance, and vigilance. According to this model, when individuals face a
decision, they may perceive uncertainty for decision outcomes and experience conflict (de
Heredia, et al., 2004). This may be extended to the Afib population who are faced with a decision
for stroke prevention choice. Inherent within the Conflict Theory of Decision making is the
assumption that decision making is a stressful process, influenced by the risk, ambiguity, and
conflict present within the choice situation. According to Janis and Mann (1977), high-quality
decision making takes place when adaptive pattern of cognitive and behavioral processes occurs
that limits post-decisional regret and increased adherence to the final choice (Balneaves & Long,
1999).
Bandura’s theory of self-efficacy is captured within the ODSF. This study highlights the
emergence of self-efficacy theory within the findings. Self-Efficacy Theory originated from
Bandura’s Social Cognitive Theory, which posits that learning occurs in a social context with a
dynamic and reciprocal interaction of the person, environment, and behavior (LaMorte, 2018).
Self-efficacy refers to the level of a person’s confidence in his or her ability to successfully
perform a behavior and is influenced by a person’s specific capabilities and other individual
factors as well as by environmental factors. Efficacy Theory stresses the nature of human agency,
which posits, “People can exercise influence over what they do.” If people believe they have no
power to produce results, they will not attempt to make things happen. Self-Efficacy Theory
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acknowledges the diversity of human capabilities in which cognitive, social, emotional, and
behavioral subskills must be organized and effectively orchestrated to serve a purpose. Social
cognitive theory subscribes to operative agency, where the effective exercise of control requires
the orchestration of knowledge, cognitive and behavioral skills, along with emotional and
motivational self-regulative skills (Bandura, 1997, p. 3-8).
Self-efficacy beliefs are constructed from four principal sources of information: enactive
mastery of experience that serve as indicators of capabilities; vicarious experiences that alter
efficacy beliefs through the transmission of competencies and comparisons with the attainments
of others; verbal persuasions and other social influences; and physiological and affective states.
Individuals judge personal capabilities through cognitive processes and reflective thoughts
(Bandura, 1997, p. 80-106). According to Bandura’s Self-Efficacy Theory, one would expect that
as one is more experienced in treatment modalities, these will become more efficient. This has
yet to be explored, as age, the presence of comorbidities, and frailty status may influence one’s
efficacy in decision making. Although this study acknowledges additional theoretical
frameworks that influence decision making (e.g., Lazarus and Folkman’s Transactional Model of
Stress, Appraisal and Coping, Edmund Husserl’s concept of “lifeworld,” and Leventhal’s Health
Belief Model and Self-Regulatory Model), they will not be the focus of this dissertation.
Summary
Afib is a common arrhythmia with individual, social, and economic impacts.
Transitioning from paternalistic patterns of medical decision making and incorporating patientcentered care by incorporating SDM into clinical practice as an ethical imperative provides
individuals with opportunities to consider alternative treatment options based on their values and
preferences and may allow for a sustainable health care environment. However, most research
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has focused on the use of DAs to mitigate paternalistic monologues and promote the decisionmaking dyad through communication between clinician and individuals. It is recommended and,
in some cases, mandated that patients and health care providers take part in SDM. However, the
implementation of this concept can be challenging, as there is currently a lack of understanding
of the influences of patient-related factors such as how a patient wants to be involved in the
decision-making process and how individual characteristics (e.g., self-efficacy, decisional
conflict, and frailty status) may influence an individual’s participation in SDM. Findings from
this study may assist in the development of the epistemology of individualized patient decisionmaking needs and behaviors in the Afib population. To this researcher’s knowledge, this is the
first study considering multiple individual characteristics that may affect the perception of
individuals with Afib and participation in shared medical decision making for thromboembolic
stroke prevention.
The use of theoretical frameworks provided a comprehension and explanatory factor
related to individual characteristics in stroke prevention decision making in an Afib sample.
Frameworks to support the individual characteristics may explain relationships such as:
decisional self-efficacy (ODSF and Bandura’s Self-Efficacy), decisional conflict (ODSF, Janis
and Mann Conflict Theory), control preference (ODSF, Bandura’s Self-Efficacy), frailty (ODSF),
and relationships on perceptions of participation in SDM for thromboembolic stroke prevention
in Afib.
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CHAPTER TWO: LITERATURE REVIEW
The focus of this section is on existing literature describing individual characteristics and
the relationship to SDM for thromboembolic stroke prevention in Afib. Decision making is one
of the basic cognitive processes of human behaviors by which preferred option or course of
actions is chosen from among a set of alternatives based on certain criteria (Wang & Ruhe,
2007). Afib is associated with significant complexity of choices and options, each associated
with several outcomes. Advances in pharmacology and technology have improved outcomes in
patients with Afib. Management of Afib consists of three distinct areas: rate control, rhythm
control, and prevention of thromboembolic events (January et al., 2014). Stroke prevention
therapies for Afib include mitigating modifiable risk factors, pharmacological interventions, and
newer surgical and non-surgical technologies focused on left atrial appendage isolation. The
focus of this research is on individuals with Afib who have recently or are currently considering
therapeutic options for stroke prevention in the management of their Afib.
Afib
Afib is the most common type of heart arrhythmia. Afib is described as an irregular
rhythm where blood does not flow as well as it should from the atria to the lower chambers of
the heart (Centers for Disease Control and Prevention, 2017). Uncoordinated atrial activation and
consequently ineffective atrial contraction may lead to hemodynamic consequences.
Electrocardiogram characteristics include an irregular R-R interval (when atrioventricular
conduction is present), an absence of distinct repeating ‘P’ waves, and irregular atrial activity
(January et al., 2014). Afib creates electrical and structural remodeling in the atria by shortening,
mismatching, and lengthening the effective refractory period, depressing the intra-atrial
conduction and depriving its contractile function (Karamichalakis et al., 2015).
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Afib can be described in terms of duration of episode. Paroxysmal Afib terminates
spontaneously or without interventions within seven days of onset and may recur with variable
frequency. Persistent Afib is continuous and sustained for greater than seven days. Longstanding
Afib is continuous with a greater than 12 months. Permanent Afib is a “therapeutic attitude” used
when there has been a joint decision by the patient and clinician to cease further attempts to
restore and or maintain normal sinus rhythm (January et al., 2019). In paroxysmal Afib, repeated
episodes lead to substrate abnormality through structural and electrophysiological remodeling,
which can reduce threshold for Afib triggers. This mechanism has the potential to sustain Afib
explaining how paroxysmal episodes progress into permanent sustained episodes (Zathar et al.,
2019). Afib is also categorized as non-valvular or valvular. Non-valvular Afib is the absence of
moderate-to-severe mitral stenosis or the absence of a mechanical heart valve (January et al.,
2019). Valvular Afib designates a higher risk of thromboembolic stroke, so recommendations
include the use of a specific anti-thrombotic strategy such as warfarin (Fauchier et al., 2015).
This study includes individuals with valvular and non-valvular Afib. Current 2019 Guidelines on
Afib include a Class IC recommendation that therapies should be individualized on the basis of
SDM, considering absolute and relative risks of stroke and bleeding, as well as the patient’s
values and preferences (January et al., 2019).
Factors that increase incidences of Afib include increased age, male sex, hypertension,
diabetes mellitus, metabolic syndrome (Borg Xuereb et al., 2016), European ancestry, body size,
presence of cardiovascular disease, sub-clinical hyperthyroidism, heavy alcohol consumption
(Mozaffarian et al., 2015), chronic kidney disease, enlargement of the chambers on the left side
of the heart (Centers for Disease Control and Prevention, 2017), and sleep apnea (Morin et al.,
2016). Whites have shown an increased risk compared to Blacks, Asians, or Hispanics (Dewland
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et al., 2013). One study demonstrated a 10-year predictive relation between measures of anger
and hostility to the development of Afib in men (Eaker et al., 2004). Genetic susceptibility to
Afib has been documented, where offspring of parents with Afib had a significantly increased
risk (2-3 times greater risk), even after controlling for comorbidities. Additionally, common
genetic variants are known, which encode cardiac ion channels and signaling molecules and
transcription factors that are associated with increased development of Afib (Anumonwo &
Kalifa, 2014). Although 15% to 30% of individuals with Afib are asymptomatic (Rienstra et al.,
2012), physical signs and symptoms may include irregular heartbeat, lightheadedness,
palpitations, shortness of breath, fatigue, chest pain (Centers for Disease Control and Prevention,
2017), hypotension, syncope, heart failure (January et al., 2014), reduction in exercise tolerance
(Rienstra et al., 2012), and cognitive impairment independent of cerebral infarcts (Kalantarian et
al., 2013).
Psychological and Physical Impact of Afib
Anxiety and reduced quality of life have been reported in individuals with Afib (Serpytis
et al., 2018). A recent Harris Poll of more than 400 people with Afib aged 45 and older identified
individuals living with Afib had both a physical and emotional impact. According to the survey,
56% reported that they are constantly worried that if they have a stroke, they will be a burden on
their families, and 71% said that reducing their risk of stroke is the most important
(StopAfib.com, 2018). Individuals with Afib have been shown to have feelings of anxiety,
emotional concerns, reduced capacity in everyday activities, and reduced capacity in leisure
activities. For individuals whose onset of Afib was difficult to predict, they expressed a constant
feeling of “readiness” for it to appear (Ekblad, et al., 2013).
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Patients with Afib typically have other cardiovascular comorbidities and have an elevated
risk of cardiovascular and cerebrovascular events and mortality (Benjamin et al., 2018).
Although in-patient hospital mortality has decreased from 1.2% in 2000 to 0.9% in 2010 (relative
decrease, 29.2%; p < .001), mortality rates remains highest in individuals >/=80 years, females,
non-Whites, and those with comorbidities such as heart failure and chronic renal failure (Patel et
al., 2014). Emergency room visits and hospital admissions for Afib increased from 2007 and
2014, with a relatively stable high rate of 69% to 70%. Greater admission rates have been noted
in individuals >/= 75 years, female sex, individuals with Medicare and Medicaid coverage, and
low-income status. Independent comorbidity predictors of hospital admissions include
congestive heart failure, diabetes mellitus, hypertension, valvular heart disease, chronic kidney
disease, chronic pulmonary disease and a high CHA2DS2-VASc score (Rozen et al., 2018). Afib
is associated with a three-fold increased risk of heart failure, two-fold increased risk of dementia
and mortality, and a five-fold increased risk of stroke (Dooley, et al., 2017). The most common
causes of death within the first four months after the diagnosis of Afib was 22% coronary artery
disease, 14% heart failure, and 10% ischemic stroke. Later deaths were reported at 15% coronary
artery disease, 16% heart failure, and 7% ischemic stroke (Mozaffarian et al., 2015).
Stroke in Afib
Although therapies for Afib include both rate and rhythm control, the purpose of this
study is to focus on thrombo-embolic stroke prevention and health care decision making. Afib is
an independent risk factor for ischemic stroke and is estimated to cause a five-fold increase in
ischemic stroke risk owing to the formation of atrial thrombi (Lakshminarayan et al., 2006),
usually in the anatomical location of the left atrial appendage (January et al., 2014). Ischemic
stroke is defined as a focal neurologic deficit of sudden onset as diagnosed by a neurologist,
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lasting greater than 24 hours and caused by ischemia (Lip, 2010). Afib causes 15% to 20% of
ischemic strokes, which occur when the blood flow to the brain is blocked by a clot or by fatty
deposits called plaque in the blood vessel lining (Centers for Disease Control and Prevention,
2017), and it is estimated that 25% of all strokes among the elderly are consequences of Afib.
The risk of stroke increases from 1.5% for patients with Afib who 50-59 years of age to 23% for
those aged 80-89 (Sanders et al., 2018). Thrombogenic tendency in Afib is related to several
underlying pathophysiological mechanism such as abnormal changes in the flow and stasis of
blood in the left atrium, atrial dilatation, endocardial denudation, edematous or fibrotic infiltrates
in the extracellular matrix, abnormal changes in blood constituents including hemostatic and
platelet activation, inflammation, and growth factor changes. These factors lead to the propensity
for thrombus formation in Afib and reflect components of Virchow’s triad for thrombogenesis
(Watson et al., 2009).
Strokes associated with Afib are associated with considerable long-term morbidity,
fatality, stroke recurrence, and nursing home requirements (Hayden et al., 2015). Afib-related
strokes are more severe than other types of strokes. Individuals with Afib who have a stroke are
twice as likely to become bedridden than those with a stroke of other etiology, and individuals
with Afib are more likely to die from stroke than non-Afib individuals who had a stroke (Sanders
et al., 2018). A lower blood pressure in the acute stage of stroke may contribute to the increased
stroke severity in patients with Afib (Jorgensen et al., 1996), along with the potential for a large
clot burden (Hoskins et al., 2018). Although paroxysmal Afib is associated with a somewhat
lesser risk of stroke and systematic embolism than non-paroxysmal Afib, all types of Afib are
associated with a sufficiently increased risk of stroke (Morillo et al., 2017). Results from the
ENGAGE AF-TIMI 48 trial (n = 21,105) demonstrated lower stroke/systemic embolic events
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with paroxysmal Afib (1.49%/year) compared to persistent (1.83%/year) and permanent Afib
(1.95%/year). Mortality rates were lower in paroxysmal Afib (3.0%/year) than in persistent
(4.4%/year) and permanent Afib (4.4%/year) ( Link et al., 2017).
Independent risk factors for stroke include prior TIA/stroke or thromboembolism;
advancing age; hypertension; diabetes; congestive heart failure; female gender; and history of
vascular disease such as prior myocardial infarction, peripheral artery disease, and complex
aortic plaque (Lip, 2010). A sub-analysis from the Fushimi AF Registry (n = 2,713) identified
that left atrial enlargement (defined as a diameter greater than 45mm) is an independent predictor
of stroke and systemic thromboembolism in non-valvular Afib patients whether or not they were
on oral anticoagulation (Hamatani et al., 2016).
Personalization of the risks and benefits of treatment options in Afib are important to
facilitate individual decision making in therapeutic management and the mitigation of thromboembolic stroke. Current professional society guidelines recommend the use of the CHA2DS2VASc score in the assessment of stroke risk (January et al., 2019). The CHA2DS2-VASc risk
score is calculated based on the following clinical characteristics: Congestive heart failure/left
ventricular ejection fraction </= 40% [1 point], Hypertension [1 point], Age >/=75 [2 points],
Diabetes mellitus [1 point], prior Stroke/transient ischemic attack/thromboembolism [2 points],
Vascular disease [1 point], Age 65-74 [1point], and Female Sex [1 point]. Scores range from ‘0’
to ‘9’, with increased scores corresponding to an increased risk for stroke. The CHA2DS2-VASc
risk assessment can be used as a continuous scale or by grouping different risk scores into
categories (Sanders et al., 2018).
Guideline recommendations for pharmacological management include individuals with
non-valvular Afib, and a CHA2DS2-VASc score of ‘0’ in men and ‘1’ in women designate an
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option to omit anticoagulant therapy (January et al., 2019). Whereas, in individuals with an
elevated CHA2DS2-VASc score of two or greater in men or three or greater in women, oral
anticoagulants are recommended and include warfarin, Dabigatran, Rivaroxaban, Apixaban, and
Edoxaban. For individuals with mechanical heart valves, warfarin is recommended. The
selection of anticoagulant therapy should be based on the risk of thromboembolism, irrespective
of the type of Afib (e.g., paroxysmal, persistent, or permanent). Alternatives to pharmacological
management for stroke prevention include percutaneous left atrial appendage occlusion (LAA)
for individuals who have contraindication to long-term anticoagulation therapy or surgical
occlusion of the LAA in individuals with Afib undergoing cardiac surgery (January et al., 2019).
Stroke Prevention in Afib Treatments
NVAF is associated with complexity of therapeutic choices. Stroke prevention therapies
for NVAF include mitigating modifiable risk factors, pharmacological interventions, and newer
surgical and non-surgical technologies focused on left atrial appendage isolation. The focus of
this research is on individuals with Afib who have recently or are currently considering
therapeutic options for stroke prevention in the management of their Afib.
Afib is a growing epidemic, and with advances in stroke prevention therapies, choices for
treatment in stroke prevention have expanded (e.g., more health care providers might be referring
patients for alternative options, such as left atrial appendage occlusion procedures). In the case of
stroke prevention depending on the stroke risk defined by the CHA2DS2-VASc score, NVAF
patients have a choice between long-term anticoagulant therapy, and if applicable for left atrial
appendage occlusion (LAAO). In individuals who consider LAAO, research has demonstrated
LAAO is non-inferior to warfarin therapy regarding stroke, cardiovascular death and systemic
embolism (Centers for & Medicaid, 2016, p. 32).
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Pharmacological Treatment in Stroke Prevention in Afib
Anticoagulation therapy is proven and effective for thromboembolic stroke prevention.
Oral anticoagulation is highly effective at preventing strokes in patients with Afib and therefore
consensus guidelines recommend oral anticoagulation therapy for patient with Afib and elevated
stroke risk (Lubitz et al., 2018). Afib treatment requires chronic therapies, daily medication
adherence, accurate symptom reporting, along with close monitoring and follow-up to prevent
complications (Montbleau et al., 2017). Warfarin has been the mainstay of therapy, but in recent
years, newer direct oral anticoagulants have become available. Four direct oral anticoagulants are
available in the United States to prevent stroke in patients with Afib. These agents demand less
frequent monitoring and fewer diet restrictions than warfarin (Zeballos-Palacios et al., 2019).
The benefits of anticoagulants in reducing the risk of stroke and mortality have been
estimated at 68% and 33%, respectively (Bahri et al., 2015). In a meta-analysis comparing
adjusted dose warfarin with placebo or no treatment, there was a 67% relative risk reduction in
ischemic stroke (CI, 54% to 77%) (Hart et al., 2007; Hoskins et al., 2018). A meta-analysis of
71,683 participants in the RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials
comparing warfarin to direct oral anti-coagulation (DOAC), demonstrated DOACs significantly
reduced stroke or systemic embolic event by 19% (p < 0.0001), mainly driven by a reduction in
hemorrhagic stroke (p < .0001). DOACs also decreased all-cause mortality (p = .0003) and
intracranial hemorrhage (p < .0001), but DOACs increased gastrointestinal bleeding ( p =.04)
( Karamichalakis et al., 2015; Ruff et al., 2014).
When prescribing oral anticoagulation therapy for an Afib patient, one must consider the
“net clinical benefit” of such treatment. Although warfarin (vitamin K antagonist) is effective in
stroke prevention, side effects include bleeding complications and require routine monitoring.
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The literature supports physicians fearing elderly Afib patients may neglect blood monitoring
and are at risk of injuries due to falls, which place Afib patients at further risk for bleeding
(Karamichalakis et al., 2015). DOACs overcome some of the limitations of warfarin because
they include factor II inhibitors (e.g., dabigatran) and factor Xa inhibitors (e.g., apixaban,
Endoxaban, and rivaroxaban). Benefits of the DOACs include no routine monitoring, more
predictable pharmacokinetic profile, and fewer interactions with drugs. One major limitation of
DOACs is the cost (López-López et al., 2017).
The net clinical benefit of oral anticoagulation appears to be greatest in patients with the
highest risk for bleeding. More than half of people with the highest risk of stroke are not
prescribed important anti-blood clotting medications. One theory is that physicians rely on their
guts rather than objective risk scores (Dooley et al., 2017). Physicians may consider geriatric
syndromes such as falls, head injuries, errors in medication, chronic anemia, and cognitive
disorders to be potential contraindications to administering anticoagulation (Bahri et al., 2015).
Additional consequences of oral anticoagulation (OAC) may be interactions with other drugs,
under-prescription, low compliance with guidelines, and poor patient adherence to treatment.
Advantages and disadvantages as perceived by the patient play an important role in the decisionmaking process when determining antithrombotic treatment (Siouta et al., 2012). One
consequential factor may be an individual who is prescribed warfarin but does not have the
resources to have weekly blood checks due to the lack of transportation to facilities.
Despite the evidence in favor of OAC for stroke prevention, there is reported underuse of
OAC, particularly among individuals at highest risk, where the physician’s overestimation of the
patient’s bleeding risk is a key barrier to OAC prescription, particularly among elderly patients
(Lane & Lip, 2012). Henrard and colleagues (2017) identified OAC underuse in 35% of geriatric
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patients with Afib. However, with the advent of DOACs, there is a trend toward increase of oral
anticoagulants use, where pre-implementation of DOAC demonstrated a 37.3% rate of underuse
and a 29.7% post-DOAC implementation. Another study found that recurrent falls, cognitive
impairment, and advanced age were the major reported contraindications for prescribing
anticoagulation (Bahri et al., 2015). Approximately 30% to 50% of individuals prescribed an
anticoagulant stop treatment within one year. As individuals may have trouble implementing
OAC regimen due to factors such as the impact on daily routine, associated dietary or lifestyle
restrictions, or direct out-of-pocket costs (Noseworthy et al., 2018).
Despite the evidence and recommendation from professional organizations, the
underutilization of anticoagulation use has been demonstrated by 51% of patients with a
guideline-based indication for anticoagulation are receiving therapy (Seaburg et al., 2014). The
decision to prescribe warfarin for stroke prevention in Afib is based on multiple prescriber and
patient characteristics. A recent meta-analysis evaluated the association between prescriber
and/or patient characteristics and subsequent prescription of warfarin for stroke prevention in
patients with Afib. This observational study used multivariate analysis to determine the
relationship between characteristics and the odds of receiving warfarin for stroke prevention. Out
of 28 studies, 33 unique multivariate analysis were identified. Warfarin use across studies ranged
from 9.1% to 79.8% (median = 49.1%). Characteristics associated with a statistically significant
increase in the odds of warfarin use included history of a cerebrovascular accident (OR = 1.59),
heart failure (OR = 1.36), or male gender (OR = 1.12). Those associated with a significant
reduction in the odds of warfarin use included alcohol/drug abuse (OR = 0.62), perceived
barriers to compliance (OR = 0.87), contraindication(s) to warfarin (OR = 0.81), dementia (OR =
0.32), falls (OR = 0.60), gastrointestinal hemorrhage (OR = 0.47), intracranial hemorrhage (OR
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= 0.39), hepatic impairment (OR = 0.59), renal impairment (OR = 0.69) and age per 10-year
increase (OR = 0.78) was associated with significant reductions in warfarin use (Baczek et al.,
2012).
Data from the American College of Cardiology’s Practice Innovation and Clinical
Excellence Registry (PINNACLE) evaluated 429,417 outpatients with Afib to assess prescription
practices of oral anticoagulation medications in this population. Results demonstrated that less
than half of high-risk patients received an oral anticoagulation prescription. In this population of
Afib, oral anti-coagulation was prescribed in 44.9%, aspirin only 25.9%, aspirin plus a
thienopyridine 5.5%, or no antithrombotic therapy 23.8%. Patients with Afib who had CHADS2
score of 3 and a score of 5 were most often prescribed anticoagulation at 50.6% and 49.7%,
respectively. Oral anticoagulant prescription did not exceed 50%, even in higher-risk patients
(Hsu et al., 2016).
Recently, a systematic qualitative review (n=9) examined patient and physicians’
perceptions and attitudes about oral anticoagulation therapy. This study revealed three major
themes: need for information to reinforce anticoagulation use, balance of benefits and downsides,
and roles in decision making and therapy management. Additional patient interests were
knowledge and understanding, impact on daily life, and satisfaction with therapy. Physicians
perceived uncertainty, need of individualized decision making, and the feeling of delegated
responsibility as their major concerns related to the underuse of oral anticoagulation, while for
patients, the major factors were the lack of information and understanding (Mas Dalmau et al.,
2017).
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Mechanical Alternatives for Stroke Prevention
Both individuals with Afib and health care providers continue to seek alternatives to oral
anticoagulation for various reasons such as intolerable side effects of OAC and adherence to a
medication regimen. The left atrial appendage has been thought to serve as the major nidus for
Afib-related cardiac thrombo-emboli (Blackshear & Odell, 1996; Jazayeri et al., 2016). Thus, a
non-pharmacological alternative has recently been developed and include surgical ligation and
clipping (which may be performed concurrently with cardiac operations) and percutaneous
techniques (Jazayeri et al., 2016). The recommendation for percutaneous approaches to LAAO
may be considered in patients with Afib at increased risk of stroke who have contraindications to
long-term anticoagulation (January et al., 2019).
Observational studies comparing different LAAO devices have suggested no significant
differences in risk of stroke, thromboembolism, or mortality among the different devices. Left
atrial appendage occlusion trends toward a benefit over warfarin for all strokes, including
ischemic or hemorrhagic and all-cause mortality. However, the risk of the invasive nature of the
procedure is associated with a higher rate of adverse effects such as pericardial effusion and
device embolization (Sanders et al., 2018). However, improvement in implantation techniques
has led to a reduction of peri-procedural complications. The EWOLUTION registry (examining
Watchman Left Atrial Appendage Occlusion devices) demonstrate high success rates with low
peri-procedural risks, reporting a serious adverse event rate of 2.8% at 7 days post procedure and
3.6% within 30 days of procedure. The most common serious adverse event was major bleeding
that required transfusion (Boersma et al., 2016).
Although health care providers may be apprehensive about prescribing OAC for various
reasons, there is evidence to demonstrate that patients view a minor stroke as marginally worse
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than major bleeding, but a moderate or major stroke are viewed by patients as equal to or worse
than death. Patients are often willing to accept a higher risk of bleeding in order to prevent a
stroke (Lane & Lip, 2014). Therefore, their preference for treatment should be incorporated to
examine a comprehensive net benefit of options for stroke prevention treatment. Current
professional society guidelines require a formal SDM interaction with an independent noninterventional physician using an evidence-based decision tool on oral anticoagulation in NVAF
prior to percutaneous left atrial appendage closure (Hoskins et al., 2018).
One must consider all domains in SDM such as decisional characteristics (e.g., role
preference), decision-making process (deliberation/pre-decisional process and the decision
itself), and the decision outcomes (Scholl et al., 2011). The focus of this research is on individual
characteristics such as demographics, decisional self-efficacy, decisional conflict, control
preference, and frailty status on SDM for stroke prevention.
Decision-Making Theories and Health Care Decisions
Cerebrovascular accident or stroke is a devastating consequence of Afib. Individuals with
Afib are asked to make decisions for therapeutic management to mitigate their chance of a
thrombo-embolic stroke. Choices for management are not without potential risks, including
bleeding, thrombo-embolic stroke, or procedural complications with mechanical occlusion. In
the face of uncertainty, health care decisions may be based on personal circumstances, values,
and preferences of the patient. In preference-sensitive medical decision making, a detailed
description of the deliberation and coping processes are not well understood. Decision making in
health care requires a patient’s input, particularly in situations of equipoise, when no precise
medical guidance is available or when decisions are preference sensitive (Witt et al., 2012).
Clinical equipoise is the assumption that there is not one “better” intervention present or when
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one has no good basis for a choice between two or more care options based on clinical data. In
the face of equipoise, decisional context can lead to uncertainty (Cook & Sheets, 2011).
Often in times of complex decision-making involving uncertainty, heuristics may
dominate the decision-making process. Heuristics are described as “shortcuts or simple rules of
thumb” (Zeijlmans et al., 2019). The goal is to make decisions more quickly, frugally, and/or
accurately than more complex methods by ignoring part of the information. These rules are
considered simple compared to more analytical rules that require comparing the attributes of all
alternatives. Social heuristics are based on social information and are most likely to be used in
settings of SDM because an individual may know more about one aspect of the decision, thus
changing or forming the judgment of another (Zeijlmans et al., 2019).
Decision theories are categorized into two paradigms: descriptive and normative. The
descriptive is based on empirical observation and on experimental studies of choice behaviors.
Normative theories assume a rational decision maker who follows well-defined preferences that
obey certain axioms of rational behavior. Normative theories include expected utility paradigms
of decision making (Wang & Ruhe, 2007). The major theory of decision making under risk is the
“expected utility” model that is based on rational choices. In this model, the utility of risk is
equal to the expected utility of its outcomes, which is obtained by weighting the utility of each
possible outcome by its probability. When faced with a choice, a rational decision maker will
prefer the prospect that offers the highest expected utility (Tversky & Kahneman, 1981).
Gaps exist in decision theories where descriptive theories assist in explaining “what we
are observed to do” and normative “what we should do” (Dillon, 1998). In utility theory, a
“rational” decision maker is one that chooses the option with the highest expected utility.
However, the Normative-Expected Utility Theory is often violated in practice and does not
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appear to be suitable for medical decision making because expectations involve a measure of
personal worth rather than expectations of a non-personal value. Utility may change when the
principle to preferences is formed in the face of uncertainty (Cohen, 1996).
According to Tversky and Kahneman (1981), a “decision problem” is theoretically
defined by the acts or options among which one must choose the possible outcomes or
consequences of these acts as well as the contingencies or conditional probabilities that relate
outcomes to acts. The decision maker may frame the decision by formulating the problem by
their own individual and societal norms, habits, and personal characteristics. Framing of a
decision refers to the decision maker’s conception of the acts, outcomes, and contingencies
associated with a choice. Decisional hazards may occur as a consequence of clinical or
individual framing, where the attractiveness of one option may prevent an individual from
accurately appraising other relevant information (Pierce & Hicks, 2001).
Embedded in the ODSF is Janis and Mann’s Conflict Theory, which describes four
descriptive styles of decision making, operationalized as “nonquality” styles: unconflicted
adherence (with low stress), unconflicted change (with low stress), defensive avoidance (with
high stress), and hypervigilance (with high stress). These four styles lead to outcomes of more
regret, less satisfaction, and a greater likelihood of changing one’s choice. Vigilance is the
normative style of decision making that is operationalized as a “quality” decisional style, based
on clarifying goals and values involved in the decision, canvassing options, searching and
evaluating information, contrasting and weighing alternatives, and making contingency plans for
implementation. Vigilance implies a stress where there is enough interest to pay attention by
seeking cues and information but not too much to be distracted or immobilized by anxiety. This
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style leads to less regret, more satisfaction, and less likelihood of reversing one’s choice (Jones et
al., 2018).
Four frequently discussed decision-making models in the literature include paternalism,
interpretive, informed, and shared. These models vary in the respective roles that doctors and
patients take in the final selection of their treatment. In the paternalistic role, doctors choose the
treatment after evaluating information about the disease of the patient, the treatment options, and
the probabilities of outcomes. In the interpretive model, the doctor decides about a treatment plan
but does so by taking the values and preferences of the patient into consideration. In the
Informed Decision-Making Model (consistent with informed consent), the patient independently
decides after the doctor discloses information about benefits, risks, and alternative treatment
options. In “shared” (as in SDM), at least two participants (i.e., the doctor and the patient) are
involved, where both parties take steps to participate in the process of treatment decision making
by sharing information and a treatment decision. However, the SDM model lies in the theory that
incorporating patients’ subjective experience of disease into clinical practice is an essential
element of good medicine (Wirtz et al., 2006).
Patient-Centered Care
In 1988, The Picker/Commonwealth Program for Patient-Centered Care coined the term
“patient-centered care” to call attention to the need for clinicians, staff, and health care systems
to shift their focus away from diseases and back to the patient and family. The focus was to better
understand the experience of illness and of addressing patients’ needs. Characteristics of care
were identified as important indicators of quality and safety: respect for patient values,
preferences and expressed needs, coordinated and integrated care, clear and high-quality
information and education for the patient and family, physical comfort and emotional support
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with alleviation of fear and anxiety, involvement of family and friends as appropriate, continuum
of care, and access to care. Adopting this concept, the Institute of Medicine defined patientcentered care as “care that is respectful of and responsive to individual patient preferences, needs
and values” and that ensures “that patient values’ guide clinical decisions” (Barry & EdgmanLevitan, 2012). Some concerns have arisen that patient-centered care focusing on individual
needs may be at odds with the evidence-based approach. According to Mishler, there is an
ongoing struggle between the voice of medicine and the voice of the life-world (Walseth &
Schei, 2011), where patient-centered care and evidence-based medicine consider both the art of
generalizations and the science of particulars (Epstein & Street, 2011).
A key element in patient-centered medicine is to acknowledge the medical importance of
clarifying the patient’s perspective, so that the clinician and the patient may construct a shared
understanding of the situation. Clinicians should develop a good relationship with the patient and
explore the patient’s biological, psychological, and social circumstances, as an individual should
not be separated from his “lifeworld” context. According to Husserl, a “lifeworld” is the frame of
a human being’s lived life, a horizon of “taken for granted” knowledge, norms, and expectations
(Walseth & Schei, 2011).
Individual participation may be practiced in health care and promotion, mental and social
care, and decision making in treatment. A concept analysis of “patient participation” identifies as
being involved in the decision-making process concerning the delivery and evaluation of the
their own care. Determining means treating patients as individuals, considering patients’
opinions, and giving them control with regards to their own care. Partnering with patients is an
essential process that underpins participation by identifying the values and beliefs on which
negotiation is based. Clinicians should consider both internal and external factors influencing
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patient participation as internal: patients’ physical abilities, willingness and ability to make
rational decisions, attitude toward self-care, level of medical knowledge, and previous
experiences. External factors include items affecting a patient’s desire to participate, such as
conflict between the patient and the provider, limited communication, and environmental
constraints limiting patients’ privacy (Sahlsten et al., 2008).
SDM
SDM is a process undertaken between a clinician and a patient with a preferencesensitive condition to help the patient decide among multiple acceptable health care choices in
accordance with his or her preferences and values. A basic tenet of SDM is that clinicians are the
experts in the evidence and the patients are the experts in what matters most to them (Spatz et al.,
2017). SDM strategies are often used with patients who have “preference-sensitive” conditions
or treatment options that-is, they may or may not choose particular treatments or to be treated at
all, depending on their own feelings about the risks versus the benefits of treatment and impact
on their quality of life (James, 2013). SDM has been shown to improve decision quality by
enhancing knowledge, patient satisfaction with the decision-making process and realistic
expectations, or by decreasing fears and decisional conflict (Kasper et al., 2012).
National efforts to transform health care quality in the 21st-century call for patientcentered approaches. In the Institute of Medicine Report (2001), six items for re-designing 21stcentury health delivery pertain to the following SDM constructs: customized care according to
patient needs and values, the patient is the source of control, knowledge is shared, and
information flows freely between the patient and clinicians, and transparency is necessary when
making informed decisions. As efforts to promote empowerment and self-efficacy in health care
grow, patients are increasingly encouraged to move from passive participants to activated,
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informed consumers of health and health care. Health care providers must pay attention to how
patients’ access, understand, and use health information provided to them to promote, protect,
and manage their health (Parker & Ratzan, 2010). SDM aims to promote patient autonomy, to
limit practice variation, and ensure that treatment decisions reflect patient preferences (Gartner et
al., 2018).
Key ethical tenets of SDM are both self-determination and relational autonomy. Selfdetermination is concerned with our intrinsic tendencies to protect and preference our wellbeing. Relational autonomy describes the view that we are not entirely free, self-governing
agents but that our decisions are related to interpersonal relationships and mutual dependencies
(Elwyn et al., 2012). Patients have their lived experience and knowledge of what gives their life
value, meaning, purpose, and quality (Patel et al., 2008). SDM allows patients to report the
“lived experience of their disorder” and the provider to bring their expertise about the science of
medical diagnosis and treatment (Alvarez et al., 2016; Patel et al., 2008).
The goal of SDM is to increase the likelihood that patients receive the care they need in a
manner consistent with the best available research evidence and their values and preferences
(Seaburg et al., 2014). Three conditions must be in place for SDM to become part of mainstream
clinical practice: ready access to evidence-based information about treatment options, guidance
on how to weigh the pros and cons of different options, and a supportive clinical culture that
facilitates patient engagement (Elwyn et al., 2010).
The Process of SDM
The quality of health care decisions is increasingly viewed as sensitive to individual
factors such as preferences. Since choices reveal little about the quality of a decision, the process
of making decisions might be a better indicator. The decision process is performed internally and
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includes negotiating information about possible benefits and risks with preferences, values, and
attitudes. The decision-making process is a stressful and iterative process that reflects the
complex and transactional relationship between a person and the environment (Balneaves &
Long, 1999), which include complex cognitive, perceptual, and affective activities that are
multidimensional and often inaccessible to direct observation (Pierce & Hicks, 2001).
SDM requires four characteristics: (1) there are at least two participants, (2) both parties
take steps to participate, (3) both parties share needed information, and (4) treatment decisions
are agreed to by both parties. The critical step of informed SDM is the quality and completeness
of the information given by professionals and the understanding of that information. Achieving
SDM in routine practice requires interventions targeted at both clinicians and patients (JosephWilliams, et al., 2014). Clinicians need to use techniques that incorporate and understand
patients’ perspectives (Feeg, 2007), and individuals with Afib need skills to support self-efficacy
in decision making; this contrasts with a historical pattern of paternalism in health care decisions.
Facilitators and Barriers of SDM
Despite considerable interest in SDM, implementation has proved difficult and slow.
Facilitators of SDM in individuals considering an internal cardioverter defibrillator for primary
prevention have been attributed to trust in physicians’ knowledge, expertise, years of training,
established patient-physician bonds, social support, and health state (Carroll et al., 2011).
Barriers to the implementation of SDM include patient-specific characteristics, clinician
attitudes, organizations’ lack of policies at an organizational level, and regulatory bodies’ lack of
implementation guidance. Although the Centers for Medicare & Medicaid Services have
provided some guidance on the activities required for SDM, other aspects of implementation
have not been delineated. Requirements by the Centers for Medicare & Medicaid Services raise
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the question of what additional steps clinicians must take beyond high-quality pre-procedural
informed consent to satisfy the SDM requirement. Coverage policies for left atrial appendage,
internal defibrillators, and lung cancer screening require that physicians use decision aids but
leave other key decisions about the timing and content of the decision-making interaction up to
physicians and hospitals (Merchant et al., 2018). Past research has indicated gaps in clinician
skill sets such as the inadequate assessment of patient preferences (O'Neill et al., 2017).
Dy and Purnell (2012) recognized structural, process–related, and external variables that
influence this SDM process. Structures include the accessibility and availability of a support
system and the availability of decisional support at an appropriate health-literacy level. Processrelated variables include characteristics of the provider-patient relationship, provider decisionmaking style, communication method, cultural training, and a patient’s prior experiences with a
health care decision. Additional variables include an individual’s illness characteristics, patient
beliefs and decision-making approach, social support, patient motivation and self-efficacy, along
with provider and patient knowledge and expectations (Dy & Purnell, 2012).
Health care provider barriers to SDM have been investigated and include clinicians’
perceptions about the patients such as assuming that individuals do not want to participate in the
decision-making process, lack of capacity or ability, speculations of an individual making a
“bad” decision, or worry that SDM is not practical given time constraints in clinical practice or
clinicians’ claims of “we already do it” (Elwyn et al., 2012). Providers may also lack the
disposition, skill, time, training, tools, and resources on how to support an SDM process
(Hoskins et al., 2018; Seaburg et al., 2014).
Patient-related barriers may include low literacy and cultural barriers, as some cultures
lack a tradition of individuals making autonomous decisions (Elwyn et al., 2012). Many patients
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undervalue their ability to understand the information and underplay their knowledge and may
defer the decision to the expert. Until patients believe that they can understand the complex
information and believe that personal expertise and medical expertise are equally important, they
are unlikely to become actively engaged. Another barrier is an individual’s adoption of the
“good” patient role that is ingrained in many older people with lower educational attainment.
This passive role has been neglected in the role of SDM, as the focus has been on supporting the
process rather than working on how to engage individuals in SDM processes (Joseph-Williams et
al., 2014). Elderly individuals may demonstrate alterations in cognition and social functioning.
These changes can result in decision-making impairments such as adherence to medication
schedules or refusal of medical treatment (National Center on Elder Abuse, 2017). There is
evidence that attitudinal barriers are hindering progress in the implementation of SDM. Even
when patients are well educated and well informed, many still find it difficult to use their
knowledge to participate meaningfully in decisions and patients may often feel prohibited from
speaking up (Joseph-Williams et al., 2014).
One study of individuals undergoing coronary arteriography demonstrated that physicians
do not tailor patient involvement according to patient preferences of involvement. Outcomes
suggested that cardiologists did not appear to adjust how much they involved the patient
according to his or her role preference along with consistently failing to elicit whether and how
patients wanted to be involved in the decision about their treatment. This study demonstrated that
patients older than 45 years have a tendency toward passive decision making, where 7% wanted
to take an active role, 33% preferred the shared role, and 60% preferred a passive role.
Demographic factors such as age, gender, social class, education level, and medical history were
not found to be statistically significance in preferred roles. However, those with more extensive
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coronary artery disease trended for a greater involvement in the decision-making process ( p
= .056) (Burton et al., 2010).
Time has been noted to be a barrier because incorporating SDM will increase
consultation time. Reimbursement for time spent on SDM during consultation has not been
incorporated under the National Coverage Determination plan of the Centers for Medicare &
Medicaid Services. A review of 10 studies for various medical conditions indicated a median
increase in the consultation time of 2.6 minutes longer (7.5%) than the usual consultation time.
Of importance was a study in Afib, where a computerized DA was used during the consultation
visit, with an increased consultation time of 23 minutes. The delivery time of DAs has been
discussed as before, during, or after consultations (Stacey et al., 2017).
Participation in SDM and Engagement
SDM is indicated if there are multiple possible treatments and the alternatives have
different and uncertain outcomes, as is the case in most chronic diseases or if the treatment
outcome is considered subjectively important (Doherr et al., 2017). According to the ODSF,
participants’ decisional needs will affect decision quality, which in turn affects actions or
behavior, health outcomes, emotions, and the appropriate use of health services. The ODSF
prescribes that health care providers tailor decision support to an individual’s decisional needs,
which include age, gender, education, marital status, ethnicity, diagnosis and duration of
condition, health status (physical, emotional, cognitive, & social), socio-economic status, and
social status within the health care relationship (Jacobsen et al., 2013).
Greater patient involvement in treatment decisions is associated with less decisional
conflict, which can be viewed as a moderator for patient satisfaction (Doherr et al., 2017). In
health care across the world, engagement with patients is considered as a key strategy to improve
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patients’ adherence, clinical outcomes, and satisfaction toward the level of received care
(Graffigna et al., 2015). SDM emphasizes the importance of facilitating the engagement of
patients in their own health care decisions (Sepucha & Scholl, 2014).
The principles of SDM are well documented, but there is lack of guidance on how to
accomplish the approach in routine clinical practice (Elwyn et al., 2012; Elwyn et al., 2010).
Departing from paternalistic models, SDM in health care has been recognized as one of the most
important components of current clinical care. The process is described as an open exchange of
information provided by clinicians on the risks and benefits of available treatment options and
patients sharing their values and preferences regarding the presented options. This process
involves reflection and discussion, leading to a plan of care that respects the patient’s health care
goals and preferences (Sanders et al., 2018).
Distinction between exhibited participation and preference is important because some
people may not have appropriate information, skills, or support to feel they can participate in a
knowledgeable way. Self-perception of inadequate skills may lead to lower participation in
decision making (Bynum et al., 2013). A three-step model has been described, including Choice,
Option, and Decision talk, which is supported on a process of deliberation and understanding that
decisions should be influenced by exploring and respecting “what matters most” to individuals.
Key to this exploration is to integrate good communication skills and the use of decision support
tools (Elwyn et al., 2012).
Communication Dyad
Key concepts in SDM include provider competence, trustworthiness, and cultural
competence; communication with patients and families; information quality; patient/surrogate
competence; and roles in involvement (Dy & Purnell, 2012). Effective and clear communication

71
of risks and treatments benefits for patients is crucial in Afib to avoid uncertainty and to promote
the process of SDM (Hedberg et al., 2018). Communicating complex clinical information is a
challenge for providers. It can also be challenging to receive details in a highly specialized
domain of health care (Feeg, 2007) and translate the information in an easy-to-understand
format. Providers need to develop a planned conversation based on communication models to
integrate all the moving parts (Feeg, 2007). Understanding how an information exchange occurs
between the provider and the patient can identify paternalistic, informed, or SDM patterns. In
both paternalistic and informed models, information flows from the physician to the patient. In
the shared model, however, information exchange is bidirectional; medical information flows
from the doctor to the patient, and value information flows from the patient to the doctor (Bynum
et al., 2013).
Towle and colleagues (2006) outlined a model that includes a set of eight competencies to
assist in decision-making communication, including partnership, information, role, ideas, choice,
evidence, decision, and plans of implementing the decision. Patient competencies include
defining the relationship and establishing partnerships, articulating health problems, feelings,
beliefs and expectations, relevant information, and feedback, so that the action plan can be
accessed, evaluated, and negotiated with the health care provider. Questions that providers and
patients may ask are the following: Is the patient encouraged to be involved? Is the patient asked
about the amount or the form of information he or she would prefer to get? Is the patient asked
about preferences for decision involvement or if others should be involved? Is the patient asked
about his or her thoughts about choices? Is it clear to the patient that there are options? Is the
patient guided to sources of information based on current evidence? Is it clear who does what
and by when? (Feeg, 2007; Towle & Godolphin, 1999).
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Risk Communication
Risk communication is defined as the open two-way exchange of information and
opinion about risks, leading to better understanding and better decisions about clinical
management. This two-way exchange about information and opinion is important if decisions
about treatment are to reflect the attitudes of the people who will live with the outcomes and
potential risk and benefits (Edwards et al., 2002). One of the challenges is the ability of
clinicians to accurately interpret statistical conclusions from clinical trials and present the data in
a way that is meaningful to patients. Translational statistics aim to bridge the divide between
complex statistical analyses and clinically actionable information, thereby facilitating SDM
conversations that are patient friendly (McCaw et al., 2018). This interpretation of risks cannot
be divorced from the importance of the harm, which includes the meaning of the harm and its
implications on lifestyle and health because the meaning of a “stroke” may have different
meaning according to an individual’s personal experience. However, care should also be taken to
avoid the overload of information (Edwards et al., 2002). Risk communication must be
presented in a balanced manner and avoidance of “framing” manipulation techniques, where
clinicians can persuade to a particular option on which the way the information is presented.
Therefore, information should be presented in a “balanced,” “unbiased” manner, which is also
“valuable” to individuals rather than a generic presentation about average population data
(Edwards et al., 2002).
Facilitating SDM
Clinicians who seek to understand individual needs and preferences can facilitate patient
involvement in the decision (Joseph-Williams et al., 2014). Providing patients with evidencebased knowledge about treatment options is necessary for patients’ involvement in decision
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making, but this information alone is not enough (Joseph-Williams et al., 2016). Positive
attitudes toward SDM do not automatically result in implementation into practice (Doherr et al.,
2017). Certain centers are on the forefront in SDM science, such as the Ottawa Decisional
Support Network, the Dartmouth Institute at Dartmouth-Hitchcock, the Mayo Clinic, and the
University of Colorado. The Ottawa Decision network provides a free online tutorial designed to
help practitioners develop skills in providing decisional support. This target audience is for
individuals wishing to develop or enhance decision support skills (Dartmouth Hitchcock, 2018)
and is available online (https://decisionaid.ohri.ca/training.html). Stacey and colleagues (2008)
recommend the use of the Ottawa Decision Support Framework to guide individuals through the
decision-making process, including: (1) assessing for decision conflict and related modifiable
deficits in knowledge, values clarity, and support; (2) tailoring decision support by facilitating
the use of DAs or by providing evidence-based information, verifying understanding, clarifying
values, building skills in deliberation, communication, and accessing support; (3) monitoring and
facilitating patients’ progress in decision making; and (4) screening for influential factors
pertaining to decision such as patients’ motivation and self-efficacy. Factors influencing a
clinician’s intent to involve patients in decision making have been shown to be strengthened after
attending a workshop on SDM. Following the workshop, clinicians demonstrated using the
Decisional Conflict Scale in practice, changes in attitudes about SDM, perceived control over
their behaviors, and influencing SDM practices of others within their working environment
(Stacey et al., 2008).
Dy and Purnell (2012) developed a list of key concepts for decision making and included
these items: provider competence, trustworthiness, cultural competence, communication with
patient and families, information quality, patient/surrogate competence, and roles and
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involvement (Dy & Purnell, 2012). Promoting competency in SDM should be required for all
health care professionals. To foster a culture of SDM, an organizational structure should promote
competency by introducing decision aids in the clinical encounter, communicating options and
discussing areas of uncertainty, and eliciting patient values and goals (Spatz et al., 2017).
Physician-related factors supporting SDM include not feeling strongly about one
treatment over another and being less supportive of SDM in situations where the compelling
evidence or well-established evidence of clinical practice guidelines favor one treatment over
another. In the presence of strong guidelines in favor of one treatment over another, cardiologists
were less likely to support the involvement of the patient in decision-making. In situations where
guidelines recommend one treatment option over another, physicians may feel pressured to
follow such recommendations (Pollard et al., 2015).
It has been suggested that an interprofessional approach to SDM must comprise an
interprofessional team that identifies the best options and facilities the patients’ involvement in
decision making using those options (Holm et al., 2016). Decisional coaching are trained health
care professionals to support the patient’s involvement in health care decision making but do not
make a decision for the patient. This role aims to develop the patient’s skills in deliberating on
the options, preparing for discussing the decision in consultation with their health professional,
and implementing the chosen option. Decisional coaching is provided face to face or via
telephone by a member of the health care team. Coaching may be used in combination with DAs
(O'Connor et al., 2015). Decision coaching involves assessing factors influencing patients’
decisional conflict, providing support to address decisional needs, monitoring progress in
decision making, and screening for factors influencing implementation (Stacey et al., 2008).
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Decisional Aids (DAs)
SDM involves a unique set of skills, most notably the elicitation of patients’ values
(Coylewright & Holmes, 2017). Patient DAs are educational tools designed to help patients
make treatment decisions in collaboration with their clinician and promote SDM (Bailey et al.,
2016). DAs are intended to supplement rather than replace patient-practitioner interactions.
Cochrane Collaboration’s systematic review of patient DAs found they consistently improved
knowledge, helped subjects match their values to their choices, and reduced passivity in decision
making (Stacey et al., 2017). Numerous institutions have successfully implemented SDM; one
such program is the Dartmouth Hitchcock Medical Center in New Hampshire, where since 1999,
clinicians have integrated decision-making tools and aids into the workflows and electronic
medical records (Elwyn et al., 2010). The International Patient Decision Aids Standards is an
excellent resource for the development and evaluation of decision aids and provides links to
validated tools for Afib (Coylewright & Holmes, 2017).
Decision aids tools help patients participate in making decisions by providing detailed,
specific, and personalized information regarding the benefits and risks of various potential
treatment options for a diagnosis. As these aids can influence choices made, they should be
supported by evidence and be unbiased. DAs can reduce the level of uncertainty and mental
anguish associated with choosing a course of action ( e.g., decisional conflict) (United States
National Library of Medicine, 2019). The use of DAs asks the patient to prepare for the decision
by educating themselves to read about their disease and treatment options, watch educational
videos, hear other patients’ experiences, and weigh the pros and cons of treatment. These actions
may place greater burdens on patients who already feel overwhelmed by their illness or the
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demand of medical care as they may not have the capacity to review or absorb the information
provided by these tools (Noseworthy et al., 2018).
Decisional aids may be leaflets, interactive media, or video or audio tapes. At a
minimum, they are intended to provide information about the options and their associated
relevant outcomes with the intent to engage the patient and personalize the information to
include the clarification of personal values, discussion of potential benefits and harms, or the
opportunity for the patient to communicate their values and to gain skills in the collaborative
process (Elwyn et al., 2006). When used successfully, DAs can increase understanding of a
decisional task, clarify patient values, decrease decisional conflict and stress, and improve
decision satisfaction (Pierce & Hicks, 2001).
The American Heart Association, the American College of Cardiology, and the Heart
Rhythm Society have designated SDM as a class I recommendation for patients and clinicians to
individualize patients’ antithrombotic care and improve the quality of care based on an
individual’s risks, comorbid conditions and socio-personal contexts (Noseworthy et al., 2018). In
2016, the Centers for Medicare & Medicaid Services expanded coverage in therapies for stroke
prevention in Afib to include the procedure of left atrial appendage closure. As part of monetary
reimbursement, the Centers for Medicare & Medicaid Services requires a formal SDM
interaction in individuals with NVAP, with an independent, non-interventional physician using an
evidence-based decision tool describing anticoagulation and LAAO options (Centers for
Medicare & Medicaid Services, 2016). Despite the mandate by the Centers for Medicare &
Medicaid Services to use DAs in patients considering left atrial appendage occlusion in stroke
prevention, none has been rigorously tested in the Afib population. Although the use of DAs has
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become mandated for certain health care conditions, there are currently no funded mandates to
support the development, certification, and maintenance of decision aids (Spatz et al., 2017).
The International Patient Decision Aids Standards group has established consensus
around the importance of measuring the involvement of patients in the decision-making process
and decision quality to evaluate the effect of patient decision aids. There is considerable evidence
that patient DAs improve the decision-making process, but when measuring decision-making
constructs, no tool has been developed to measure all five constructs: (1) recognize a decision to
be made; (2) be informed about options and outcomes; (3) be clear about goals and preferences;
(4) discuss goals and preferences with a health care provider; and (5) be involved in decision and
decisional quality constructs such as knowledge, realistic expectations, and values-choice
agreement. Research is recommended to develop and evaluate measurement instruments and
further explore theoretical issues to advance future research on DA effectiveness (Sepucha et al.,
2013). The challenge for the use of DAs is to help patients understand the role of their values and
preferences in the process of decision making while acknowledging that many patients may not
want to be the primary decision maker (Fraenkel et al., 2011).
Decisional support tools for the Afib population are in their early stages of development
and none have been validated by large studies (Sanders et al., 2018). The use of DAs has
demonstrated to decrease decisional conflict in patients with osteoporosis ( p <.01) (Cranney et
al., 2002) and diabetes ( p < .01) (Bailey et al., 2016). In a randomized control trial of DAs for
individuals with Afib deciding on long-term anticoagulation demonstrated no difference on
decisional conflict (p = .14) or decision satisfaction (p = .10). However, there was improvement
in knowledge and realistic expectations about stroke ( p < .001), and when evaluating medication
adherence behaviors at six months, there was no statistical significance in those exposed to the
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DAs and individuals who had usual care ( p =.44) ( Man-Son-Hing et al., 1999; Pierce & Hicks,
2001).
Another randomized control trial utilizing a computerized DA for Afib, and antithrombotic treatment demonstrated improvement in decisional conflict after consultation (p
= .036), but when evaluating decisional conflict at three months post consultation, the decreased
decisional conflict did not persist. Interestingly in this study, individuals who used the DA were
less likely to start warfarin (73.5% vs. 81.7%, RR 0.82, 95% CI 0.68-0.99), which has real-life
implications such as burden in terms of avoidable strokes (Thomson et al., 2007).
Fraenkel and colleagues (2012) performed a randomized trial to pilot a DA to improve
the quality of communication and decision making in individuals with Afib (n = 135). The DA
was administered to the intervention cohort prior to the consultation visit. After a consultation
visit, individuals who received the DA reported lower scores on the ‘informed’ (mean difference
= –11.9, 95%, CI = –21.1 to –2.7) and ‘values’ (mean difference = –14.6, 95%, CI = –22.6 to –
6.6) subscale of the Low-Literacy Decisional Conflict Scale. The intervention group also had a
greater knowledge of medication for stroke prevention (p < .001). Although this was not
statistically significant, individuals had greater knowledge of side effects (49% to 37%, p = .07).
Also, in the intervention group, there was an increase in discussion for stroke and bleeding risk
(p < .001) during the consultation visit. However, there was no difference between groups in
anxiety ( p = .48), worry about stroke ( p = .47), and worry about bleeding ( p =.24) (Fraenkel et
al., 2012).
A systematic review and meta-analysis examining older adults reported the effectiveness
of DAs (including two studies on Afib and DAs) in a subsample of participants aged 65+ years.
They demonstrated improved self-efficacy skills such as knowledge and increase in their
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individual risk perception. In addition, there was a decrease in decisional conflict and an effect
seeming to enhance participation in SDM (Van Weert et al., 2016).
DAs have the potential to be confusing, may increase patients’ distress, and could induce
avoidance reactions (Molenaar et al., 2001). Both reading comprehension and cognitive abilities
are likely to be important for gaining health information and interacting with the health care
system. Interventions to improve patient knowledge and self-management skills should consider
both the reading level and cognitive demands of the materials (Baker et al., 2008). Studies
demonstrate that individuals with Afib may have cognitive impairment (Kalantarian, 2016;
Kilander et al., 1998; Lavy et al., 1980; O'Connell et al., 1998; Sabatini et al., 2000; Yang et al.,
2017) and inadequate health literacy (Aronis et al., 2017; Reading et al., 2017), which may
influence health-related behaviors and limit the use of DAs.
In the Afib population, numerous DAs have been developed to facilitate discussions
around treatment options (Table 2.1). However, there are no DAs that have been rigorously
tested to provide acceptable validity and reliability in this patient population. The intention of
this study is to explore relationships such as demographic characteristics, decisional self-efficacy,
decisional conflict, control preference, and the influence of frailty on SDM participation in a
sample of individuals with Afib, which may assist in the ongoing development of DAs for
individuals with Afib.

80
Table 2.1
Organizations Providing Decisional Aids for Shared Decision Making in Atrial Fibrillation
Organization

Decisional Aid Weblink

American College of
Cardiology (CardioSmart)

https://www.cardiosmart.org/SDM/Decision-Aids/FindDecision-Aids/Atrial-Fibrillation

Ottawa Hospital Research
Institute (link to
healthdecision.org)

https://decisionaid.ohri.ca/AZsumm.php?ID=1805

Option Grids at EBSCO
Health

https://health.ebsco.com/products/option-grid/clinicaldecision-support

Keele University (in
collaboration with
Boehringer Ingelheim Ltd
and Prescribing Decision
Support)

https://www.anticoagulation-dst.co.uk/

National Institute for Health
and Care Excellence

https://www.nice.org.uk/guidance/cg180/resources/patientdecision-aid-243734797

Needs Assessment
The purpose of this study is to establish an initial epistemology of decisional needs
assessment in individuals with Afib seeking thrombo-embolic stroke prevention in the context of
SDM. A decisional need is usually derived from a needs assessment that addresses or focuses on
a situation where multiple options need to be deliberated (Bujold et al., 2017) . For the Afib
population, medical model options for stroke prevention include pharmacological and potentially
a mechanical strategy. In a holistic framework, lifestyle modifications, along with individuals’
values and preferences with health care goals, should be incorporated. According to the ODSF,
decisional needs assessment and unresolved decisional needs can lead patients to less likely
make informed decisions and can adversely affect the decision outcomes (O'Connor et al., 2015).
For the purpose of this study, individual decisional needs to be investigated include
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demographics, clinical characteristics, decisional self-efficacy, decisional conflict, preferred role
in decision making, and frailty status.
Individual decision making can be evaluated by cognitive measurement (knowledge, risk
perceptions), behavioral measures (decisions, intentions, and adherence behaviors), and affective
measures (anxiety, satisfaction, decisional conflict, assessment of the information and decisionmaking process; Elwyn et al., 2016). Research on relationships between individual
characteristics and SDM can target modifiable factors that have the potential to enhance patient
and clinician reported outcomes. Identifying variables within decision making that are
significantly associated with satisfaction in a health care decision can better target modifiable
variables to enhance both patient-reported and clinical outcomes (Glass et al., 2012). A synthesis
of twenty-nine papers focusing on older people with complex needs identified what ‘needs’ to be
in place for SDM to work for older people with complex needs, including: understanding and
assessing individual values and capacity to access and use care, having systems to support and
prioritize SDM, supporting and preparing patients to engage in SDM, and fostering a personcentered culture (Bunn et al., 2018).
SDM requires that health care professionals understand individual needs and present the
alternatives in a way that enables patients to select their preferred treatment option. This is
particularly important for patients with chronic diseases who are undergoing equipoise treatment
alternatives that have long-term consequences (Mah et al., 2016) as in the Afib population.
Demographic Factors and SDM
Preferences to participate in SDM are variable at all ages, although numerous studies
have shown that a higher proportion of older adults prefer less participation. One of the most
noted barriers to SDM in the elderly are perceptions by physicians that elders wish to defer
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decision making to their providers. In a study of individuals 80 years and older, a major barrier
for low levels of participation in SDM was noted when no alternative options for therapeutic
management were presented. Additional barriers included low patient activation, obstructed
communication with the clinician, patients not seeking information from other sources, patients’
beliefs that the provider knows his or her values, and patients not addressing discord with their
doctor (conflict avoidance). Individuals who felt they knew too little about their health were
more likely to report that the physician had made their health care decision. These findings
suggest that conflict avoidance may be interpreted by providers as patients’ desire not to be
involved in the decision-making process (Bynum et al., 2013).
Holm, Berland, and Severinsson (2016) performed a systematic review of nine
quantitative studies to extrapolate qualitative themes investigating older patients’ needs to
strengthen involvement in SDM. Two themes emerged: older individuals require (1) an increased
understanding of self-management and (2) a desire to strengthen one’s position in relationship.
Findings suggest that age, gender, and health status may influence older patients’ chance of being
respected and taken seriously in the communicative dyad. In this analysis, older patients were
more likely to feel comfortable if physicians made decisions for them. Although there was a
negative correlation between age and perceived involvement in decision making, males were
found to have nearly 50% greater frequency of high self-advocacy expressions than females
(Holm et al., 2016).
A study of hypertensive patients (n = 210) conducted in a Malaysian demonstrated
individuals < 60 years old (p < .001) and those with higher education levels (p < 0.01) preferred
to participate in SDM for treatment, whereas gender, ethnicity, marital status, or the duration of
diagnosis were not statistically significant (Mah et al., 2016). Another study using data from the
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National Health and Aging Trends Study (NHATS) demonstrated that all ages had a preference to
actively participate in decision making (86.2% for 65-74 years, 82.7% for 75-84 years, and
71.8% for older than 85 years). However, using logistic regression models, older age, lower
education, lower English proficiency, and limited mobility among older adults were associated
with a trend toward passive role preference in health care compared with cohorts and older adults
with multi-morbidity indicated that they preferred a passive role compared with those without
multi-morbidity (8.9%, OR = 2.35, p < .01) (Chi et al., 2017).
Decisional Self-Efficacy
Decisional self-efficacy is a measurement of self-confidence or belief in one’s abilities in
decision making, including SDM (O'Connor, 2002). Self-efficacy begins with Bandura’s (1977)
social learning theory and is embedded in the ODSF that guides this research. Self-efficacy
makes a difference in how people feel, think, behave, and motivate themselves. It is not
concerned with specific skills one has but rather with the judgment of what a person can do with
those specific skills. Self-efficacy beliefs produce diverse effects through four major processes:
cognition, motivation, affective, and selection. Four major strategies for developing self-efficacy
are through the mastery of experiences, vicarious experiences provided by social models, social
persuasion, and physiological and affective measures (Bandura, 1997). A sense of low selfefficacy is associated with stress, depression, anxiety, and helplessness and may breed pessimism
about accomplishments and development. A strong sense of self efficacy facilitates cognitive
processes and performance, including the quality of decision making (Zulkosky, 2009).
Achieving SDM depends on tasks that help confer “agency,” which refers to the capacity of
individuals to act independently and to make their own choices. Implementation of SDM
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methodology can confer agency by providing information and supporting the decision-making
process (Elwyn et al., 2012).
Historically, patterns of paternalism have been part of health care decisions, where the
health care provider “instructs” the patient on therapeutic management. Therefore, individuals
may be at risk for low self-efficacy in decision making, as they have not had prior experiences to
build the construct internally. Bandura described the importance of self-efficacy as beliefs that
function as an important set of proximal determinants of human motivation, affect, and action.
Attributes inherent to self-efficacy include cognitive processes, affective processes, and
perceived locus of control. Self-efficacy focuses on a person’s belief in the ability to perform a
specified task (Zulkosky, 2009). For the purposes of this dissertation, the task is considered
participation in SDM. To gain a sense of self-efficacy in participating in SDM, a person may
have evaluated a prior experience as successful or observed another individual or health care
provider participating in SDM methodology, given a “prep-talk,” or education provided by a
health care team, or experienced physiological cues such as provider comfort level with engaging
individuals in SDM. To gain a sense of self-efficacy, a person can complete a skill successfully,
observe someone else doing a task successfully, acquire positive feedback about completing a
task, or rely on physiological cues (Zulkosky, 2009). Therefore, individuals with Afib with a low
sense of decisional self-efficacy may avoid complex responsibilities, such as anticoagulation
adherence or participation in SDM. The key to promoting self-efficacy is to help patients learn
new behaviors through modeling or learning to modify existing maladaptive behavior by
changing the anticipated reinforcement. Self-efficacy is an important concept because it
ultimately affects behavior and outcomes (Zulkosky, 2009).
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People who have a high sense of efficacy are likely to view their state of affective arousal
as an energizing facilitator of performance, whereas those who are troubled by self-doubts regard
their arousal as a debilitator. However, the most effective way of creating a strong sense of
efficacy is through mastery of experiences (Bandura, 1994). According to Bandura, human
behavior is regulated by embodying valued goals. The higher the perceived self-efficacy, the
higher the goal challenges people set for themselves. Most courses of action are initially
organized in thought. An individual’s belief in one’s efficacy shapes the types of anticipatory
scenarios he or she constructs and rehearses (Bandura, 1994), including medical decision
making.
Hedberg and colleagues (2018) demonstrated that decreased vitality and mastery of daily
life (SF-36) and uncertainty in illness (Mishel’s Uncertainty in Illness Scale-Community) were
independently associated with lower confidence in decision making. Initially in step 1 analysis
using simple linear regression, the researchers identified that permanent Afib was associated with
lower confidence in decision making ( p = .003). However, in multiple regression analysis,
permanent Afib was no longer significant in confident decision making ( p = .949). Other
variables included comorbidities, SF-36 questions (physical and mental health and vitality),
anxiety and depression, mastery of daily life, and increased uncertainty in illness. In this
multivariable analysis, decreased vitality ( p = .029) and mastery of daily life ( p = .023) and
increased uncertainty in illness ( p < .010) were independently associated with lower confidence
in decision making. Uncertainty in illness has been identified as the single greatest psychological
stressor for patients with arrhythmia (Hedberg et al., 2018).
Patients’ greater perceived self-efficacy in patient-physician interactions has been related
to participation in decision making. Individuals interacting with physicians were more likely to
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question their surgeons and to perceive themselves as the final decision maker than those who
were less certain about their ability to interact with physicians (Maly et al., 2004). However, one
randomized control trial involving DAs versus usual care demonstrated a decreased self-efficacy
in the usual care group (non-DA group) at follow up. Bailey & colleagues (2016) acknowledged
this as the first study to demonstrate these findings and rationalized that when people are
confronted with a challenging task such as health care decisions, some may become less sure of
their efficacy (Bailey et al., 2016).
According to Self-Efficacy Theory, advancing age is said to produce losses in physical
stamina, sensory functions, intellectual facility, memory, and the speed with which cognitive
operations are executed. However, gains in knowledge, skills, and expertise may compensate for
some loss in reserve capacity. Therefore, older adults have the potential to enhance their level of
functioning by adaptive mechanisms (Bandura, 1997). This study explores relationships of age
and SDM, as previous literature suggests older people prefer a passive role in health care
decisions (Chi et al., 2017; De las Cuevas & Peñate, 2016; Lechner et al., 2016; Mah et al.,
2016).
Cognition Impairment, Health Literacy, and Values
Although cognitive status, health literacy, and values were not investigated in this study
(Afib: DMSP), they are briefly presented on how each concept may be related to decision
making and constitute part of self-efficacy theory.
Decision making is a complex process that entails the ability to generate and evaluate
multiple possible choices to select an optimal one. There is a certain degree of cognitive
functioning necessary for optimal decision making. Numerous studies have assessed links
between Afib and cognitive dysfunction with potential contributory factors, such as relating to
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thromboembolic hypothesis (e.g., cerebral lacunar infarcts or chronic cerebral ischemia). The
hemodynamic hypothesis recognizes that the difference in the length of cardiac cycles and
characteristics of Afib cause a beat-to-beat difference in stroke volume and blood pressure,
resulting in the instantaneous reduction in cerebral perfusion (Sabatini et al., 2000). Several
studies have shown an increased incidence of cognitive decline and dementia, including
Alzheimer’s and vascular dementia in Afib patients. The Atherosclerosis Risk in Communities
Neurocognitive study demonstrated a 23% higher risk of dementia, even after adjustments were
made for cardiac and cerebrovascular risk factors as well as prevalent and incident ischemic
stroke. The Rotterdam study demonstrated those individuals in Afib for a longer duration were
more likely to develop dementia (Zathar et al., 2019).
Afib is an important and independent risk factor for cerebrovascular disease and vascular
dementia. There is increasing evidence that Afib is associated with an increased risk of
asymptomatic or silent cerebral infarction and as a result may confer an increased risk of
progressive cognitive impairment on a person. A small prospective case-controlled design of 27
NVAF patients were compared with 54 age and sex-matched controls in sinus rhythm found no
significance differences between cases and controls for general cognitive function and premorbid
intelligences (although controls scored significantly higher). Multiple regression analysis was
performed and demonstrated significant result between groups on the PASAT 4 test (p = .0028).
Overall, the study demonstrated the presence of Afib was consistently associated with poorer
performance on the test battery, although significant differences between cases and controls
existed only for the logical memory test, PASAT 2 seconds test, and PASAT 4 seconds’ test. The
presence of Afib was consistently associated with poorer performances on all the subtests of the
neuropsychological battery. There was no association between the duration of atrial ﬁbrillation
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and performance. The PASAT 4 second test relies to a significant degree on memory function as
well as attentional function. This may suggest that Afib has effects on memory and new learning.
Although this study was limited by the sample size (n = 81 [27 with Afib, 54 without Afib]),
there appears to be evidence to justify further examination of the hypothesis in a larger
prospective study to determine whether antithrombotic therapy may protect against cognitive
decline in patients at maximal risk of silent cerebral ischemia (O'Connell et al., 1998).
With the focus on development of DAs in the Afib population, the concept of cognitive
load should be of part of the development of DAs. Cognitive load refers to the deliberate
engagement in cognitive processes that are beneficial to learning, including asking the right
questions, appropriate self-explanation of content, accurate meta-cognitive monitoring of
learning and performance, and following up on that monitoring with adequate learning activity.
Incompleteness and lack of development or lack of automation of a learner’s cognitive schemas
imposes intrinsic cognitive load (Leppink, 2017). Cognitive load involves an individual’s
cognitive capacity, which is used to work on a task, to learn, or to solve a problem. Therefore, the
measurement of cognitive load can provide insight into the cognitive demands of tasks. High
cognitive load may hinder understanding and should therefore be considered when developing
instructional designs or assessment tasks (Krell, 2017).
SDM extends the patient’s role in clinical reasoning required for patients and physicians
to discuss and evaluate complex medical information. Activating patients to participate in health
care decisions depend on patient cognition on a variety of levels, from the routine challenges to
memory and problem solving for high-stake decisions. Individual cognition can be vulnerable to
deficiencies and biases that may introduce error in performing cognitively complex tasks (Lippa
& Shalin, 2016).
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Health literacy is the “capacity to obtain, process, and understand basic health
information and services needed to make appropriate medical decisions.” Health literacy
includes the behavioral activities such as the ability to interact with health professionals,
comprehend medical information, ability to act on health-related information, evaluate treatment
courses, and the ability to navigate the system. National surveys have demonstrated that 36% of
adults in the United States have limited health literacy (Aronis et al., 2017). Limited health
literacy has been shown to be independently associated with a nearly twofold increase in
mortality among the elderly (HR 1.75; 95% CI, 1.27-2.41) (Sudore et al., 2006). Individuals with
limited health literacy are at an increased risk for disease-related mortality, have worse disease
management, engage less in participatory decision making during health care visits and are less
adherent to provider-prescribed medication (Reading et al., 2017).
Limited health literacy is associated with poor warfarin and Afib knowledge. In a study
examining the relationship between health literacy and adherence to oral anticoagulation therapy
(OAC), participants with inadequate health literacy had a significantly lower mean knowledge
score (p < .05) and lower self-reported adherence to OAC (p < .05) compared to individuals
with adequate health literacy (Rolls, 2017). Fang and colleagues (2006) reported that 60.9% of
patients taking warfarin for stroke prevention in Afib had limited health literacy, with 33.5%
having no more than an eighth-grade education. Patients with limited health literacy were more
likely to be older (p < .001), female (p = .07), nonwhite (p < .001), and taking warfarin for a
longer period of time (p = .04) ( Fang et al., 2006). Another study demonstrated that limited
health literacy in Afib was associated with male sex, blacks, less education and lower incomes
(all p < .001), and in those reporting “fair to poor” health status (p = .05; Sudore et al., 2006).
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Other studies in Afib populations demonstrate inadequate health literacy in 20.4% (Reading et
al., 2017) to 62.5% (Montbleau et al., 2017) of individuals.
Value is defined in decisional science literature as a “measure of the attractiveness” of a
possible outcome or the “desirability” of each outcome. Individuals make decisions based on
what is important to them and perhaps not based on statistical outcomes set out by professional
guidelines (Pierce & Hicks, 2001). Value congruent is defined as the match between the chosen
option and the patient’s value. A key element in SDM is that practitioners understand what
matters to patients to support them in choosing a treatment option that matches their values
(Munro et al., 2015). Values and preferences with respect to the recommended therapies,
personal beliefs health states and attitudes toward them, past experience, and the current
psychological state, can influence the context of decision making and choice (Pierce & Hicks,
2001).
Decisional Conflict
Decisional conflict refers to an individual’s internal conflict or uncertainty about what to
do when choice among competing actions involve risks, loss, regret, or challenge to personal life
values (Légaré et al., 2012; O'Connor, 1995). Janis and Mann’s Conflict Model of Decision
Making is embedded in the ODSF, as “human beings, programmed as they are with emotions and
unconscious motives as well as with cognitive abilities, seldom can approximate a state of
detached affectlessness when making decisions that implicate their own vital interests or those of
their organization or nation” (Janis & Mann, 1977, p. 45). The Conflict Model acknowledges the
potential influence of stress on the decision-making process and subsequent coping strategies
(Balneaves & Long, 1999).
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Decisional conflict is a state of uncertainty about a course of action. Such uncertainty is
more likely when a person is confronted with decisions involving risk or uncertainty of
outcomes, when high-stakes choices with significant potential gains and losses are involved.
Conflict may arise when there is a need to make value tradeoffs in selecting a course of action, or
when anticipated regret may be an influential factor (Thomson et al., 2007). Clinical signs of
decisional conflict include the expression of uncertainty or worry over one’s options, an inability
to choose, delayed decision making, and doubts about personal values. A key phrase of “What
would you do?” should raise awareness to the practitioner (Wittmann-Price & Fisher, 2009).
Uncertainty is the hallmark of decision making, subject to ambiguous or risky outcomes,
recognition of potential losses as well as potential gains, and anticipated regret in forgoing the
positive aspects of options that were not selected (Légaré et al., 2012). Uncertainty is greater
when a person feels uninformed about the alternatives, benefits, and risks; is unclear about
personal values; and feels unsupported in making a choice or pressured to choose a course of
action (O'Connor & Jacobsen, 2001).
According to Conflict Theory, there are five coping patterns: (1) unconflicted inertia, (2)
unconflicted change, (3) defensive avoidance, (4) hypervigilance, and (5) vigilance. The final
coping pattern of vigilance occurs when a decision maker can complete a thorough search and
evaluation of all alternatives without being rushed or limited by unacceptable choices. Vigilance
allows an individual to make high-quality decisions and occurs only when a moderate level of
stress is experienced in response to a challenging threat (Balneaves & Long, 1999).
Screening for decisional conflict is an important SDM competency and a critical step in
ensuring that informed consent is truly informed and good decisions are made (Ferron Parayre et
al., 2014). When conditions such as inadequate informational and psychological support, social
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pressures or norms that favor certain choices, limited time for careful deliberations, and unclear
expectations from health care providers about possible alternatives and their consequences are
not addressed, patients and SDM are more likely to experience decisional conflict (Hickman et
al., 2012). Decisional conflict may have temporal characteristics. In a study of patients with
localized prostate cancer, overall decisional conflict substantially improved over time. Where
46% of patients experienced decisional conflict at baseline, 22% by one month (p < .05), and
28% at six months (p < .05). Participants with higher than an elementary school education (p
< .05) and preference for a collaborative role (p < .01) demonstrated less decisional conflict
(Chien et al., 2014).
Inadequate knowledge and support for decision making can increase the likelihood of
decisional conflict, which may manifest as delaying the decision-making, vacillating between
choices, questioning values and tension (Bailey et al., 2016). Individuals who regret their
treatment decision may experience an inferior quality of life and side effects (Chien et al., 2014).
Bailey and colleagues (2016) investigated individuals with Type 2 diabetes considering
medication intensification. Participants (n = 225) were randomized to usual care or the use of a
DA. Compared with usual care, the DA users demonstrated increased knowledge (p < .0001),
improvement in self-efficacy (Decisional Self-Efficacy Scale; p < .001) and decrease in
decisional conflict (p < .0001). One important finding in this study was a decrease in reported
decisional self-efficacy at follow-up in the usual care group (M = -3.9, p = .0018). The authors
suggested that when people are confronted with a challenging task, some may become less sure
of their efficacy (Bailey et al., 2016). Efficacy beliefs may demonstrate different levels of
perceived self-efficacy but also alter functional levels of individuals over time, even with
variations in the task performed and self-doubt in performance (Bandura & Locke, 2003).
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Greater patient involvement in treatment decisions is associated with less decisional
conflict, which can be viewed as a moderator for patient satisfaction (Doherr et al., 2017).
Studies focusing on decisional conflict reduction have suggested that reducing the experience of
decisional conflict improves patient satisfaction, increases patient-provider interactions, and
decreases post-decisional uncertainty (Power et al., 2011). The most recent Cochrane Systematic
Review regarding educational and behavioral interventions for anticoagulant therapy in patients
with Afib included two studies examining relationship between DAs and the impact on
decisional conflict. Data from the two trials were pooled and the random-effects analysis favored
use of DAs versus usual care in terms of reducing decision conflict (M difference = -0.10, 95%
CI -0.17 to -0.02; Clarkesmith et al., 2017). Preliminary results from an ongoing study
investigating the use of a web-based iPad as a DA versus usual care in individuals with coronary
artery disease demonstrate no difference in decisional conflict with the use of the DA and usual
care (p = .53; 95% CI, -1.22-0.64 ; Case et al., 2019).
Many studies investigating decisional conflict focus on the use of DAs in Afib. In a
randomized control trial of usual care and the use of a computerized DA, decisional conflict fell
in both groups post-clinic compared to pre-clinic, and the difference between groups post clinic
was significant. The use of a decisional aid demonstrated less decisional conflict. However, after
three months, this difference was not maintained. Researchers speculated, perhaps because
participants have become more accepting of the decision made (May et al., 2007).
Although not part of this research, the concept of decisional regret is discussed, as this
can influence decision making. Negative experiences during or after decision making can lead
patients to regret about the choices that were made. Decisional regret is associated with lower
satisfaction with care, negative experiences with the health care system, and reduced quality of
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life. In bivariate analysis, greater decisional regret has been shown to be associated with
decisional conflict (p < .01). In multivariate analysis, greater decisional regret was associated
with older patient (p = .02), and lower education levels (p = .03), which the authors suggested
may be related to lower health literacy (Becerra-Perez et al., 2016). Anticipatory regret refers to
the fear of “buyer’s remorse” as an important influence on individual choices across a range of
domains including health care. In one “hypothetical” study, researchers incorporated the concept
of post-decisional regret into an experimental DA while the use of standard decision aid was
used in the parallel cohort. Outcomes examined the rates of subjects choosing lumpectomy
versus mastectomy and the proportion reporting that regret played in the decision. In the control
group, 77% of participants chose lumpectomy over mastectomy, whereas in the experimental
group (receiving the regret-incorporated DA) reported 91% choosing lumpectomy over
mastectomy (p = .011). These findings suggest that activating patients to think pre-operatively
about consequences could inform the decision-making process (Speck et al., 2016).
Decision Control Preferences
SDM is viewed as fundamental to safe and effective health care, but implementation
efforts still face considerable difficulties. The word autonomy comes from the Greek autos (self)
and nomos (rule, governance, or law), which has become a term that is used to refer to
individuals and is found in moral, political, and bioethical philosophy. In a medical context,
respect for a patient’s autonomy is considered a fundamental ethical principle and is the central
premise of the concept of informed consent. Yet studies suggest that 10% to 20% of all patients
do not want to know the details of their condition and 9% to 17% prefer to leave the decision to
their family or their physician (Rodriguez-Osorio & Dominguez-Cherit, 2008). Patient
statements regarding self-efficacy and role preferences strongly depend on patients’ self-image,
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the specific situational context, their own understanding of the underpinning’s concepts, and
social desirability (Heesen et al., 2013).
An essential component of an SDM model includes health professional and patient
participation in all steps of the decision-making process, including professional disclosure,
exchange of information, deliberation about options, patients’ preferences, negotiation, and
agreement on a decision to implement. However not all patients are prepared, suitable, or want to
participate to the same degree in the decision-making process based on socio-demographic
variables such as age or education level, the type of decision and personal variables such as
patient preferences, or the responsibility of the clinician (De las Cuevas et al., 2013).
Control preferences construct is defined as “the degree of control an individual wants to
assume when decisions are being made about medical treatment” (Degner et al., 1997). The
origins of the concept developed from a qualitative study by Degner and Beaton (1987) designed
to answer the question, “What happens when treatment decisions are made for patients with lifethreatening illness?” in which the central factor appeared to be that decisions are made within a
social context with considerations of who actually selected the treatment that the patient
received. Four patterns of decision making emerged: provider controlled, patient controlled,
family controlled, and jointly controlled (Degner et al., 1997). Patients are hypothesized to have
differing preferences about keeping control over treatment decision making, sharing control with
their physician, or relinquishing control to their physician. Patients’ reports of their experiences
with health care are increasingly important because SDM has been reported to improve patientreported outcomes, but not all patients prefer to participate in medical decisions (Kehl et al.,
2015).
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Studies have found that treatment outcomes are more successful when patients are
actively involved and understand the rationale behind their care. However, not all patients may
desire or are prepared to participate to the same extent in the treatment decision-making process
with their physicians. Researchers have argued the importance of determining and
accommodating patients’ preferred role in the decision-making process, as this is consistent with
patient-centered-care (Mah et al., 2016). Patients who perceived that their level of involvement
in decision making is consistent with their role in decision-making preferences were more
satisfied with their care, had less decisional conflict, or reported less psychological distress
compared with patients who believed their actual decision role mismatched their initial
preferences (Street et al., 2012).
A patient’s preference to be passively involved in decision making may be a hindrance to
implementing SDM. A recent systematic review of 44 studies focused on the patient perspective
identifying two key themes: (1) how the health care system is organized and (2) what happens
during the decision-making interaction. A building taxonomy of both knowledge and power was
identified as a requirement for an individual to possess and influence participation in SDM.
Knowledge includes treatment options and personal preferences and goals of the individual.
Power refers to the patient’s perceived capacity to influence the decision-making encounter such
as self-efficacy to use skills that include knowledge and the ability to participate in discussions
(Joseph-Williams et al., 2014).
Individual preference for involvement in the decision-making process may vary
according to factors such as demographic variables (age, education, gender); types of clinical
decisions and previous experience of medical care; amount of knowledge they have about their
condition; their attitude toward involvement; and the interactions and relationships they
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experience with the health care team (Mah et al., 2016; Say et al., 2006). Numerous studies have
demonstrated a passive role in health care decisions associated with older age (Chi et al., 2017;
De las Cuevas & Peñate, 2016; Lechner et al., 2016; Mah et al., 2016), male gender (Chi et al.,
2017; Lechner et al., 2016), multimorbid conditions (Chi et al., 2017; Lechner et al., 2016),
cognitive impairment defined as “confusing names” (Lechner et al., 2016), lower educational
attainment (Chi et al., 2017; De las Cuevas & Peñate, 2016; Mah et al., 2016; Zhang et al.,
2011), limited English proficiency (Chi et al., 2017), patients undergoing longer treatments (De
las Cuevas & Peñate, 2016), and the presence of an informal caregiver during a medical visit
(Chi et al., 2017). The level of decisional control may vary based on the novelty of the disease
and its severity where passive preference has been noted (Pierce & Hicks, 2001).
In one study, the concept of decision-making process was explored using a grounded
theory methodology in patients considering an internal cardioverter defibrillator implant for
primary prevention of sudden cardiac death. Three major factors influencing participation in the
final decision included trust in the physician’s knowledge, expertise, and years of training and
established patient-physician bond. A poorer health state created a sense of urgency for
participants and their families to accept the internal cardioverter defibrillator. The study found
that active decision makers posed many more questions to physicians; they sought details,
simplified explanations regarding the technology, and wanted to comprehend the purpose and
function of the device and trust in it. Active decision makers took time and balanced their
perceptions about personal risk against benefits. Participants who took a more passive role were
less likely to report having sought information beyond what was given to them and would often
defer decision making to the physician or a family member. Some passive decision makers
verbalized that they did not see the decision as theirs to make (Carroll et al., 2011).
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In their study, Levinson and colleagues (2005) revealed wide variation in preferences for
participation in decision making, where approximately half of the respondents preferred to rely
on physicians for information about their condition and half preferred to leave final treatment
decisions up to the doctor. These findings are consistent with “paternalistic models” in which
patients rely on physicians to make treatment decision rather than using a more collaborative
process. Demographic characteristics related to decision-making preferences demonstrated that
women are more likely to prefer a collaborative style of communication by assuming an active
role in their health care. There was a greater preference to delegate decisions about treatment to
physicians among African American and Hispanic respondents than among Whites. Furthermore,
the researchers found that older people tend to prefer a physician-directed style of care and a
shift in preference toward a physician-directed style beginning after 45 years of age, and
respondents in poorer health markedly preferred a physician-directed style of decision making.
The researcher speculated that those who are ill may feel more dependent on trusted
professionals to whom they wish to relinquish control. The researchers suggested the imperative
of physicians to assess the needs of individual patients and understand the role each patient
wishes to play in his or her care (Levinson et al., 2005). An active role in decision making may
require new skills for older populations who may have grown up in the paternalistic era of
medicine and who may be less savvy about information technology such as DA tools (Bynum et
al., 2013).
Frailty
Circumstances of clinical complexity are closely linked to uncertainty, which may come
from the consideration of multiple options in decision making (Amblàs-Novellas et al., 2015).
Frailty is a complex syndrome characterized by reduced resilience to stressors and increased
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physiological vulnerability associated with a progressive loss of physiological functions (Tse et
al., 2017). Frailty provides a better approach toward “biological age” than “chronological age,”
which is usually useless as a prognostic marker. With the aging population, frailty will become a
concern in regard to consequences on individuals, society, and the health care system (Basic &
Shanley, 2015).
Frailty is an independent risk factor for adverse outcome in cardiovascular disease and
cardiac intervention. Afib has been strongly associated with high frailty scores. Frailty
assessments can help in risk stratification and decision making, thereby improving outcomes and
quality of life, and preventing unnecessary harm among the frailest. Afib may be a surrogate for
frailty (Rowe et al., 2014).
Frail older adults are at greater risk of multiple adverse outcomes, including procedural
complications, adverse drug reactions, hospitalizations, and shorter survival. Afib with associated
comorbidities as risk for stroke and prevalence of heart failure can contribute to worsening
functional status, eventually leading to a state of frailty and later to overt disability. Elderly Afib
patients often present with an elevated number of comorbidities and polypharmacy status, which
may influence therapeutic choices. A recent systematic review (n = 2,803) suggests that frailty is
common in persons with Afib, ranging from 4.4% to 75.4%, while Afib prevalence in the frail
population ranged from 48.2% to 75.4% (Villani et al., 2018). Literature suggests that frail
patients have a lower use of oral anticoagulation, higher risk of bleeding complications from oral
anticoagulation, and higher risk of stroke and mortality. A recent study demonstrated that in spite
of the novel (direct)-oral-anticoagulants (e.g., dabigatran), frail patients continue to be less likely
to receive medication for stroke prevention (Bibas et al., 2016; Steinberg et al., 2013).
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Polidoro & colleagues (2013) demonstrated that Afib was strongly associated with frailty
status, independent of age, sex, hypertension, diabetes, stroke, acute myocardial infarction, and
heart failure (OR 4.09, 95% CI 1.51-11.07, p = .005). This study also examined cognitive
function using the mini mental status exam at baseline in both the Afib and non-Afib cohort,
which demonstrated all patients with abnormal frailty index (n = 109) had a score significantly
lower than those of the non-frail group (n = 31, p = .005), the Afib group had a 4.09-fold frail
risk than the control patients, and the frailty index was significantly and inversely correlated with
cognitive decline (Polidoro et al., 2013).
Health status has been demonstrated to be related to satisfaction with health care decision
(p = .001) (Holm et al., 2016). One study evaluated two groups (disability free and those with
chronic conditions and comorbidities, n = 268). They were administered questionnaires on
attitudes and experiences on SDM, including the SDM-Q-9 and the Autonomy Control Index.
There was a significant difference (p < .001) between groups as the disability-free group
expressed a significantly higher desire to participate in a SDM process, but there was no
difference in the desire for information (Kiselev et al., 2018). Frailty assessment may help reduce
uncertainty by providing better understanding on the patient’s global reality and facilitate a
dialogue about expectations and objectives in the SDM process (Amblàs-Novellas et al., 2015).
From a clinical perspective, understanding frailty is important because its effect will generate
greater complexity in treatment choices, care planning, and costs of care. Also, a better
understanding of frailty may increase the likelihood of finding practical interventions to reduce
negative outcomes (Basic & Shanley, 2015).
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Satisfaction with Decision
Patients have become health care consumers and have been given a voice in outcomes
research, such as Patient Press Ganey Scores. It is important to understand the psychosocial
outcomes related to decision-making processes of individuals in relation to decision-making
constructs such as knowledge about treatment options, expectations of treatment outcomes,
satisfaction with the decision, and regret about the final decision made (Stryker et al., 2006).
Patient perception of involvement in the decision-making process have been found to be
significantly related to satisfaction with their care and treatment at one year (F = 7.249, p < .001;
Pipe et al., 2005).
The concept of Satisfaction with Medical Decision is consistent with patient-centered
care and has been shown to be a predictor of behavior as it is closely related to a patient’s “intent
to act”. The satisfaction with decision conceptual model builds on O’Connor & O’Brien-Pallas’
model of effective decision as one that is informed, consistent with an individual’s values, and
behaviorally implemented. In deliberative models of decision making, which is consistent with
SDM, a patient’s involvement in a decision is the objective. However, satisfaction with the
decision does not assume high patient involvement in the decision making, as some patients
prefer surrogate/alternative decision makers. Satisfaction with decision is negatively correlated
to decisional conflict and positively related to decision confidence (Holmes-Rovner et al., 1996).
SDM in Afib
For patients with Afib, treatment recommendations from clinical practice guidelines may
differ from patient preferences. Since patient preferences can have a substantial impact on the
clinical decision-making process, acknowledgment of their importance should be incorporated
into clinical practice guidelines (Man-Son-Hing et al., 2005). A systematic review on patient
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values and preferences in decision making for antithrombotic therapy found that values and
preferences were highly variable among individuals (MacLean et al., 2012). Therapeutic
management in stroke prevention is recognized as having complex considerations where there is
an interplay of treatments, risks and benefits, along with variability in patient adherence and
health literacy (Eckman et al., 2017). Patients differ widely in their risks, making generic
information about therapies far less useful than individualized recommendations that are based
on patient-specific risks, individual patient values, and preferences for health outcomes (Eckman
et al., 2015). Participant responses may depend on their prior experience with the treatments or
health outcomes considered as well as on the methods used for preference elicitation. It should
be standard for clinical practice guidelines to conduct systematic reviews of patient values and
preferences in a speciﬁc content area (MacLean et al., 2012).
Individual risk stratification is important in clinical decision making and aids in patient
counseling and informed consent. The exploration of factors such as comorbidities, cognitive
impairment and disability, frailty status, and social support should be required to reorganize care
and management (Murali-Krishnan et al., 2015) and be part of the SDM process. Since both
stroke and bleeding risks vary widely according to each patient’s specific comorbidities, decision
making about appropriate therapy to reduce stroke risk involves the considerations of trade-offs
among the benefits, risks, and inconveniences of different treatment options (Fraenkel et al.,
2011).
Current Studies in SDM
In 2012, sixteen high-value health care collaborative centers, one of which is DartmouthHitchcock Medical Center, received a $26 million grant from the Center for Medicare and
Medicaid Innovation to fund a program to engage patients and implement SDM for patients
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facing hip, knee, or spine surgery and those with diabetes or congestive heart failure. The
expectation of incorporating SDM is to result in a $64 million saving over three years, largely
due to reduced utilization and cost that has been shown when patients are engaged and
empowered to make health care decisions based on their own values and preferences. Dartmouth
used these funds to train patients and family activators to engage in SDM, focusing on
preferences and supplying sensitive care choices (Dartmouth-Hitchcock Medical Center, 2012).
Currently, a randomized control trial funded by the National Institutes of Health is
underway to study the use of DAs for Afib- SDM4Afib. The study (NCT 02905032) is expected
to enroll 2,700 patients with an anticipated completion date of September 2021. The goal of this
study is to determine the extent to which a behavioral DA; the Anticoagulation Choice tool,
promotes SDM and its impact on anticoagulation use and adherence versus standard care in
patients with nonvalvular Afib. The tool will measure (a) knowledge transfer, (b) concordance,
(c) quality of communication and satisfaction with SDM, and (d) satisfaction with the decisionmaking process (U.S. National Library of Medicine, 2018).
The most recent trial (NCT04118270) is an open-label study examining the feasibility of
using a mobile app (Afib 2gether) developed by Pfizer pharmaceuticals with the intent to
facilitate SDM. In this study, patients can determine their risk of stroke due to Afib and prioritize
questions and concerns for discussion with their cardiology provider. Outcomes include app
usage and appropriate patient risk assessment (United States National Library of Medicine
Clinical Trials, 2019).
Summary
The implementation of SDM models is no longer a choice; it has become a legislative
and economic mandate in the United States for certain therapeutic options and is endorsed by
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professional guidelines. There is a call for ongoing trials for atrial fibrillation in assessing the
quality of SDM in outcomes, including the Decisional Conflict Scale (DCS), measures of patient
and clinician satisfaction, and by direct observation of the dialogue between clinician and
patients (Noseworthy et al., 2018). According to the theories underlying the Ottawa framework,
an individual needs assessment can assist in understanding the context of decision making and
identify the determinants that may be suboptimal for individuals such as decisional conflict,
inadequate knowledge, unrealistic expectations, unclear values or lack of readiness to make a
decision, and inadequate perceptions of clinicians. Perceptions of clinicians may include
unwanted pressure, inadequate support, and a mismatch between actual and preferred roles in
decision making (O'Connor & Jacobsen, 2001). Individual behavior and decision making are
reliant on self-efficacy and role preferences, which strongly depend on patients’ self-image, the
specific situational context, their own understanding of the underpinning concept, and social
desirability (Heesen et al., 2013).
Paramount to needs assessment include assessment of individuals who have problems
with personal and external resources to decide limited self-confidence and skills in
communication and deliberation about options, or limited resources such as finances or
accessible programs. Decision making in Afib should be patient centered and include an
assessment of the patient capabilities such as their experience with the disease, their values and
preferences, their attitude toward assuming risks, and their social circumstances. Decisional
support should be tailored to a participant’s characteristics such as gender, age, and medical
diagnosis and health status, as these are important determinants of decisions. A medical problem
may interfere with a person’s ability to make decisions by either reducing physical or cognitive
capacity or producing emotional distress (O'Connor & Jacobsen, 2001). The literature on SDM is
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still poor and more research needs to be done so as to better comprehend longitudinal,
interactive, and interdisciplinary processes of decision making (Amblàs-Novellas et al., 2015).
In the Freirian Model, education is a means of “freeing people” from a “culture of
silence.” However, Friere believed the focus should be on acts of cognition, not merely a transfer
of information. Paulo Friere believed in a reciprocal relationship. Through his theories,
educational systems were revolutionized to include students as empowered participants. Friere
also believed that knowledge did not come from experts but rather from a group sharing
experiences, and then understanding those influences that affected their lives (Ickes, 2011). SDM
will not become the norm in health care without simultaneously addressing patient-reported
barriers (Joseph-Williams, Edwards, & Elwyn, 2014). It may be difficult to identify patients who
prefer greater involvement from any simple demographic or personal characteristics (Burton et
al., 2010). The purpose of this study is to investigate relationships between decisional needs
(e.g., age, gender, educational attainment, decisional self-efficacy, decisional conflict, control
preferences, and frail status) and participation in SDM for stroke prevention. This investigation is
expected to provide an epistemology of decisional needs based on the ODSF and add to the
knowledge base on individuals with Afib and participation in SDM for stroke prevention.
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CHAPTER THREE: METHODOLOGY
Afib is a common cardiac arrhythmia affecting an estimated 2.7 to 6.1 million people in
the United States (January et al., 2014). With the aging population, this number is expected to
increase up to 15.9 million Americans by the year 2050 (Andrade et al., 2014). Treatment options
for thrombo-embolic stroke prevention vary for individual patients based on their individual risk
profile. With the advent of patient-centered-care and outcomes, patients and health care providers
are expected to participate in SDM methodologies. Although the use of DAs may assist
individuals with decisions regarding stroke prevention in Afib and decisional conflict, none has
been rigorously tested since newer treatment modalities emerged and no DA in Afib has been
tested for its effect on SDM. Additionally, a “one size fits all” DA may be limiting in some
populations, including individuals with Afib, where demographics, self-efficacy (e.g., cognitive
function and health literacy), decisional conflict, functional status, and standards of social norms
such as the role an individual plays in health care decisions may limit an individual’s capacity or
preference to participate in SDM. Therefore, individual characteristics in the patient with Afib
and participation in SDM is an important concept that should be explored, as this may assist
clinicians to individualize their approach for consistency with patient-centered care.
The purpose of this study is to explore characteristics in individuals with Afib such as
demographics, decisional self-efficacy, decisional conflict, role preferences and frailty status, and
the influence of these constructs on an individual’s participation in an SDM process. This chapter
describes the setting, subjects, and procedures conducted in this study, including enrollment
criteria, instruments for measurement, and method of analysis.
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Research Design
This study included an exploratory and a descriptive correlation designed to evaluate
constructs of individual characteristics that may impact individuals with Afib participating in
SDM. In addition, prediction models were used to investigate constructs associated with SDM
and decisional conflict. Initially, an exploratory design described normative data and examined
rates of self-reported SDM using the 9-items Shared Decision-Making Questionnaire (SDMQ-9).
Second, sociodemographic characteristics (i.e., gender, age, educational attainment, and
partnership status) of participants were studied for relationships between decisional self-efficacy,
decisional conflict, role control preference, and participation in SDM. Third, the relationship
between clinical factors (e.g., CHA2DS2-VASc score, and type of Afib) and receiving an
educational packet/DA were examined for relationship decisional constructs. Fourth, the
relationship between time from decision and decisional conflict were examined for the temporal
nature of decisional conflict. Fifth, relationships between decisional self-efficacy, decisional
conflict, control preference, frail status, and SDM were investigated. Sixth, individuals who have
decided on a treatment choice were examined for relationships between their perception of
participating in SDM in thromboembolic stroke prevention and their satisfaction with their
decision. To examine patient-reported outcomes, an analysis examining the consequence of the
decision and satisfaction with the decision was explored. Final analysis included logistic
regression models that examined individual characteristics and prediction of participation in
SDM in this sample.
Setting and Subject
Recruitment for this study began after receiving Institutional Review Board approval
from Molloy College, Rockville Centre, New York, on August 14, 2019 (Appendix A1). A
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patient engagement form was reviewed for an alternative site (Appendix A2). The primary
method of recruitment was through an online Afib Support Group (StopAfib.org; Appendix B)
and a large health care network located on Long Island, New York. The StopAfib.org website
provides information about AF symptoms, causes, risks, treatments, resources, and the latest Afib
news and videos. StopAfib.org is certified by the Health on the Net Foundation, which assesses
authority, complementarity, privacy, attribution, justifiability, transparency, financial disclosure,
and advertising policy on its website (Pandya & Bajorek, 2016). Participants from StopAfib.org
were recruited directly from the StopAfib.org website with a direct link from the homepage at
https://www.stopafib.org/ with recruitment flyers (Appendix C and D). Participant recruited from
the health care network on Long Island received an IRB-approved flyer (Appendix D) from the
sites that directed them to the Afib: Decision-Making in Stroke Prevention online survey.
Although there was no directed contact from participants, the flyer was posted with the
researcher’s contact information provided. No participants contacted the researcher directly. The
survey did not identify which source of recruitment the participants came from. The setting for
this study was as online survey created by the researcher, Atrial Fibrillation: Decision-Making in
Stroke Prevention Study (Atrial Fibrillation: DMSP), supported by Survey Monkey (Appendix
E).
Inclusion Criteria
The online survey included four inclusion criteria questions: (a) 18 and older, (b) selfidentifying as having Afib diagnosed by a health care provider, (c) currently considering or
within the last three months has decided on a treatment option for stroke prevention related to
Afib, (d) residing in the United States. If participants responded yes to all four questions, they
were considered as enrolled. Self-reported Afib was defined as a “yes” response to the survey
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question, “Has a health care provider diagnosed you as having atrial fibrillation?” A “no”
response to any one of the four questions disqualified the intended participant. When
disqualified, individuals were thanked for considering participating and an explanation was
provided, “Thank you for your interest in this survey. Due to your responses, you are not
applicable to participate. Again, we thank you for your interest.”
Three months was considered as the time frame for participation in this study and is
consistent with Glass and colleagues’ (2012) study. Although researchers identified recall bias as
potentially influencing the outcomes, justification for time was provided because this window of
time is relatively small and substantially briefer compared to one other study (e.g., limited the
decision to the previous two years; Zikmund-Fisher et al., 2010). The rationale for the threemonth period also recognizes the instructions for the use of the Satisfaction with Decision
(SWD) scale, as it is recommended to be given when a health care decision has been made and
the consequences are not yet clear (Holmes-Rovner et al., 1996). Therefore, for the purposes of
this study, a question was added to include any potential consequences that could influence SWD
responses: “After making this decision on stroke prevention, did you have an event requiring a
visit to a health care provider, emergency room, or hospital related to your decision?”
Procedures
Recruitment for this study began after receiving Institutional Review Board approval
from Molloy College, Rockville Centre, New York, on August 14, 2019 (IRB Approval
16140104-0814, Appendix A1). Enrollment began on December 2, 2019 and ended on February
10, 2020. While being cognizant of the average response rates for online surveys of 20% to 30%,
factors suggested by Safdar and colleagues (2016) were used to mitigate low response rates
including review of clarity of instructions, and minimize survey questions to reflect what is
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being investigated, while providing a user-friendly survey format (Safdar et al., 2016). For the
purposes of this study, an anonymous approach was used to lead to more honest responses.
SurveyMonkey allows for a default of “anonymous” as IP address tracking and email address
tracking are disabled. To avoid authentication of one user submitting multiple surveys, the survey
invitation stated, “Each individual’s response is important; therefore, you are asked to complete
only one survey.” All scales and instruments used in this survey were granted permission for use
by their developers (Appendix F). SurveyMonkey’s online platform supported the survey
instrument and included 4 inclusion questions, 14 sociodemographic questions (Appendix G), an
11-item Decisional Self-Efficacy Instrument (Appendix H), 4-item SURE test (Appendix I), 5
statement Control Preference Scale with images (Appendix J), 5-item (six question) FRAIL
Scale (Appendix K) that included two additional questions for a total of 7 questions, and the 9item SDM-Q (Appendix L). Participants were asked if they have decided in stroke prevention. If
the response is “yes,” they were directed to the six-item SWD Instrument (Appendix M), with an
additional question on the outcome of decision. The total survey had a potential for a total of 55
minimum questions to a maximum of 65 questions and optional response, “Describe any factors
that may have influenced your decision that may not have been addressed in the survey.”
SurveyMonkey estimated time to take survey as 12 to 15 minutes, but the participants who
completed the Shared Decision-Making Questionnaire (SDM-Q-9, n = 181) had a mean time
approximately 13 minutes with a mode of 9 minutes 21 seconds. This survey consists of 13
mandatory fields, including these components: four inclusion questions, two demographic
questions pertaining to sex and age (as this was part of the calculation for CHA2DS2-VASc
scoring), all four SURE questions (as the SURE instrument developers indicate that a score
cannot be computed without all questions being answered), two questions on the FRAIL scale
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(which are required to compute the FRAIL score and the CHA2DS2-VASc scores), and one
question on whether a decision has already been made (as branching logic was embedded in this
final questions to complete the Satisfaction with Decision scale; see Figure 3.1).
Data Safety and Management
The researcher assumed responsibility for granting access to committee members’ access
on SurveyMonkey. Access to data was password protected. SurveyMonkey privacy policy states
that all surveys/forms/applications/questionnaires and any responses collected are private by
default (except if the researcher has made them available via a public link). SurveyMonkey
stores and processes content in a manner consistent with industry security standards and has
implemented appropriate technical, organizational, and administrative systems, policies and
procedures designed to ensure the security, integrity, and confidentiality of survey content and to
mitigate the risk of unauthorized access to or use of survey content (Appendix N;
SurveyMonkey, 2019).
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Figure 3.1
Methodology- Afib: Decision-Making Stroke Prevention Study
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Measurements: Instrumentation
According to the ODSF, decisional needs assessment for individuals contemplating a
decision should include an assessment of personal and clinical characteristics and decisional
conflict (Jacobsen et al., 2013). These characteristics were explored in relation to participation in
SDM in individuals with Afib who are contemplating a decision or have decided within three
months in regard to thromboembolic stroke prevention. Care was taken in researching suitable
tools in the literature that could be useful in measuring concepts in SDM. Several tools were
identified, and all tools were given permission by developers. Instrument reliability in this
sample is described in the analysis section for each instrument.
Once individuals decided to participate in the survey by accepting a link and answering
four qualifying questions, they were directed to the survey and were asked to complete sociodemographic and self-reported clinical questions (e.g., type of Afib).
Socio-Demographic and Clinical Questionnaire
Participants’ questions related to Afib include self-reported type of Afib, the duration of
Afib, and the time since decision making (Appendix G). Sociodemographic characteristics in the
questionnaire included gender, ethnicity, race, age, education level, age, relationship status, and
social support during decision making. Included in this section was a question on the distribution
of DAs and an open-ended statement asking: “If you would like to comment: Did your healthcare
provider share with you materials such as an education packet or decisional aid packet or brochures
to assist you in your decision making for stroke prevention?” The purpose of asking these questions
was to see if in real-life practice, individuals are receiving DAs and if there are any additional factors
that may contribute to a developing epistemology of decisional needs in the Afib population.
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Decisional Self-Efficacy Scale
The Decisional Self-Efficacy scale (DSES) assesses a subject’s self-confidence or belief
in one’s ability in decision making (Bunn & O'Connor, 1996). Self-efficacy has been shown to be
an important mediator of health decisions and health behaviors (Anderson, 1995; Bailey et al.,
2016). Low self-efficacy is associated with lack of follow-through on healthy intentions and
decisions as they harbor self-doubts and tend to procrastinate (Schwarzer, 2007).
Self-efficacy was measured using the Decision Self-Efficacy scale, an 11-item scale in
which participants rate their level of confidence in various aspects of the decision- making
process (Bunn & O'Connor, 1996). The Decision Self Efficacy Scale was developed by Annette
O’Connor and based on Bandura’s (1977) concept of self-efficacy. Bandura described selfefficacy as a feeling of adequacy and efficiency in dealing with life situations. According to
O’Connor, this measurement elicits clients’ appraisal of their abilities to engage in the task of
obtaining information about treatment options, expressing their concern and views, and making
an informed choice. This instrument assesses their social role in working with the health team.
O’Connor views self-efficacy as the perceived ability to engage in treatment-related behaviors,
and the instrument was developed to measure self-confidence or beliefs in one’s abilities in
decision making, including SDM (Bunn & O'Connor, 1996). The Self-Efficacy Scale can be used
over time, or before or after an intervention is provided (O'Connor, 2002). While reviewing the
instrument, two items had minor changes and were discussed through personal email with the
original developer (A. O’Connor, personal communication, April 7, 2019) for item #1 and item
#10. The term in item #1 “medications” was changed to “treatment options” because with the
advent of newer technologies, medication is not the only choice for individuals at high risk for
stroke (e.g., CHADS2 score of “2” and/or CHA2DS2-VASc score of “3”), and in item #10,
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“clinic team” was changed to “health care team” because multiple health care providers may
participate in assisting patients making decisions and the U.S. the term “clinic” may be
misconstrued by individuals.
There are two versions of the Decisional Self-Efficacy Scale (DSES), one with five
response categories and one with three response categories (alternative format that has been used
in patients with schizophrenia), and these scales can be converted to a scale ranging from 0 to
100. The scale is comprised of 11 questions. The total score is calculated for the original 5-point
scale, 0 to 4, where raw scores can range from 0 to 44. For simplification, scores can be
converted from a range of 0 to 100 by (a) summing the scores, (b) dividing by 11, and (c)
multiplying by 25. Scores range from 0 (not at all confident) to 100 (very confident). A score of 0
means extremely low self-efficacy and a score of 100 means extremely high self-efficacy. This
scale was developed for patients with schizophrenia and may be appropriate to use with a lower
literacy population (O'Connor, 2002). The DSES is summed to create one global item that
measures the patient’s self-confidence or belief in their ability to obtain relevant decision-making
information, including SDM (Miller et al., 2013). An example would be that a raw score of 27
would be equivalent to 61.4 (27/11 * 25 = 61.4) if using the five-item response scale. These data
provide for continuous data element for statistical analysis. The Decisional Self-Efficacy Scale
has been used in the context of research in individuals with osteoporosis (Cranney et al., 2002),
individuals considering participating in cancer clinical trials (Miller et al., 2013), schizophrenics
(Bunn & O'Connor, 1996), and most recently among diabetics (Bailey et al., 2016). The
Decisional Self-Efficacy Scale has been translated from English into German and Mandarin
Chinese.
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For the purposes of this study, the five-item response was used. Respondents were asked
to reflect on how confident they feel in making an informed choice on a scale ranging from 0 =
not all confident to 4 = very confident (O'Connor, 2002). Face validity for the scale was
established by a panel of experts in decision making. The original scale demonstrated internal
consistency in 60 women considering hormone replacement therapy with an alpha coefficient of
0.89 (Bunn & O'Connor, 1996). In another study, the five-item scale demonstrated an alpha
coefficient of 0.92 and correlated with the “feeling informed” and “supported” subscale on the
Decisional Conflict Scale (r = .47, r = .45, respectively) in a sample of individuals with
osteoporosis who used a DA (O'Connor, 2002). Most recently, the DSES was used in a
randomized control trial of diabetics (n = 225) who were randomized to either DA or usual care;
the findings suggest that the use of DAs was associated with an increase in decisional selfefficacy (p < .0001; Bailey et al., 2016). The tool (available at
https://decisionaid.ohri.ca/docs/develop/Tools/Decision_SelfEfficacy.pdf) is protected by
copyright, easily accessible, and free to use provided appropriate citation (O'Connor, 2002). For
the purposes of this study, Annette O’Connor gave permission for use of the Decision SelfEfficacy Scale. An extensive literature review revealed that this tool has not been used in an Afib
population, and through personal communication, Dr. Annette O’Connor responded: “I am not
aware of its use in cardiac population, but you may wish to do a citation search to confirm this”
(Dr. Annette O’Connor, personal communication, October 29, 2018).
Decisional Conflict Using the SURE test
Decisional conflict refers to a patient’s uncertainty about the course of action to take
when the choices involve risk, loss, regret, or a challenge to personal life values (Légaré et al.,
2010). Uncertainty is more likely when a person is confronted with decisions involving risk or
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uncertainty of outcomes, when high-stakes choices with significant potential gains and losses are
entertained, when there is a need to make value tradeoffs in selecting a course of action, or when
anticipated regret over the positive aspects of rejected options is probable (May et al., 2007).
Clinicians should assess individuals for decisional conflict to reduce the downstream effects of
unresolved decisional conflict (Légaré et al., 2010), which can lead to adverse effects in patients,
such as increased heart rate, muscle tension, restlessness, emotional stress, and decisional regret.
Therefore, the screening for decisional conflict is an important competency in SDM (Ferron
Parayre et al., 2014).
The original 16-item DCS is the “gold-standard tool” to assess decisional conflict and is
the most used outcome measure in decision aid trials. The original DCS measures overall
uncertainty in making a health-related decision and includes subscales that address the factors
that contribute to uncertainty (e.g., feeling uncertain, informed, clear about values, supported in
effective decision making and effective choice; O'Connor, 2010). The original DCS
discriminated significantly between those who had strong intentions for and ultimately acted
upon decision making and those whose intensions were uncertain (O'Connor, 2002). This scale
has demonstrated good test-retest reliability (0.81); internal consistency coefficients range from
0.78 to 0.89, and in a recent study on women with rheumatoid arthritis considering motherhood,
a coefficient of 0.95 was obtained (Meade et al., 2015). Also, youths with cardiac implantable
devices deciding on participating in sports reported a Cronbach’s alpha of .87 (Beery et al.,
2011).
The DCS has been adapted to four versions: one for clinical practice (SURE test) and
three for research purposes. Version A is represented as a 16-item, 5-response scale in a statement
format; version B is 16 items with 5 responses in a question format; version C is a 10-item, 3-
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response category for low-literacy individuals; and the SURE test is a 4-item, 2-response
category test that was developed for use in clinical practice (Légaré et al., 2010). For the
purposes of this study, the 4-item SURE test (Appendix I) was administered to limit cognitive
burden due to length of the survey on participants. The researchers did consider the trade-off of
continuous variables that the 16-item DCS would provide but strongly felt the SURE test was the
best choice because of the conciseness of the survey. Although this test should be performed
before a decision is made, for the purposes of this study, screening was performed for individuals
continuing to contemplate a decision and retrospectively for those who have decided in the last
three months. This comparison allowed for pre- and post-decisional conflict, which allowed an
investigation into a temporal nature of decisional conflict.
The 4-item SURE test is intended to appraise an individual’s readiness to make a decision
as well as his or her comfort with making the decision (Ferron Parayre et al., 2014). The 4-itemSURE was inspired by the 4-item CAGE questionnaire on drinking habits, and one of the
developers (Annette O’Connor) was the original 16-item developer of the DCS. The SURE test
was developed on the concepts of the ODSF, which accounts for all stages of decision making,
such as feeling uncertain, feeling informed, feeling clear about values, and feeling supported in
decision making. This was designed to assist primary care providers in assessing decisional
conflict quickly. The SURE test consists of two responses, 1 = yes and 0 = no, where the
acronym SURE- S (Sure of myself) = Do you feel SURE about the best choice for you? U
(Understand information) = Do you know about the benefits and risks of each option? Riskbenefit ratio = Are clear about which benefits and risks matter to you? And E (encouragement) =
Do you have enough support and advice to make a choice? (Légaré et al., 2010). The total score
of “uncertainty” can only be calculated if all items are answered. Therefore, for the purposes of
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the survey, all four questions on this instrument were noted as mandatory fields. The four items
are summed, and scores range from 0 = extremely high decisional conflict to 4 = no decisional
conflict. A score of </= 3 indicates decisional conflict. The SURE test has been tested in patients
with spinal stenosis, chronic back pain, prostate cancer, and breast cancer. The tool is available in
English and French (O'Connor, 2010).
The SURE test is a self-administered instrument and was initially validated for decisional
conflict in a group of French-speaking women in Quebec considering prenatal screening for
Down Syndrome and in one rural academic medical center (Dartmouth Hitchcock Medical
Center) in English-speaking individuals who were referred to watch condition specific video
decision aids that addressed chronic low back pain, spinal stenosis, prostate cancer treatments,
early stage breast cancer surgery, and breast reconstruction after cancer. In this study, criterion
validity was assessed using Pearson Correlation coefficient with Decisional Conflict Scale
(DCS) in a one hundred-twenty-three French-speaking pregnant cohort and 1474 Englishspeaking patients referred to watch a condition-specific video DA. The researchers hypothesized,
the SURE test scores would correlate negatively with decisional conflict scores because a higher
score on the DCS indicates greater decisional conflict and higher scores on the Sure test indicate
less decisional conflict. Reliability of the SURE was moderate (Cronbach alpha was 0.54 in
French-speaking pregnant women and 0.65 in English-speaking treatment-option patients).
SURE test correlated negatively with the DCS (r = -.46; p < .0001) and discriminated between
those who had made a choice for treatment and those who had not (p < .0001). This study
demonstrated SURE test as having acceptable psychometric properties and suitable for screening
for decisional conflict in patients facing clinical decisions in primary care (Légaré et al., 2010).
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In another study, the SURE test was used in a large heterogeneous group of patients (n =
654) consulting for possible antibiotic treatment for acute respiratory infection. The SURE test
demonstrated adequate psychometric properties, with an internal consistency using the KuderRichardson 20 coefficient (KR-20 coefficient = .070). The Spearman correlation test showed a
moderately strong negative association between DCS and SURE test scores (ρ = - 0.45, p
< .0001). Results from the Kruskal-Wallis rank test demonstrated that DCSs were significantly
associated with SURE test scores (p < .0001). The overall accuracy of SURE was 90.1% (95%
CI: 87.8-92.4), sensitivity was 94.3% a (95% CI: 78.9-99.0), and specificity was 89.9% (95% CI:
87.1-92.0). These authors recommended that the future use of SURE testing for internal
consistency and diagnostic validity to be tested in populations with high prevalence of clinically
significant decisional conflict and in a variety of clinical context (Ferron Parayre et al., 2014). In
a study examining the use of DAs for patients considering an implantable cardioverter
defibrillator, decisional conflict was examined using the 16-item DCS and the SURE test, in
which SURE demonstrated a Cronbach’s alpha of 0.75 and corroborated with the full 16-item
DCS (Carroll et al., 2017).
Control Preference Scale-Role of Participation
Patient preferences for the process of care, such as preferred involvement in decision
making, vary across several socio-cultural factors, including age, marital status, gender,
education, and ethnicity. Regarding the process of care, younger and more educated patients
generally want more active roles in decision making. However, these preferences may also
change, depending on the progression of an illness or given the onset of other conditions.
Therefore, patient preferences for control and decision making are relevant and important
considerations in the medical encounter as they can affect the quality-of-care patients receive and
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can influence subsequent health-related outcomes preferences (Street et al., 2012). Folkman
(1984) was particularly interested in how personal beliefs about control influence the appraisal of
the transactional person-environment choices (Balneaves & Long, 1999).
Control preference construct is defined as “the degree of control an individual wants to
assume when decisions are being made about medical treatment” (Degner et al., 1997). Degner
and colleagues described the degree of control desired by an individual to include three
categories: passive, collaborative, and active. Although mandates and clinical guidelines
recommend a physician-patient dyad in SDM, patients should engage in the SDM process to the
extent they desire, making explicit their values and preferences, and arrive at a consensual
decision with their clinician (Seaburg et al., 2014). The Control Preference Scale (CPS) has been
used extensively in terms of assessing the concept of social role model between patient and
physician in consultation (Kasper et al., 2012).
The CPS is the most frequently used measure of patients’ preferred roles in treatment
decisions. It measures the amount of control the patients want to assume in the process of
making decisions about the treatment of their diseases (De las Cuevas & Peñate, 2016), with
numerous modified versions to include patient preference, patient perceived role, and physician
perception of the role (Janz et al., 2004). The development of CPS was guided by Coomb’s
(1997) unfolding theory based on the premise that an individual’s preference corresponds to an
ideal point on a continuum and that this ideal point can be derived by presenting successive
paired comparisons of stimuli that fall along the continuum (Degner et al., 1997). Degner and
Russell suggested that unfolding theory allows investigators to test directly for the existence of
the dimensions in a given population rather than relying on indirect evidence of dimensionality
such as alpha or factor analysis. Advantages to the use of unfolding theory include patients’
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direct involvement in making choices based on paired comparison; preference order completed
over a series of alternatives (which may be a more sensitive measure of preference other than
first choice alone); and a variety of options, which is superior to the direct questioning of patients
about their preference (Degner & Russell, 1988). CPS has been applied in studies across the
world, including in Sweden, the United Kingdom, Germany, Italy, and Norway (Singh et al.,
2010), in Spain (De las Cuevas & Peñate, 2016), and in China (Zhang et al., 2011). The CPS has
been shown to have good psychometric properties (Singh et al., 2010). Reliability of the CPS
was originally performed in cancer patients. Analysis was based on unfolding theory and
Coombs’s criterion of 50% plus 1 subject falling on the hypothesized dimensions. One would
expect 50% plus 1 of the subjects to have congruent permutations on the CPS (Degner et al.,
1997).
Unfolding theory is a scaling method based on the theory of preferential choice (Davison
et al., 2002). Individual preference orders are “unfolded” to determine whether they are
consistent with the existence of an underlying psychological dimension, providing a direct test of
the hypothesis that participants had systemic preferences about the degree of control in decision
making (Degner et al., 1997). The original CPS involved subjects making paired comparisons to
provide their total preference order over five cards labeled as A, B, C, D, E, representing most to
least preferred involvement, respectively. This procedure has proven very useful in clinical
populations because subjects can locate their ideal point in general terms (active, collaborative,
passive) in their paired comparison (Degner et al., 1997). The unfolding theory indicates that if
an individual chooses order ABCDE, he or she wants the greatest degree of control in decision
making and if EDCBA is chosen, this individual wants the least degree of control. Five cards
generate a possible 120 orders, with only 11 valid preference orders (i.e., ABCDE, BACDE,
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BCADE, BCDAE, CBDAE, CDBAE, CDBEA, CDEBA, DCEBA, DECBA, and EDCBA).
When individuals give inconsistent responses (i.e., AEDBC), their responses should be dropped
from the analysis (Degner et al., 1997) as in a preference order of “AE” or “BD” would be
inconsistent, demonstrating an active-passive decision making. The original scale describes three
methodologies for administration: (1) a comparison of subsets of 2 paired cards in which the
subject makes 10 paired comparisons (i.e., AB, CB, DC, DE, AC, BD, CE, AD, AE and BE) to
develop a rank order; (2) a random-order presentation in which 5 cards are placed in random
order through shuffling, the first 2 cards are presented to subject, the subject selects the preferred
card, and this is continued until a comparison between 5 and 10 paired comparisons can be
made; and (3) a fixed-order presentation in which 5 cards are placed in the fixed order of
BDCEA. Beginning with the first two cards “BD,” the subject chooses the preferred card and
then the next card “C” is compared to the preferred card and continues until all the cards have
been compared in pairs. For the purposes of computer analysis, the data can be used as string
variables based on an individual’s preference order on a hypothetical metric, and ordinal
variables are created to represent their location on the metric, with a range from 1 to 11. Degner
also described the use of CPS as five categorical data such as Active (A, B), Collaborative (C),
and Passive (D, E), or categorical based on the two most preferred roles: Active-Active (AB or
BA), Active-Collaborative (BC), Collaborative-Active (CB), Collaborative-Passive (CD),
Passive-Collaborative (DC), and Passive-Passive (DE, ED). A “pick one” approach and “fixed
order” presentation of two comparisons by computers have been used as a clinical assessment
tool (Degner et al., 1997). Lechner et al. (2016) treated the CPS as an ordinal variable with five
categories describing an ordered list of preferences in decision making, ranging from completely
active to completely passive. Then they categorized the five CPS cards into three groups as
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“active,” “passive,” and “collaborative” roles, according to the first card picked (Lechner et al.,
2016; Table 3.1). While the original tool had only five statements, images were added as a result
of researcher feedback (Degner & Russell, 1988). The images have been updated and used in an
electronic format (Solari et al., 2013) and permission was granted for electronic figure use in this
study by Alessandra Solari (personal communication, December 6, 2018).
Table 3.1
Control Preference Categorical Variables Source. Adapted from Degner & Sloan, 1992
Control Preference Role
A. Active Role

•

B. Active Role

•

C. Collaborative

•

D. Passive

•

E. Passive

•

Narrative
I prefer to make the final selection about which treatment I
will receive
I prefer to make the final decision about my treatment after
seriously considering my doctor’s opinion
I prefer that my doctor and I share responsibility for
deciding which treatment is best for me.
I prefer that my doctor makes the final decision about which
treatment will be used but seriously considers my opinion.
I prefer to leave all decisions regarding treatment to my
doctor.

The CPS has proven to be a clinically relevant, easily administered, valid, and reliable
measure of preferred roles in health care decision making (Degner et al., 1997). It has been used
as ordinal or categorical data. Original developers described the data as ordinal data that can then
be used as five (A, B, C, D, or E) or three categorical data (Active, Collaborative/Shared or
Passive). CPS can provide ordinal data based on an individual’s selection (Degner & Russell,
1988), where valid permutations for the ABCDE Scale range from 1 to 11 (Degner et al., 1997;
Table 3.2).
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Table 3.2
Valid Permutations of Control Preference Scale. Source: Adapted from Degner et al., 1997
CPS Ordinal
Scale
1
2
3
4
5
6
7
8
9
10
11

Permutation
ABCDE
BACDE
BCADE
BCDAE
CBDAE
CDBAE
CDBEA
CDEBA
DCEBA
DECBA
EDCBA

Although Degner et al. (1997) stated the scale is “easy” to administer, these concepts are
abstract, so the researchers who utilized the CPS were contacted for clarification of
administration methodology, as this was unclear in the research papers and did not appear to
follow the prescribed methods. For the purposes of this study, the principal investigator reached
out to two previous researchers for the justification of their methodology for administering the
CPS. The comments were as follows: “We use it (the CPS) modified. We don’t use the images just too hard. Most trials in the Cochrane review of patient decision aids don’t use the pictures.”
(Dr. Daniel Matlock, UC Denver, personal communication, March 14, 2019) and “We used the
version (Control Preference Scale) adapted to a survey but not images and asked questions of
approximately 10,000 patients or family proxies in a telephone survey, and they did not have
difficulty with the items.” (Dr. Nancy Keating of Harvard, personal communication, March 22,
2019)
The modified versions described above, by Dr. Keating (2019) are noted in Figure 3.2.
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Figure 3.2
Modified version of Control Preference Scale “pick-one” methodology
Source. Email communication with Dr. Nancy Keating, 2019

The instrument is viewed extensively in the literature and has been used for patients
seeking treatment options in breast cancer (Degner, 1997; Janz et al., 2004), psychiatry (De las
Cuevas & Peñate, 2016), prostate cancer (Davison et al., 2002), lung and colorectal cancer (Kehl
et al., 2015), and anxiety and depression related to the type of decision making (Anderson et al.,
2009), Hepatitis C (Zhang et al., 2011), and multiple sclerosis (Giordano et al., 2008). The scale
has been translated into Italian (Giordano et al., 2008), German, and Spanish, and has been
administered with varying alternative methods such as by a multiple-choice questionnaire and
through a telephone interview without images (Kasper et al., 2012). Solari et al. (2013)
developed an electronic self-administered version with updated images of the CPS to standardize
test presentation and eliminate the need for an interviewer and data entry. Validity testing was
performed in a German and Italian population. The reliability of this electronic version in
relation to the face-to-face CPS was moderate; observed agreement was 85% wK0.53 (95% CI,
0.40-0.65; p < .001) and was consistent with findings in Italy (90% wK0.65 [95% CI, 0.450.81]; p < .001). Contrary to Degner et al. (1997), these researchers allowed participants one
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additional chance to complete if an inconsistent pattern such as active-passive or passive-active
(i.e.,- AE, DB) was initially performed (Solari et al., 2013).
Administration methods have shifted over time from the original card-sorting method to a
“pick one option” method and from analytic groupings of the original five response options into
three categories consistent with Charles’s model of decision-making styles: active, passive, and
shared (Henrikson et al., 2011). Giordano and colleagues (2008) adopted the simultaneous
administration method in which the examiner asks the subject to choose the preferred card,
which is then covered up. The participant is then asked to choose the preferred card from the four
remaining cards until one card is left. If the second preference is incongruent with the first, the
test is stopped and explained again and immediately re-administered. In the event of no further
congruence, the test is not restarted. Six scores are possible based on the person’s two most
preferred roles: active-active (AB or BA), active-collaborative (AC or BC), collaborative-active
(CA or CB), collaborative-passive (CD or CE), passive-collaborative (DC or EC), and passivepassive (DE or ED). This method and Italian translation of the instrument in a multiple sclerosis
sample demonstrated a test-retest weighted Kappa 0.65, p < .001 (Giordano et al., 2008). This
methodology has been used again in multiple sclerosis (Solari et al., 2013), chronic hepatitis
(Zhang et al., 2011), and in a sample of outpatients psychiatric patients (De las Cuevas & Peñate,
2016).
Rodriguez et al. (2008) used a telephone assessment of the CPS with veterans who had
heart failure. The telephone survey consisted of asking each question and then selecting the
statement closest to their preferred role in decision making, with high scores indicating a
preference to assume a more passive role. In this study, control preferences exhibited an
independent effect on perceived involvement in medical decision making (β = -.306, p = .003).
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Findings suggested that patients’ preferred role in treatment decisions may be a stronger,
independent predictor of patients perceived decision-making involvement. Implications of this
study are important for medical providers to provide patient-centered care by communicating
effectively with each patient to determine the role that the patient wants to play in medical
decision making (Rodriguez et al., 2008). Zhang and colleagues (2011) translated the CPS into
Chinese and investigated control references in chronic hepatitis using Giordano’s modified
version, whereas Janz and colleagues (2004) used the CPS using five parallel statements in place
of images, incorporating patient preference, patient perception, and physician perception of
control in decisions.
De las Cuevas and Penate (2016) established the validity of the Spanish-translated CPS in
a psychiatric outpatient sample (n = 621) in Spain. The scale showed a moderate level of internal
consistency and an appreciable level of convergent validity. Cronbach’s alpha of 0.72 was
attained, pointing out a moderate internal consistency, and construct validity was performed by
five independent primary care physicians, psychiatrists, and psychologists who rated the degree
that each item of the instrument covered for content. Older patients and those undergoing long
treatments preferred a passive role, while patients with higher levels of education preferred a
collaborative role. Findings demonstrated that the most common preferred role was the
collaborative-passive role (64.9%), in which the doctor and patient share responsibility for
deciding which treatment is best, with the doctor making the final decision after considering the
patient’s opinion. The second preferred alternative was passive-passive (24.2%), followed by
passive-collaborative and active-collaborative (24.2%). Reliability was assessed through the four
card choices as they were transformed into four items (De las Cuevas & Peñate, 2016).
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Kehl and colleagues (2015) examined overall preferred roles in decision making in a
sample of 5,315 individuals considering cancer treatment (e.g., surgery, radiation, and
chemotherapy), using the 5-item CPS comparing the preferred and actual role taken. Results
demonstrated 58% preferred shared roles in decision making (p < .001) and 44% participated in
shared decision (p < .001). In adjusted analyses examining preferred and actual roles in
decisions, the interaction of preferred and actual role was not statistically significant (p = .29).
Preferred role was not associated with a patient’s perceived quality of care, but patient reports of
treatment decisions controlled by a physician (vs. shared) were associated with lower odds of
excellent patient-reported quality (p < .001). These findings suggest SDM was associated with
higher perceived quality, even for patients preferring a less active roles in medical decision
making (Kehl et al., 2015).
Bansal and colleagues (2018) used a comparison table viewed by both the patient and the
physician in a dialysis sample (n = 21). On the left side of the column, patients were asked to
choose from one of five original statements on the CPS that was modified to include “dialysis”
as their best answer. On the right side of the survey, physicians were asked to choose the best
answer that would correspond to their perception of how the patient made the final decision.
These responses were then evaluated for concordance, which demonstrated that out of 21 paired
responses (patient or surrogate/physician), only 9 (43%) were concordant because the provider
chose the same item from 5 choices (Bansal et al., 2018). This finding may suggest a discordance
in how health care providers view patient’s perception of their involvement in decision making,
which may impact patient-centered care and outcomes.
Henry’s (2015) pilot study examining older adults with cognitive impairment (n = 37)
utilized the modified CPS to determine if the scale captured nuances of decision preferences in
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ranges of cognitive function. Although the administration methodology was not described, in this
small sample (n = 37), reliability demonstrated α = .764. Convergent validity was supported by
comparison of results to a study that excluded participants with cognitive impairment, and by
analysis of within-subject responses to related modified CPS questions, where 70% were fully
aligned, 28% were misaligned but recognizable, and 2% were fully discrepant. Correlations
between related items was not significant (p = .71), which perhaps reflects the small sample size
(n = 37). However, qualitative descriptive analysis demonstrated that participants’ narrative
descriptions of their preferences were highly aligned with their modified CPS responses (Henry,
2015).
For the purposes of this study, the card-sorting version of the scale was used, consistent
with Giordano et al.’s (2008) methodology. However, since this measure is categorical, a
modified version using five cards was used, and participant were asked to select their preferred
card (method of decision making) and then to choose from the remaining four cards. There was
no additional pairing after the two-card selection was chosen because the first two choices
determine preference. This is inconsistent with Giordano’s method in which the subject continues
until one card remains. However, this method is chosen for the purpose of practicality on survey
length and the first two choices will ultimately determine the preference if valid or invalid
permutations exist. Consistent with Giordano et al.’s method (2008), if incongruent (nonadjacent pairing) cards were selected (e.g., AE), this process was repeated one time (where
branching logic was embedded in the survey). If the second attempt produced incongruent
permutation, participants were given one more chance at five statement to choose from,
producing only one letter (e.g., A, B, C, D, E). Consistent with the unfolding theory of
consecutive choices, six scores are possible based on the subject’s two most preferred roles:
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active-active (AB-BA), active-collaborative (BC), collaborative-active (CB), collaborativepassive (CD), passive-collaborative (DC), and passive-passive (DE-ED). These scores were then
collapsed into three categories as active (active-active or collaborative-active), collaborative
(collaborative-active or collaborative-passive), or passive (passive-collaborative or passivepassive). The updated images have been approved for use by Dr. A. Solari to be used in this
study (Afib: DMSP).
Figure 3.3.
Control Preference Statement and Images. Source. Solari et al., 2013 (permission for use granted
by Dr. A. Solari, personal communication, December 6, 2018).
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FRAIL Scale
The importance of frailty has been acknowledged by the American Heart Association,
which has called for a better understanding of frailty in cardiac care. Rowe and colleagues (2014)
described how there is a need for clinicians to include frailty assessment in decision making for
clinicians, as this may assist in risk stratification to distinguish older patients who may benefit
from intervention from those who would gain little benefit or may even be harmed by aggressive
interventions (Rowe et al., 2014). Frailty is operationally defined using the FRAIL Scale
developed by the International Association of Nutrition and Aging. Two of the most commonly
used tools to screen for frailty include frailty phenotype by Fried and colleagues (the
Cardiovascular Health Study Index [CHS]) and the Frailty Index by Mitnitski and colleagues.
However, these scales may not be practical in clinical or large epidemiological settings, as
trained staff or clinical databases may be required. Therefore, alternative assessments have been
recommended to a broader clinical context (Aprahamian et al., 2017). Recently, the International
Association of Nutrition and Aging proposed the FRAIL scale, which is similar to the Fried
model and requires answers to only five simple questions on fatigue, resistance, ambulation,
illness, and loss of weight (all self-reported; Tse et al., 2017). FRAIL can predict adverse health
outcomes, such as mortality, physical impairment, and dependence in daily activities
(Aprahamian et al., 2017). For the purpose of this study, the FRAIL scale was used because this
has been validated for self-administration.
FRAIL (Appendix K) contains four questions directed at components of the CHS 7- item
scale and one from the Rockwood scale. The FRAIL scale is a simple questionnaire that can be
rapidly administered by health care providers or self-administered. This questionnaire does not
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require face-to-face interaction but can be administered by telephone or by self-administration,
which makes repeated administration to large groups of patients feasible. The FRAIL scale
includes five components: Fatigue, Resistance, Ambulation, Illness, and Loss of weight. Frail
scale scores range from 0 to 5 (0 = best to 5 = worst), where scores represent frail (3-5), pre-frail
(1-2), and (0) robust health status. The original scale was validated in a sample of African
American men (n = 998) between the ages of 49 and 65. These men were part of a longitudinal
study, the African American Health project, where data were collected over nine years. In the
first phase (Wave 1), participants were visited in their home where interviews and physical
performance measures were taken. Comparative items included basic activity of daily living
(ADL; bathing, dressing, eating, transferring to bed or chair, walking across a room, getting
outside, and using the toilet), and independent activities of daily living (IADL; preparing meals,
shopping for groceries, managing money, making phone calls, doing light housework, doing
heavy housework, getting to places outside walking distance, and managing medications).
Physical performance was measured using the Short Physical Performance Battery (SPPB) for
lower body performance, isometric grip strength, gait speed, history of falls, one leg stand
measure, and falls efficacy. The FRAIL scale showed strong convergent and predictive validity
in this sample of middle-aged African Americans. The analysis demonstrated significant
correlations in individuals with no ADL dependence (n = 883), IADLs (pre-frail: p < .001, frail:
p < .001), SPPB (pre-frail: p < .001, frail: p < .001), gait speed (pre-frail: p =.003, frail: p =
.002), grip strength (pre-frail: p < .001, frail: p = .005), and one-leg stand (pre-frail: p < .001,
frail: p <.001), all of which are classically associated with frailty. At the nine-year follow-up in
the sample with no reported ADL dependence (n = 528), FRAIL predicted mortality (pre-frail: p
= 0.27, frail: p = <.001), and an increase in the disability level for ADL disability (pre-frail: p =
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.012, frail: p < .001) and IADL disability (pre-frail: p = 0.29, frail: p = .006). The authors
suggested FRAIL as a valid tool and an excellent screening test for clinicians identifying an
individual developing a disability (Morley et al., 2012).
The FRAIL scale questionnaire has been used by researchers at Vanderbilt University in
a secondary analysis and has predicted functional status (p = .001) and mortality at one year (p =
.001) in a sample of geriatric trauma patients (n = 188). After controlling for age, comorbidities,
injury severity, and cognitive status, findings demonstrated that pre-injury FRAIL scores
explained about 13% of the variability in physical function as measured by the Barthel Index (p
< .001). Bedside nurses at Vanderbilt are currently using FRAIL in the trauma unit to screen
patients 65 years and older (Maxwell et al., 2018).
The Australian Longitudinal Study on women’s health longitudinal study followed three
female cohorts related to health and well-being. In this study (n = 12,432), the FRAIL scale was
compared with the 36-item Short Form Health Survey (SF-36) instrument and self-reported
chronic conditions along with weight. Disability was compared with the Katz Index of
independence on activities of daily living and the Lawton IADL scale. In this study, FRAIL was
used as a 6-point measure of continuous data where 0 is designated as not frail and 5 as most
frail. FRAIL-6 item demonstrated stronger associations between disability and activity of daily
living and instrument activity of daily living. Face validity was assessed by examining FRAIL
scores at different participants’ ages; as individuals aged, so did their frailty scores. Construct
validity in a sample of participants (n = 5,104) was assessed by examining the correlation for the
FRAIL scale with the scores for ADLs and IADLs. FRAIL-6 item, and disability scores
correlated with ADLs (Spearman rank correlation 0.48) and IADLs (Spearman rank correlation
0.52-0.58). The Six-item FRAIL scale as compared to FRAIL 2 and FRAIL 3 was responsive to
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changes in self-rated health. FRAIL was originally designed using three categories, and this
study suggested the utility in using the scale as a 6-point scale because it demonstrated a stronger
relationship with disability (Gardiner et al., 2015).
In this study (Afib: DMSP) scores designated as: 3-5 = frail, 1-2 = pre-frail, and 0 =
robust health status. Within the survey instrument, two additional items were added but were not
quantified for FRAIL scoring (i.e., type of stroke and history of vascular disease such as
peripheral arterial disease, history of coronary artery bypass surgery, or a stent placed in an
artery). The rationale for the addition was to calculate the CHA2DS2-VASc scores, where data
would be aggregated from the FRAIL along with gender, age, and type of stroke, which can then
calculate the CHA2DS2-VASc score to identify annual stroke risk. Although weight was
categorized as question number 5, for the purposes of the survey and calculations, a sixth item
was part of the FRAIL scale, which is logical if a calculation is expected.
FRAIL Scale Items
1) How much of the time during the past 4 weeks did you feel tired?
•

1 = All of the time, 2 = Most of the time, 3 = some of the time, 4 = a little of
the time, 5 = None of the time

•

Responses of 1 or 2 scored as 1; all others are 0

2) By yourself and not using aids, do you have any difficulty walking up 10 steps
without resting?
•

1 = Yes, 0 = No

3) By yourself and not using aids, do you have difficulty walking several hundred yards?
•

1 = Yes, 0 = No

4) Did a doctor ever tell you that you have the following conditions?
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•

Hypertension, diabetes, cancer (other than a minor skin cancer), chronic lung
disease, heart attack, congestive heart failure, angina, asthma, arthritis, stroke,
and kidney disease.
i. Additional items not included on the original score were used to
calculate the CHA2DS2-VASc score and were not summed into final
score for the purposes of FRAIL. For the purposes of the survey, these
items are consistent with the questions asked and include:
1. Do you have a history of vascular disease such as narrowing of
the arteries in the heart, legs, or arms, or have had coronary
bypass surgery or a stent placed in the body?
2. Type of stroke with options; bleeding stroke, clot type stroke
(e.g., blood clot, plaque) and “I am unsure.”

•

Scoring for total illness (0-11) are recoded as; ‘0’ for score of 0-4, and ‘1’ for
scores of 5 through 11.

5) Weight
•

How much do you weigh with your clothes on but without shoes (current
weight)? (Open box for response of actual weight)

•

One year ago, how much did you weigh with your clothes on but without
shoes? (Open box for response of actual weight)

•

Scores as percentage of weight change; this is not asked but calculated from
prior responses
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i. [(weight 1 year ago - current weight) / weight 1 year ago)] * 100.
Percentage weight changed > 5% weight (representing a 5% weight
loss) is scored as 1 and <5% is scored as 0
SDM
SDM has been shown to improve patient treatment compliance, knowledge, and
satisfaction; activation of and increasing involvement in decision making; fewer psychiatric
symptoms; and an overall trend toward a decline in hospitalizations (De las Cuevas et al., 2013).
SDM is less prominent among invasive interventions. Further research should describe the
reasons for the limited use of shared decisions among conditions with invasive interventions
along with its consequences for healthcare quality (Maldonato et al., 2017). Since mandated and
clinical practice guidelines have incorporated SDM methodologies in the Afib population, it is
imperative that health care organizations assess for SDM from the patient’s perspective.
The original 26-item German SDM-Q (shared decision-making questionnaire) was built
on Elwyn’s model of competencies for involving patients in decisions. With refinement, the
revised SDM-Q-9 instrument represents the first psychometrically sound self-assessment tool
measuring the SDM process. The SDM-Q-9 was developed in a theory-driven manner and
measures the extent to which patients are involved in the process of decision making from the
perspective of the patients. Over the past years, the SDM-Q-9 has become a frequently used
instrument to measure SDM in clinical practice and has been translated into several languages,
including English, Spanish, French, Italian, Chinese, Japanese, Korean, Persian, Hebrew, and
Dutch (Rodenburg-Vandenbussche et al., 2015). The Spanish version of the scale showed a high
level of internal consistency in individuals with emotional disorders (Cronbach’s α = .89; De las
Cuevas et al., 2015; De las Cuevas & Peñate, 2016).

138
Development of the SDM instrument was a result of a study in which 2,351 participants
were asked to think about their last medical consultation and to use this consultation as a
reference for the rating. A multi-step, classical test theory guided the analysis. The core
instrument consists of nine statements that are rated on a 6-point scale from 0 = completely
disagree to 5 = completely agree. The group was split in two for cross-validation (development
scale included 1,188 persons and the test sample included 1,163). Face validity was performed
by two independent raters who were not members of the original developers. Items were rated as
optimal, fair, or poor. Only those items considered optimal were considered in the analysis. By
factor analysis using varimax rotation, this instrument was determined to be unidimensional with
a Cronbach’s alpha of .980 in the development group, .938 in the test sample, and .933 with a
corrected item-total correlation of 0.686-0.808 in the cardiovascular group of 153 participants
(Kriston et al., 2009).
The 9-item SDM Questionnaire has two versions: one assesses the perspective of a
patient (SDM-Q-9) and another that assesses the perspective of a health care provider (SDM-QDoc). Both versions have demonstrated acceptable reliability and have factorial validity (Kriston
et al., 2009; Sepucha & Scholl, 2014). The patient version (SDM-Q-9) is a valid, reliable, and
brief self-report questionnaire that assesses the patient’s view of the decision-making process.
SDMQ-9 consists of each step describing one step of the SDM process as demonstrated in Figure
3.2 (De las Cuevas et al., 2013).
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Table 3.3
SDM Q-9 and Steps in Shared Decision-making Process. Source. Adapted from De las Cuevas et
al., 2013
SDM-Q-9 Items Questions
1) My doctor made clear that a decision needs
to be made
2) My doctor wanted to know exactly how I
want to be involved in making the decision

Steps in the SDM process
1) Disclosure that a decision needs to be made

3) My doctor told me there are different
options for treating my medical condition

3) Equipoise statement

2) Formulation of equality of partners

4) My doctor precisely explained the
4) Information for patients of the benefits and
advantages and disadvantages of the treatment risks of the options
options
5) My doctor helped me understand all the
information

5) Investigation of the patient’s understanding
and expectations

6) My doctor asked me which treatment
option I prefer

6) Identification of preferences

7) My doctor and I thoroughly weighed the
7) Negotiation
different treatment options
8) My doctor and I selected a treatment option 8) Shared decision
together
9) My doctor and I reached an agreement on
how to proceed

9) Arrangement of follow-up

The SDM-Q-9 has been validated in sample of patients with multiple sclerosis who were
clinically stable and had low disabilities (n = 221). To assess psychometrics, Items Response
Theory analysis was used, and to assess the unidimensionality, confirmatory factor analysis was
used, which demonstrated Cronbach’s α = .91, and the Mokken reliability of 0.92 and
unidimensionality. These findings are consistent with other studies demonstrating Cronbach’s α

140
of .88 to .94. Unidimensionality was assessed by confirmatory factor analysis (Ballesteros et al.,
2017).
Glass and colleagues (2012) investigated the relationship between SDM (using the
SDMQ-9 questionnaire) and SWD (using the SWD Scale) from a health research volunteer
registry (n = 488) that had completed an online survey with reference to a recent health
consultation (within the past three months). The results demonstrated that only three of the nine
items were significantly associated with SWD, with patients weighing some aspects as more
desirable and more valued than other aspects. Others, such as Item #5 “My doctor helped me to
understand information” (p = .001), Item #6 “patient preference of treatment option” (p = .036),
and Item #7 “weighing different options together” (p = .041) had a significant association with
SDM. While item #1 “My doctor made clear that a decision needs to be made” (p = .787), Item
#4 “My doctor precisely explained the advantages and disadvantages of the treatment options” (p
= .975), Item #8 “selecting a treatment option together” (p = .591), and Item #9 “reaching an
agreement” (p = .103) did not show a relationship with SWD (Glass et al., 2012) .
Alvarez and colleagues (2016) evaluated the psychometric properties of the SDM-Q-9 in
a sample of 239 English- and Spanish-speaking behavioral health patients to assess applicability
cross-culturally. In both groups, the SDM-Q-9 tool had a high internal consistency when Item #1
was removed. The psychometric analysis focused on the question of whether there are
measurement invariances across English and Spanish samples. If measurement invariance is
established, differences in scores between two groups (English/Spanish) can be interpreted as
reflecting actual differences in the construct being measured, rather than reflecting bias due to
language, cultural, and other group differences. The SDM-Q-9 was measured for invariance with
the Kim Alliance Scale-Communication subscale, which measures therapeutic alliance between
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the patient and provider from the patient’s perspective. This communication scale is intended to
measure both instrumental and affective attributes of the patient-provider encounter such as
bonding/rapport, provision of information, and expressions of concerns. Confirmatory factor
analysis was used to systematically assess configural invariances, metric invariance and strong
invariances, and strict invariances. Exploratory factor analysis was tested for invariance levels,
which revealed that the first item (“My provider made it clear that a decision needed to be
made”) was unrelated to the general SDM dimension in the Spanish sample. Factor loading for
eight item scale (with removal of Item #1) were 0.52 to 0.88 in the total sample (n = 239), 0.51
to .87 for English-speaking participants (n = 160) and 0.48 to 0.89 for Spanish-speaking
participants (n = 79) for one factor. To assess cross-cultural consistency, Item #1 was removed
and demonstrated Cronbach’s α of .89, .88, and .90 (total sample n = 239; English n = 160 and
Spanish n = 79, respectively; Alvarez et al., 2016). This Item #1 discrepancy had been
previously reported in a Spanish sample (De las Cuevas et al., 2015). Confirmatory factor
analysis revealed 0.815 configural invariance testing, 0.842 metric invariance testing, 0.841
strong invariances testing, and 0.821 strict invariance testing. These findings suggest that Item #1
on the SDM-Q-9 scale did not have a significant loading for Spanish-speaking patients and that
an eighth-item version of the SDM-Q demonstrated better fit across cross-cultural performance
(Alvarez et al., 2016).
Although a rigorously validated tool, the SDM-Q-9 has been critiqued by De las Cuevas
et al. (2013) in that a single-factor solution may confound and mask the complex process of
SDM and the independent role of each of the nine theoretical steps. Regression analysis revealed
that the type of medical care (psychiatric care or primary care) may be the best predictor of the
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different steps in SDM; for example, sociodemographic variables and clinical context variables
play a different role according to each theoretical step (De las Cuevas et al., 2013).
When calculating the SDM-Q-9, each statement is scored by means of scoring nine items
on a 6-point Likert-type scale, ranging from 0 (completely disagree) to 5 (completely agree).
Summing up all items leads to a raw total score between 0 and 45, where 0 is the lowest possible
level of SDM and 45 indicates the highest extent of SDM (De las Cuevas et al., 2015).
Developers recommend that no score should be calculated if more than two items are missing
(Kriston et al., 2009). For the purposes of this study, missing data are handled through pairwise
exclusion where there are no final summed number and are therefore excluded from the analysis.
The developers encourage transformation of the score by multiplying of the raw score by 20/9,
which provides a score range from 0 to 100, where 0 indicates the lowest possible measure of
SDM and 100 indicates the highest extent of SDM (Kriston et al., 2009). Although not
compulsory, the developers recommend starting the questionnaire with two or more open
questions exploring the decisional context such as “Please indicate which health
complaint/problem/illness the consultation was about” and “Please indicate which decision was
made” (Kriston et al., 2009). For the purposes of this study, “problem” is known as the
consideration of stroke prevention related to Afib.
The survey also contains a self-reported sliding scale asking the question, “On a scale of
0-100, how would you rate your participation in decision making with your health care provider
regarding stroke prevention in atrial fibrillation.” This value was correlated with the SDM-Q-9.
The participant was then asked, “Have you made a final decision at this point in time in regard to
treatment for stroke prevention related to your atrial fibrillation?” If it was a “yes” response, the
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survey logic took the participant to the SWD Instrument. If it was a “no” response, the survey
ended, and participants were thanked for their participation.
Satisfaction with Medical Decision
The SWD was developed to measure global satisfaction and attributes of effective
decisions, differentiate satisfaction with the decision from related aspects of satisfaction, and to
be short and easy to use. The scale was validated by a comparison of other tools, where the
investigators hypothesized the SWD to be independent of scores of satisfactions with provider
and desire to participate and be negatively correlated with decision conflict, and positively
correlated with decision confidence. The SWD was designed not to assume a good health
outcome but to measure satisfaction with a health care decision. The SWD is a unique measure
of satisfaction with a decision and predicts a level of certainty that an individual will carry out
the decision(Holmes-Rovner et al., 1996).
The six-item SWD measures satisfaction with a health care decision. One should not
expect that all decisions assume ‘good health’ as an outcome. As it is possible that death may be
an individual’s choice for the “best” outcome. The scale was initially developed to evaluate a
decision-support intervention to assist women in decision making about hormone replacement
therapy. A pilot study had been conducted at the University of Michigan to assess reliability and
included 11 items of the SWD tool with a convenience sample (n = 120), including volunteer
students and faculty. Prior to the pilot study, discriminant validity was tested as items were
pooled from the SWD scale, and 16 item Decisional Conflict that uses the same conceptual
model of decision making. The Health Status Restriction (SF-36) measure was included to test
the hypothesis that satisfaction with the decision was confounded by perceived inability to
decide for health status reasons. Items from all three scales were subjected to principal
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components analysis to determine the uniqueness of the SWD scale relative to the DCS and
Health Status Restriction. The findings of the pilot study supported dropping five items from the
original scale, leading to the six-item scale demonstrating a Cronbach α = .88 (Holmes-Rovner et
al., 1996). In another study, a sample of volunteer women (n = 252) 40 years or older were
recruited who were seeking more information on hormone replacement therapy. Participants
were asked to complete the SWD scale, Decisional Conflict scale, Health Status Restriction
scale, Desire to Participate scale, Confidence in Decision scale, Knowledge of Menopause scale
and Perceived Knowledge scale. SWD obtained a Cronbach’s α of .86. As anticipated, the SWD
scale correlated moderately with DCS (-0.54) and positively with the Confidence in Decision
scale (0.64). Additionally, the SWD corresponded with Perceived Knowledge of Menopause
scale (0.48) yet corresponded weakly with Knowledge of Menopause scale (0.21). This finding
suggests that SWD may not be based on factual knowledge. Three scales were then included in
the principal component analysis (Decisional Conflict, Health Status Restriction Decision scale,
and SWD), which demonstrated conceptually discriminable constructs. In the prediction,
decision model participants who decided to accept the hormone replacement therapy (n = 63)
were asked to complete a daily compliance calendar regarding hormone replacement therapy.
SWD and decision certainty scores were significantly correlated (r = .27, p < .05) at 12 months.
A key finding in this study examined adherence to hormone replacement therapy and decisional
certainty. Women who were found to be less adherent to the therapy displayed responses
distributed across all levels of certainty, especially across responses such as “probably, or
maybe” (adherent to therapy). This suggests that individuals must be very certain and very
satisfied with their decisions to actually follow them because these findings may infer that the
SWD may be a surrogate for adherence to medical decisions (Holmes-Rovner et al., 1996).
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The SWD has been used by O’Connor (1994) in a study of elderly patients considering
immunization. The sample included health science students (n = 151), health employees and
visiting nurses (n = 115), and patients with cardiac or respiratory disorders (n = 283). The
reliability of the SWD scale was α = .85. Among the patient group, the SWD discriminated
between those who described themselves as being “sure” about their decision and those who
were “less sure” about their decision (Holmes-Rovner et al., 1996).
In a sample of health research volunteers with reference to a health care consultation
within a previous three-month period, SDM using the SDM-Q-9 was associated with SWD
(adjusted R2 = .368, p < .001) after controlling for sociodemographic variables (Glass et al.,
2012). The SWD scale is currently being used in a mixed-method study in Australia in
individuals with advanced or metastatic cancer surrounding decisions regarding tumor genomic
profiling and aims to examine patients’ psychosocial, cognitive, affective, and behavioral
responses to tumor genomic profiling along with measuring satisfaction with the decision to
undergo the profiling (Best et al., 2018).
The SWD is a six-item instrument in which individuals rate the extent to which each
statement is true at a point in time, using a 1-5-point Likert-type scale where 1 = strongly
disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = strongly agree, where
an increase in score indicates more satisfaction with the decision (Holmes-Rovner et al., 1996).
Scores range from 6 (strongly disagree) to 30 (strongly agree) in satisfaction with decision,
providing a continuous variable. Although there is no established cutoff for the SWD total score,
Hitz and colleagues (2013) used a pragmatic approach by considering the average of four points
over the six questions as a reasonable cutoff. In a previous study of patients seeking a new line of
palliative treatment, scores were dichotomized as scores of 24 or above were considered as high,
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and scores below 24 as low satisfaction with their decision (Hitz et al., 2013). In a univariate
analysis, several self-reported variables and disease characteristics were significantly associated
with SWD; quality of life ( p < .01), subjective health status (p < .01), consultation time (p
= .02), internal health locus of control (p < .01), treatment burden (p < .01), and physical wellbeing (p < .01; Hitz et al., 2013).
For the purposes of this study, the SWD scale was obtained as continuous, where higher
scores indicate greater satisfaction (Best et al., 2018). Additionally, data were collapsed for
categorical comparisons and regression as noted by Hitz and colleagues (2013), where a value
below 24 was considered low satisfaction and values greater than or equal to 24 was be
considered high satisfaction with treatment decision.
SWD Instrument
As an introduction participant are asked: “You have been considering or have decided
about stroke prevention regarding your atrial fibrillation. Answer the following questions about
your decision or anticipated decision. Please indicate to what extent each statement is true for
you “AT THIS TIME.” Participants are asked to use the following scale to answer the questions
which are scored as; 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 =
agree, 5 = strongly agree. Six questions include:1) I am satisfied that I am adequately informed
about the issues important to my decision, 2) The decision I made was the best decision possible
for me personally, 3) I am satisfied that my decision was consistent with my personal values, 4) I
expect to successfully carry out (or continue to carry out) the decision I made, 5) I am satisfied
that this was my decision to make and 6) I am satisfied with my decision. After the SWD
Instrument was completed, participants were asked to answer one question related to their
decision: “After making this decision on stroke prevention, did you have an event requiring a
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visit to a health care provider, emergency room or hospital related to your choice of decision?”
This was asked, as it may have influenced their SWD responses.
Data Analysis
Data collection started on December 2, 2019 and ended on February 10, 2020. Data were
exported into IBM SPSS Statistical package 25.0 for analysis, as Survey Monkey has this feature
of direct export. All questionnaires were reviewed for completeness. Missing data were handled
as a pairwise deletion (explaining variations in sample numbers for various analysis), a feature
available on SPSS (version 25).
Cronbach’s alpha coefficient was calculated for the 11-item DSES (n = 201), 9-item
Shared Decision-Making Instrument (n = 181), and SWD Instrument (n = 133). The SpearmanBrown Split-Half reliability statistic was reported for scales with dichotomous responses: SURE
test (n = 201), CPS (n = 192), and the first three items on the FRAIL scale (n = 186). To test for
reliability, the final score on the CPS is a combination of two responses, so item letters (A, B, C,
D, E) were converted to numbers corresponding to letters (A = 1, B = 2, C = 3, D = 4, and E = 5).
Individuals who attempted the CPS twice and then defaulted to the narrative option were coded
as a repeated item. For example, if in the narrative statement a participant chose A, this was
coded as AA. This is plausible as either an A or AA, which directs an individual into an Active
Category. The FRAIL Scale (n = 185) is a clinical estimate of frailty. Although not ideal, for the
purposes of this study to explore reliability, a correlation of psychometric properties of the
FRAIL scale was performed on three items as self-reported fatigue (Question #1), and difficulty
in walking and resting (Questions #2 and #3) was appropriate for psychomotor testing. All other
items were clinical data (Question #4 about medical diagnosis and #5 about weight loss).
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Descriptive statistics (e.g., means, standard deviations, frequencies, and percentages) are
summarized for all data, including questionnaire completion, participants’ characteristics, DSES,
SURE test, CPS, FRAIL scale, SDM-Q-9, and SWD scale. A 5% level of significance was used
to assess the predictive power of each concept. Boxplots for continuous data and cluster bar
graphs for categorical data were constructed to examine data and identify outliers. When data
demonstrated small numbers for categorical variables, data were collapsed, including age,
partnership status, educational attainment, and CHA2DS2-VASc score. For the purpose of
logistic regression, continuous data were collapsed into the categorical for dependent variable
analysis (e.g., SDM and decisional conflict).
Depending on the scaling of data (i.e., nominal/ordinal/continuous) of two or more
groups (i.e., those considering and those who have decided), an ANOVA or Chi-square was
performed. Where appropriate, associated categorical variables (e.g., age, gender, education
level, partnership status, etc.) were investigated with categorical dependent variables (Decisional
Conflict, SURE test) and Control Preference using Chi Square. Categorical independent
variables were investigated for relationships with continuous variables (e.g., Decisional Self
Efficacy, Shared Decision Making and SWD), with ANOVA statistics where appropriate.
Pearson’s correlation coefficient was performed for continuous variable relationship testing,
including DSES, SDM-Q-9, and SWD. This study addresses effect size where appropriate using
phi coefficient or Cramer’s V (tables larger than 2 x 2) for non-parametric tests, where Cohen’s
criteria of .10 indicated a small effect, .30 for medium effect and, and .50 for large effect. For
ANOVA, eta squared was calculated to determine the effect size, where Cohen classifies .01 as a
small effect, .06 as a medium effect, and .14 as a large effect (Pallant, 2016, p. 260).
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Logistic regression was performed to identify those factors that independently predict
participation in SDM. Variables that had previously demonstrated statistical significance for
association to participation in SDM were included in the prediction model for participation in
SDM for stroke prevention. The Hosmer and Lemeshow test were used to determine goodnessof-fit, where a value larger than 0.5 indicates support for the model. The effect size (pseudo R
squared statistics) was determined by the Cox and Schnell and Nagelkerke R square, where the
variability is explained (Pallant, 2016, p. 177). The results of the open-ended question exploring
factors were examined to explain findings and give narrative statements from individuals (e.g.,
paroxysmal Afib and decisional conflict).
Sample Size
To determine sample size, an estimate of 2 to 6 million individuals in the United States
was considered. Based on power analysis through SurveyMonkey, approximately 385
participants were required to complete the study objectives based on a population of 2 million
individuals with Afib in the United States with a 95% Confidence Interval and 5% margin of
error. G* Power a priori analysis suggests for Chi-Square analysis of 2-4 groups reflects 145 to
191 participants for a .3 effect size. ANOVA analysis using the ANOVA omnibus one-way
recommended for a .30 effect size required a sample size of 148 (2 groups), 177 (3 groups), and
196 (4 groups). A total of 201 individuals were available for analysis. However, pairwise deletion
was used for missing data, where sample size is reflected in each analysis. Effect sizes are noted
in each section of analysis demonstrating statistical significance.
Feasibility
The feasibility of this study was dependent on the availability of participants, support
from online support group (StopAfib.org), and health care team at Large Healthcare Network on
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Long Island. There was overwhelming support from online support group, StopAfib.org, where
bi-weekly communication was vital for enrollment. Although the Large Healthcare Network was
used as alternative recruitment, no enrollment was noted after recruitment flyer placement on
unit (February 9, 2020).
Summary
This study proposed addresses decisional needs by investigating individual characteristics
and relationships with SDM, decisional support as in the receipt of educational packet and/or
DAs and decisional quality such as SWD. Individuals with Afib participated in an online survey,
and the data analysis is presented in chapter four. The results are intended to support patientcentered care by identifying individual characteristics and bringing evidence to support a
beginning epistemology of decisional needs in this Afib sample. This knowledge has the intent to
influence health care providers’ perceptions of SDM.
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CHAPTER FOUR: RESULTS
The focus of this study was to examine the relationship between individual characteristics
and shared decision making in individuals with Afib seeking therapeutic management in stroke
prevention. The findings reflect responses from individuals with Afib. There were no clinicians
interviewed for this study. Therefore, perceptions of SDM are patient focused. Final finding can
be found in Appendix O, Results of the Afib: DMSP.
The ODSF was the primary theoretical model that framed this dissertation, as the model
stresses the concept of decisional needs. According to the ODSF, concepts of interest include
participants’ personal and clinical characteristic, self-efficacy, decisional conflict, and role in
decision making (O'Connor, 2006). Therefore, demographic factors examined in this study
included age, gender, education attainment, and partnership status. Clinical characteristics were
evaluated in this study by assessing for frailty status, CHA2DS2-VASc score, and type of Afib.
Additionally, time since decision was investigated regarding decisional conflict. Much of the
research in SDM has focused on the use of DAs, so participants were asked if they received
educational brochures or a DA, as this was evaluated for the outcome of decisional conflict.
Psychometrically tested instruments were used to examine relationships such as
decisional self-efficacy (DSES), decisional conflict (SURE test), role in decision making (CPS),
participation in shared decision making (SDM-Q-9), and SWD Scale. The FRAIL instrument
was used as a clinical assessment tool assessing frailty status, which includes questions on
medical history, tiredness, mobility and fatigue, and weight changes.
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Research Question 1- What are the characteristics of the participants in this Afib: DMSP
Survey?
A total of 319 individuals entered the online Atrial Fibrillation Decision Making in Stroke
Prevention (Afib: DMSP) Survey posted on SurveyMonkey between December 6, 2019, and
February 12, 2020. Of the 319 individuals, one did not agree to participate, five agreed to
participate yet did not complete inclusion questions, 30 individuals met inclusion criteria yet did
not proceed with the initial demographic section of the survey, and 67 did not meet inclusion
criteria. Therefore, a total of 216 individuals participated in the survey that was separated by
seven sections: demographics, decisional self-efficacy, decisional conflict, control preference,
frailty status, SDM, and SWD.
A pattern was identified as the survey continued, participants dropping out to reflect a
completion rate of demographics: n = 216; DSES, n = 201; decisional conflict test (SURE) n =
201; CPS n = 192; FRAIL scale n = 185; SDM-Q-9, n = 181; and for those who had made a
decision, the SWD survey, n = 133 (Figure 4.1). For analysis purposes, missing data for
examining relationships were excluded by pairwise deletion, so for analysis purposes, sample
size may vary according to the analysis. Included in the analysis were 201 participants.
Figure 4.1
Survey Progression and Participation

For pairwise comparisons, the final number of subjects analyzed for this study was 201
individuals. The average age range of participants was between 65 and 74 years old (47.8%; n =
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96). Ninety-three (46.3%) were male and 108 (53.7%) were female. In terms of race, the
response was 196 (97.5%) White/Caucasian, 1 (.5%) Asian, 1 (.5%) American Indian or Alaska
native, 2 (1.0%) multiple races, and one missing response (.5%). There were no self-reports of
black race. The ethnicity responses included 196 (97.5%) non-Hispanic, 3 (1.5%) Hispanic, and
two missing responses (1%). The level of education reported by subjects was 15 (7.5%) high
school graduate, 2 (1%) technical career training after high school, 39 (19.4%) some college, 125
(62.2%) college graduates, and 20 (10%) with a doctoral degree. Their partnership status was
reported as 15 (7.5%) widowed, 32 (15.9%) single, divorced or separated, and 152 (75.6%)
married or partnered individuals. Where appropriate, items with small sample sizes were
collapsed as described under each section.
The survey included questions focused on Afib. Participants were asked to identify type
of Afib with 56.7% (n = 114) responding Paroxysmal, 17.4% (n = 35) Persistent, 10.9% (n = 22)
Permanent, and 13.9 % (n = 28) “I am unsure” (type of Afib). There were two (1%) missing
responses. One-hundred and eighty (89.6%) reported non-valvular Afib, 10 reporting their Afib
was related to a valve problem or mechanical valve (5%), and 11 (5.5%) responded as “unsure”
whether their Afib was related to a valve or mechanical valve. Most respondents identified time
in Afib as greater than 5 years 33.8% (n = 68), 14.4% (n = 29) less than one year, 24.4% (n =
49) 1-2 years, 22.9% (n = 46) 3-5 years, and 4.5% (n = 9) who were unsure.
Decisional Factors
Participants (n = 201) were asked to identify all individuals (multiple responses
permitted) who assisted them in the decisional process: 51.2% (n = 103) responded spousal
assistance, 13.9% (n = 28) identified another health care professional (other than the physician
consulting for treatment related to stroke prevention), 11.9% (n = 24) responded a child, 8.5% (n
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= 17) responded a friend, and 3% (n = 6) responded a sibling. There were 29.4% (n = 59)
individuals who did not identify another individual who assisted in the decision process. There
were 77.6% (n = 156) participants considering medication as therapeutic management for stroke
prevention, 55.7% (n = 112) considering lifestyle changes, and 16.9% (n = 34) considering left
atrial appendage occlusion/excision as a treatment option (multiple responses permitted). In the
sample, 48.8% (n = 98) said they received an educational packet or DA pamphlet to assist in the
decisional process and 51.2% (n = 103) responded they did not receive a packet or pamphlet.
Most individuals, 52.2% (n = 105) made their decision three months ago, 12.9% (n = 26)
responded two months ago, 10% (n = 20) within one month, and 20.4% (n = 41) continued to
contemplate a decision for therapeutic management for stroke prevention related to their
diagnosis of Afib. Nine (4.5%) individuals did not respond to this question. Of the individuals
who continued to participate in this study through the SDM-Q-9 (n = 181), 74.0% (n = 134)
responded to have made a final decision and 24.9% (n = 45) continued to contemplate their
decision. Two individuals (1.1%) did not respond to the question, “Have you made a final
decision within the last three months regarding treatment for stroke prevention related to atrial
fibrillation?”
Statistical Analysis
Baseline variables were compared between groups to assess for distribution imbalances
using means/medians or proportions for continuous and categorical variables, respectively. To
address missing data for relationship testing, the method of pairwise deletion was utilized.
Questionnaire Psychometrics
For the purpose of this study, each questionnaire used for the study was measured for
their reliability of internal consistency with a Cronbach’s alpha coefficient, or for a dichotomous
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response on two-item response surveys, the Spearman-Brown half-split reliability was used. An
alpha coefficient of > 0.70 was considered an acceptable value of instrument reliability for this
study. In this sample of individuals who completed all questions on each survey to provide a total
score, the Cronbach’s alpha coefficients for continuous scales were reported as DSES (n =
201), .952; Nine-item SDM-Q-9 (n = 181), .930; and SWD Scale (n = 133),.915. Eisinga and
colleagues (2013) recommended the use of the Spearman-Brown coefficient with split-half
reliability for dichotomous scale reliability testing. The dichotomous SURE test (n = 201)
demonstrated Spearman-Brown coefficient reliability of .808, and the CPS test
demonstrated .696. Although the FRAIL scale (n = 185) is a clinical indicator with clinical
questions (Questions 4-5), items 1, 2, and 3 are self-reported measures of fatigue with mobility,
so three dichotomous items were examined using the Spearman-Brown coefficient and resulted
in .743 (item #1-3). All scales, except for Control Preference, were evaluated for reliability and
deemed acceptable to use in this sample of Afib participants. The CPS, although not meeting
>/= .7 threshold for reliability, continued to be utilized. The CPS presents five, then four, then
three then finally two images with one choice for each of the presentations. The CPS was
deemed appropriate as the instrument was reaching a threshold limit reported by SpearmanBrown half-split reliability (.696).
Relationship Analysis and Prediction
For the purposes of exploring relationships, Chi-square was used to determine categorical
variables of interest with categorical outcome variables, and one-way ANOVA for categorical
variables of interest and continuous outcome variable and Pearson’s correlation for relationships
between continuous variables. Based on the finding from this study, multiple logistic regression
was used to determine predictions for participating in SDM and decisional conflict.

156
Research Question 2. What is the incidence of participation in SDM in a sample of
individuals with Afib?
To evaluate participation in SDM, the nine-item SDM-Q-9 was utilized. This scale is a 9item instrument rated on a 6-point Likert-type scale with raw scores of 0 to 45. Raw scores are
transformed into a score of 0 to 100, where a score of 0 indicates the lowest possible measure of
participation in SDM and 100 indicates the highest measure of SDM. For comparing the SDMQ-9 and self-reporting, individuals were asked to rate on a sliding scale within the survey rating
(on a scale of 0-100, where a score of 0 reflects least participation and 100 as the most
participation), their perception of how they participated in the SDM for stroke prevention.
Overall reliability of SDM-Q-9 in this sample (n = 181) was consistent with Cronbach’s alpha
coefficient of .930.
In this study, the SDM-Q-9 was used to measure SDM for stroke prevention among
participants with Afib (n = 181). The 181 participants reported a mean score of 60.18, a median
of 60.00, and a mode of 80, with a score range of 0 to 100. The self-reported scores (n = 185)
were greater than the SDM-Q-9 scores, with a mean score of 76.77, median of 87, and mode of
100 (where 46 individuals reported 100) (Table 4.1).
Table 4.1
Comparing Self-Reported Shared Decision-Making Scores and SDM-Q-9 scores

Statistic
N
Mean
Median
Mode
Std. Deviation
Minimum
Maximum
Percentiles

Valid

25
50
75

Self-Report SDM (0-100)
185
76.77
87.00
100
27.821
0
100
68.00
87.00
99.50

SDM-Q-9 Score
181
60.18
60.00
80
24.254
0
100
45.56
60.00
80.00
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To evaluate the relationship between the self-reporting scale of 0-100 and the SDM-Q-9,
a Pearson Product moment correlation coefficient was performed. There was a strong, positive
correlation between the two variables, r = .556, n = 177, p < .001, with high levels of selfreported measure associated with high scores on the SDM-Q-9 (Figure 4.2), with 30.9% of a
shared variance. This self-reporting measure may reflect a bias due to perceptions of self-concept
and social desirability, as there is a strong ceiling effect.
Figure 4.2
Scatterplot of SDM-Q-9 scores and Self Report SDM (0-100)

Research Question 3. What is the relationship between demographics with decisional selfefficacy, decisional conflict, control preferences, and participation in shared decision
making (SDM-Q-9) in a sample of individuals with Afib?
For the purposes of this study, socio-demographics (e.g., age, gender, education
attainment, and partnership status) and clinical factors (e.g., Type of Afib) were investigated to
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view relationships between demographics and decisional self-efficacy, decisional conflict
(SURE), control (role) preference (CPS), and participation in shared decision making (SDM-Q9).
Age
The survey responses for age included seven categorical options. However, in the
analysis, there were too few responses for those 54 years and younger, where .5% (n = 1) are 2534 years, 1.5% (n = 3) are 35-44, and 6% (n = 12) reported age 45-54. Therefore, these three
categories were combined with the 55-64 age category. This yields 28.9% (n = 58) respondents
younger than 65 years, 47.8% (n = 96) ages 65-74, and 23.4% (n = 47) 75 or older (Table 4.2).
Table 4.2
Descriptives- Age of Participants
Frequency
Valid

<65
65-74
=/>75
Total

%
58
96
47
201

Valid %
28.9
47.8
23.4
100.0

28.9
47.8
23.4
100.0

Age and DSES
A one-way between-groups analysis of variance was conducted to explore the
relationship of age (three categories) on decisional self-efficacy as measured by the DSES.
Participants were categorized into three age groups for comparison (<65 years, 65 to 74 years,
and 75 years and older). There was no statistical significance difference at the p < .05 level in
decisional self-efficacy scores for the three age groups: F (2,198) = .812, p = .446. Individuals
>/= 75 reported the highest mean score of 85.98 (n = 47), and individuals younger than 65 years
reported the lowest mean score of 81.39 (n = 58). Participants ages 65-74 reported a mean score
of 84.14 (n = 96; Table 4.3).
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Table 4.3
Descriptives- Comparison of Age Cohorts and Decisional Self-Efficacy Scores

N
<65
65-74
=/>75
Total

58
96
47
201

M
81.39
84.14
85.98
83.77

SD
20.038
19.262
15.826
18.739

SE
2.631
1.966
2.309
1.322

95% Confidence
Interval for Mean
Lower
Upper
Bound
Bound
76.12
86.66
80.24
88.04
81.33
90.62
81.17
86.38

Min
16
18
48
16

Max
100
100
100
100

Age and Decisional Conflict (SURE test)
Decisional conflict was assessed using the SURE test, which describes the presence of
decisional conflict with respondents’ scores less than 4 and the absence of decisional conflict as
those scores of 4. A chi-square test of independence indicated no significant association between
age (three categories) and dichotomous decisional conflict (presence vs. absence) as measured by
the SURE test, χ²(2, n = 201) = 3.111, p = .211, Cramer’s v = .110. Of the participants reporting
the presence of decisional conflict, participants younger than 65 reported the highest percentage
of decisional conflict (43.9%, n = 25) compared to those 65 to 74 years (41.8%, n = 41), and 75
years or older (28.3%, n = 13) reporting the least decisional conflict (Table 4.4).
Table 4.4
Decisional Conflict (SURE test) and Age Comparison

SURE_test

Total

Absence of
Decisional Conflict
Decisional Conflict
Present

Count
% within age
Count
% within age
Count
% within age

Age Cohorts
<65
65-74
=/>75
Total
32
57
33
122
56.1% 58.2% 71.7% 60.7%
25
41
13
79
43.9% 41.8% 28.3% 39.3%
57
98
46
201
100.0% 100.0% 100.0% 100.0%
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Age and CPS
The CPS was used to assess an individual’s involvement in stroke prevention decision.
Individuals were given one to three attempts in choosing their preferred methods such as Active,
Collaborative/Shared, or Passive role in the decision on stroke prevention. The Atrial
Fibrillation: Decision-Making in Stroke Prevention Survey used a modified Giordano’s method
in which individuals were given five images and asked to select their preferred card. Of the
remaining four images, participants were then asked to select the next preferred card. Card
images were considered “congruent” by values reflecting AB, BA, BC, CB, CD, DC, ED, and
DE, reflecting eight congruent images. In the first attempt, there were 168 compatible
permutations: AB (n = 14), BA (n = 47), BC (n = 20), CB (n = 56), CD (n = 19), DC (n = 6),
DE (n = 1), and ED (n = 5). There were two participants who did not proceed after choosing
once (permutation of “B” or “C”) . These participants were not included as part of the analysis.
Therefore, the first-round attempt at control preference yielded 168 compatible imputations and
25 incompatible permutations: AC (n = 6), AD (n = 1), BD (n = 3), CA (n = 10), DB (n = 3),
EB (n = 1), and EC (n = 1). Responses with incompatible imputations were given a second
chance at CPS with the same images. The second-round attempt returned 12 compatible
imputations: AB (n = 2), BA (n = 2), BC (n = 4), CB (n = 3), CD (n = 1). The 13 incompatible
imputations were as follows: AC (n = 4), BD (n = 2), CA (n = 5), DB (n = 1), and EC (n = 1). In
the last attempt, those remaining incompatible imputations (n = 13) were given a narrative
option where only one letter would be generated (A, B, C, D, or E) reflecting narrative selection,
where A or B reflects active participation, C reflects collaborative participation, and D or E
reflects passive participation in medical decision making. Out of 13 people, 12 responded and 1
participant did not select one of the five narratives. Three participants chose the Card A (active
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approach), “I prefer to make the final selection about which treatment I will receive.” Four
participants chose the Card B (active approach), “I prefer to make the final selection of my
treatment after seriously considering my doctor’s opinion.” Two participants chose the Card C
(collaborative approach), “I prefer that my doctor and I share responsibility for deciding which
treatment is best for me.” Two participants chose the Card D (passive approach), “I prefer that
my doctor makes the final decisions about which treatment will be used but seriously considers
my opinion,” and one participant chose the Card E (passive approach), “I prefer to leave all
decisions regarding my treatment to my doctor.” Therefore, 192 responses were analyzed as three
categorical responses: Active (AB, BA, B and A) Collaborative-Shared (BC, CB, and C), and
Passive (CD, DC, DE, D and E). In this sample, 44.3% responded with a collaborative/shared
preference (n = 85), 37.5% (n = 72) responded as active participation, and 18.2% (n = 35)
responded as passive participation in regard to control in their health care decision regarding
stroke prevention in Afib. As discussed previously, cases are analyzed by a pairwise deletion, and
all incompatible or missing cases were not part of the final analysis (Table 4.5).
Table 4.5
Descriptive Statistics- Control Preference Scale

Valid

Passive
Collaborative/Shared
Active
Total

Frequency
35
85
72
192

%
11.0
26.6
22.6
60.2

Cumulative
Valid %
%
18.2
18.2
44.3
62.5
37.5
100.0
100.0

A chi-square test of independence indicated no significant association between age (three
categories) and the three-category CPS (Active-Collaborative/Shared-Passive), χ² (4, n = 192) =
8.086, p = .088, and Cramer’s V = .145. Individuals younger than 65 (n = 21, 40.4%) and those
75 years or older (n = 18, 40.9%) preferred an active role, whereas those 65 to 74 years preferred
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a collaborative/shared role (n = 51, 53.1%). Although passive role was the least reported
preference in all age categories, those participants 75 years and older had the greatest response
rate (27.3%, n = 12; Table 4.6).
Table 4.6
Age and Control Preference

CPS

Passive

Count
% within age
Collaborative/Shared Count
% within age
Active
Count
% within age

Cohort Age Categories
<65
65-74
=/>75
11
12
12
21.2%
12.5%
27.3%
20
51
14
38.5%
53.1%
31.8%
21
33
18
40.4%
34.4%
40.9%

Total
35
18.2%
85
44.3%
72
37.5%

Age and Participation in SDM
A one-way between-group analysis of variance was conducted to explore the impact of
age on levels of participation in SDM, as measured by the 9-item SDM-Q-9. Participants were
divided into three groups according to their age (e.g., </=64 years, 65-74 years, and 75 years or
greater). There was a statistically significant difference at the p < .05 level in SDM-Q-9 scores
for the three age groups: F (2, 178) = 3.87, p = .023. The effect size, calculated using etasquared, was .042. Post-hoc comparison using the Tukey HSD test indicated that the mean score
for individuals </= 64 years (n = 50, M = 54.93, SD = 27.375) was statistically different from
individuals 75 years or older (n = 41, M = 68.67, SD = 21.092). Individuals 65 to 74 years (n =
90, M = 59.23, SD = 22.969) did not differ significantly from other cohorts (Figure 4.3).
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Figure 4.3
Boxplot Age Cohort and SDM-Q-9 scores

Gender
Gender and DSES
A one-way between-group analysis of variance was conducted to explore the impact of
gender on DSES. There was a statistically significant difference at the p < .05 level in decisional
self-efficacy scores for the three age groups: F (1, 199) = 6.625, p = .011. The effect size,
calculated using eta-squared, was .032, with the mean score for males (M = 87.39, SD = 16.411)
being statistically different from female responses (M = 80.66, SD = 20.09). The average SDMQ-9 score for both groups was n = 201, M = 83.77; Table 4.7).
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Table 4.7
Descriptives of Gender and Decisional Self-Efficacy Scores

N
Male
Female
Total

93
108
201

M
87.39
80.66
83.77

SD
16.411
20.090
18.739

95% Confidence Interval for
Mean
SE
Lower Bound Upper Bound
1.702
84.01
90.77
1.933
76.83
84.49
1.322
81.17
86.38

Gender and Decisional Conflict (SURE test)
A chi-square test of independence (with Yates’ Continuity Correction) indicated a
statistically significant association between gender (n = 201; males = 93, female = 108) and
decisional conflict as measured by the SURE test, χ² (1, n = 201) = 4.172, p = .041, phi = .154,
where decisional conflict was reported in 31.2% (n = 29) of men and 46.3% (n = 50) of women.
There was an overall presence of decisional conflict of 39.3% (n = 79) reported for both genders,
where women reported a 15.1% higher rate of decisional conflict than men (Table 4.8 and Figure
4.4).
Table 4.8
Decisional Conflict (SURE test) and Gender Differences

SURE test

Total

Absence of
Decisional Conflict
Decisional Conflict
Present

n
% within Gender
n
% within Gender
n
% within Gender

Gender
Male
Female
64
58
68.8%
53.7%
29
50
31.2%
46.3%
93
108
100.0% 100.0%

Total
122
60.7%
79
39.3%
201
100.0%
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Figure 4.4
Gender and Decisional Conflict

Gender and Control Preference (CPS)
A chi-square test of independence indicated no statistically significant association
between gender and control preferences in decision making, χ² (2, n = 192) = 3.734, p = .155,
Cramer’s V = .139. Both men (41.4%) and women (46.7%) preferred a collaborative/shared role.
The least preferred role was passive for both males (24.1%) and females (13.3%; Table 4.9).
Table 4.9
Gender and Control Preference

CPS

Total

Passive

Count
% within gender
Collaborative/Shared Count
% within gender
Active
Count
% within gender
Count
% within gender

Gender
Male
Female
21
14
24.1%
13.3%
36
49
41.4%
46.7%
30
42
34.5%
40.0%
87
105
100.0% 100.0%

Total
35
18.2%
85
44.3%
72
37.5%
192
100.0%
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Gender and Participation in SDM-Q-9
A one-way between-group analysis of variance was conducted to explore the relationship
of a participant’s gender on levels of participation in SDM, as measured by the SDM-Q-9. There
was a statistically significant difference at the p < .05 level in SDM-Q-9 scores between genders:
F(1, 179) = 10.125, p = .002. The effect size is calculated using eta squared, .054. The mean
score for males (M = 66.27, SD = 24.277) is statistically different from females (M = 55.03, SD
= 23.129; Table 4.10 and Figure 4.5), where according to the SDM-Q-9, men had a higher score
therefore participated more in SDM for stroke prevention as reflected in compared mean scores.
Table 4.10
Descriptives: Gender and SDM-Q-9 scores

N
Male
Female
Total

83
98
181

M
66.27
55.03
60.18

Figure 4.5
Boxplot of Gender and SDM-9-Q Scores

SD
24.277
23.129
24.254

95% Confidence Interval for
Mean
SE
Lower Bound Upper Bound
2.665
60.96
71.57
2.336
50.40
59.67
1.803
56.63
63.74
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Education Attainment
Educational Attainment and Decisional Self-Efficacy
A one-way between-group analysis of variance was conducted to explore the impact of
education attainment based on five categories and decisional self-efficacy as measured by DSES.
There was no statistically significant difference at the p < .05 level in DSES scores between
educational attainment: F (4, 196) =1.611 and p = .173. The lowest and greatest mean scores
were M = 81.7 and SD = 18.763 for participant who reported “some” college and M = 97.73 and
SD = 3.214 for those reporting a “technical career training after high school.”
When reviewing the educational attainment two categories demonstrated two or fewer
frequencies, so educational attainment was collapsed into two categories for all respondents (n =
201): non-college degree (grade school, high school graduate, some college and technical career
training after high school; n = 56) and college (n = 145), which includes college graduate and
doctoral degree. A one-way between-group analysis of variance was conducted to explore the
relationship of education attainment based on two categories and decisional self-efficacy as
measured by the DSES. Findings remain not statistically significant different (comparing five to
two categorical education attainment) at the p < .05 level in DSES scores between educational
attainment: F (1, 199) =.230, p = .632. Non-college graduates scored lower (n = 56, M = 82.75)
than college graduates (n = 145, M = 84.17).
Education Attainment and Decisional Conflict (SURE)
A chi-square test of independence (with Yates’ Continuity Correction) indicated no
statistical significance association between two categorical educational attainments (n = 54 noncollege graduate, n = 141 college graduate) and decisional conflict as measured by SURE
categorical test, χ² (1, n = 195) = 3.004, p = .083. Overall, 38.5% reported decisional conflict in
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both groups. The presence of decisional conflict (SURE test) was reported in 42.6% (n = 60) of
college graduates and 27.8% (n = 15) of non-college graduates (Table 4.11).
Table 4.11
Educational Attainment and Decisional Conflict (SURE test)

SURE test

Total

Absence of
n
Decisional Conflict % within
education
Decisional Conflict n
Present
% within
education
n
% within
education

Education
NonCollege
College
Graduate
Graduate
39
81
72.2%
57.4%
15
27.8%
54
100.0%

60
42.6%

Total
120
61.5%
75
38.5%

141
195
100.0% 100.0%

Education Attainment and Control Preference
A chi-square test of independence indicated a statistically significant association between
education (two category) and control preference in medical decision making as measured by
SURE test, χ² (2, n = 192) = 7.442, p = .024, Cramer’s V = .197. Non-college participants’ most
preferred role was active (38%, n = 19), then collaborative/shared (32%, n = 16), and the least
preferred role of passive (30%, n = 15). College graduates’ most preferred role was
collaborative/shared (48.6%, n = 69), then active (37.3%, n = 53), and the least preferred role of
passive (14.1%, n = 20). The preferred role for combined groups was collaborative/shared (44%,
n = 85), then active (37.5%, n = 72), with the least preferred role reported as passive (18.2%, n
= 35). Overall, non-college graduates reported a greater passive role (30%) than college
educated (14.1%)(Table 4.12; Figure 4.6).

169
Table 4.12
Educational Attainment and Control Preference Reporting

Control
Preference
Categories

Passive

Collaborative/Shared

Active

Total

Count
% within
education
Count
% within
education
Count
% within
education
Count
% within
education

Figure 4.6
Educational Attainment and Control Preference

Education Attainment
NonCollege
College
Graduate
Graduate
15
20
30.0%
14.1%

Total
35
18.2%

16
32.0%

69
48.6%

85
44.3%

19
38.0%

53
37.3%

72
37.5%

50
100.0%

142
192
100.0% 100.0%
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Education Attainment and Participation in SDM-Q-9
A one-way between-group analysis of variance was conducted to explore the relationship of
education attainment (two categorical) and participation in SDM as measured by SDM-Q-9.
There was no statistically significant difference at the p < .05 level in DSM-9-Q scores between
educational attainment: F (1, 179) = .525, p = .470. Where non-college graduates reported
higher scores on the SDMQ (M = 62.36, SD = 27.437) than college graduates (M = 59.40, SD
= 23.060).
Table 4.13
Descriptives: Educational Attainment and SDM-Q-9 Scores
95% Confidence
Interval for Mean
N
Non-College
Graduate
College Graduate
Total

M

SD

SE

Lower
Bound

Upper
Bound

Min

Max

48

62.36

27.437

3.960

54.39

70.33

0

100

133
181

59.40
60.18

23.060
24.254

2.000
1.803

55.44
56.63

63.35
63.74

4
0

100
100

Relationship Status (Partnered Status)
For the purposes of relationships, there were only 15 reported as “widowed,” so the
determination to collapse categories into “partnered and non-partnered,” where “widowed and
single” and “divorced or separated” would combine into one category (n = 49) as compared to
the category of “Partnered” (n = 152), which includes married or partnered.
Partnered Status and DSES
A one-way between-group analysis of variance was conducted to explore the relationship
of self-reporting partnership status and decisional self-efficacy as measured by DSES. There was
no statistically significant difference at the p < .05 level in decisional self-efficacy scores DSES
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between partnership status F (1,197) = 1.200, p = .275. Non-partnered individuals (e.g.,
widowed, single, divorced, or separated) reported lower scores (M = 81.33, SD = 19.429) on the
DSES compared to married or partnered individuals (M = 84.72, SD = 18.224) (Table 4.14).
Table 4.14
Descriptives: Partnership Status and Decisional Self-Efficacy Scores
Partnership
Status
Partnered
Non-Partnered
Total

95% Confidence Interval for
Mean
N

M
152
47
199

84.72
81.33
83.92

SD
18.224
19.429
18.521

SE

Lower Bound

1.478
2.834
1.313

Upper Bound

81.80
75.63
81.33

87.64
87.04
86.51

Partnered Status and Decisional Conflict
A chi-square test of independence (with Yates’ Continuity Correction) indicated a
statistically significant association between partnership status (two category) and decisional
conflict as measured by the SURE test, χ² (1, n = 199) = 6.044, p = .014, phi = -.186, where
non-partnered individuals reported more decisional conflict 55.1% (n = 27) than married or
partnered counterparts, 34% (n = 51) (Table 4.15, Figure 4.7).
Table 4.15
Partnership status and Decisional Conflict (SURE test)

Measurement Decisional Conflict Count/%
SURE_test
Absence
Present
Total

Count
% within
Count
% within
Count
% within

Partnership Status
Not
Married/Pa
Partnered
rtnered
Total
22
99
121
44.9%
66.0% 60.8%
27
51
78
55.1%
34.0% 39.2%
49
150
199
100.0%
100.0% 100.0%
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Figure 4.7
Partnership Status and Decisional Conflict

Partnered Status and Control Preference
Overall, both groups (partnered and non-partnered) report 43.7% (n = 83) prefer a
Collaborative/Shared role, 37.9% Active role (n = 72), and 18.4 % (n = 35) a Passive role in
medical decision-making regarding stroke prevention for Afib. A chi-square test of independence
indicated no statistically significant association between control preference (three category) as
measured by CPS, χ² (1, n = 190) = 1.329, p = .514. Overall, combined cohorts preferred a
collaborative/shared role (43.7%, n = 83) and the least preferred role was reported as passive
(18.4%, n = 35). Both 46.8% of non-partnered individuals (n = 22) and 42.7% of partnered
individuals (n = 61) preferred a collaborative/shared role (Table 4.16). The least preferred role
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for both groups were passive. However, partnered individuals reported a greater passive role than
non-partnered individuals (20.3% versus 12.8%, respectively).
Table 4.16
Partnership Status and Control Preference

Control
Preference
Scale
Outcomes

Total

Partnership Status
NonPartnered Partnered
Total
29
6
35
20.3%
12.8% 18.4%
61
22
83
42.7%
46.8% 43.7%
53
19
72
37.1%
40.4% 37.9%
143
47
190
100.0%
100.0% 100.0%

Passive

n
%
Collaborative/Shared n
%
Active
n
%
n
%

Relationship and Participation in SDM
A one-way between-group analysis of variance was conducted to explore the relationship
of partnership status and participation on SDM as measured by the SDM-Q-9. There was no
statistically significant difference at the p < .05 level in SDM-Q-9 and partnership status F(1,
178) = 2.738, p = .100. Although not statistically significant, non-partnered participants reported
lower scores in SDM (M = 55.04, n = 43) compared to married or partnered individuals (M =
62.01, n = 137) ( Table 4.17).
Table 4.17
Partnership Status and SDM-Q-9
95% Confidence Interval for
Mean
N
Not Partnered
Married/Partnered
Total

M
43
137
180

55.04
62.01
60.35

SD
25.498
23.661
24.224

SE
3.888
2.021
1.806

Lower Bound Upper Bound
47.19
58.01
56.78

62.89
66.01
63.91
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Research Question 4. What is the relationship between the type of atrial fibrillation and
decisional self-efficacy, decisional conflict, control preference, and shared decision making
in an Afib sample?
Consistent with the ODSF, clinical characteristics can impact participation in SDM.
Clinical factors investigated under this section include the type of Afib and the risk for stroke
based on the CHA2DS2-Vasc stroke scoring system.
Type of Afib
Participants were asked to identify the type of Afib: Paroxysmal; Persistent; LongStanding Persistent; Permanent; and Unsure. Responses include Paroxysmal, n = 114; Persistent,
n = 35; Permanent, n = 22; and Unsure, n = 28. There were two missing responses and no
responses to Long-Standing Persistent. Consistent with the ODSF, which incorporates decisional
needs to include clinical characteristics, statistical analysis was performed to evaluate
relationships of Afib types and decisional self-efficacy, decisional conflict, control preferences,
and participation in SDM. Preliminary analysis demonstrated scores on DSES, p = .883 (n =
199), scores on SDM-Q-9, and p = .116 (n = 179). Therefore, for analysis purposes, the Unsure
category was dropped from the analysis, and the cases reporting paroxysmal, persistent, and
permanent were examined for further analysis.
Type of Afib and Decisional Self-Efficacy
A one-way between-group analysis of variance was conducted to explore the relationship
of Afib type and DSES (n = 171), where 114 reported paroxysmal (M = 83.47), 35 reported
persistent (M = 84.87), and 22 reported permanent (M = 86.05). There was no statistically
significant difference at the p < .05 level in shared SDM-Q-9 and type of Afib, F (2, 168) = .206,
p = .814, with an average mean decisional self-efficacy score for all types of Afib, M = 84.09.
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Although not statistically significant, participants with permanent Afib reported higher scores on
DSES (M = 86.05) than persistent (M = 84.87) and paroxysmal (M = 83.47; Table 4.18).
Table 4.18
Type of Atrial Fibrillation and Decisional Self-Efficacy Scores

N
Paroxysmal
Persistent
Permanent
Total

114
35
22
171

M
83.47
84.87
86.05
84.09

SD
19.102
17.211
21.553
18.975

SE
1.789
2.909
4.595
1.451

95% Confidence Interval for
Mean
Lower Bound Upper Bound
79.93
87.02
78.96
90.78
76.50
95.61
81.23
86.96

Type of Afib and Decisional Conflict (SURE)
A chi-square test of independence indicated a statistically significant association between
the type of Afib (three category) and decisional conflict (as measured by the SURE test), χ²(2, n
= 171) = 7.170, p = .028, Cramer’s v = .205. Overall, 41.5% (n = 71) of individuals reported the
presence of decisional conflict. Participants with paroxysmal Afib reported greater decisional
conflict 47.3% (n = 53) than persistent 38.9% (n = 14) and permanent 17.4% (n = 4; Table 4.19,
Figure 4.8). These findings are interesting and may be explained through the ODSF and
Bandura’s Self-Efficacy Theory stating mastery in association with progression of Afib.

Running head: SHARED DECISION-MAKING IN ATRIAL FIBRILLATION
Table 4.19
Type of Atrial Fibrillation and Decisional Conflict (SURE test)

Type of Afib

Total

Paroxysmal N
% within Type of
Afib
% within Decisional
Conflict
Persistent N
% within Type of
Afib
% within Decisional
Conflict
Permanent N
% within Type of
Afib
% within Decisional
Conflict
N
% within Type of
Afib
% within Decisional
Conflict

Decisional Conflict
Absence
Present
Total
59
53
112
52.7%
47.3% 100.0%
59.0%

74.6%

22
61.1%

14
36
38.9% 100.0%

22.0%

19.7%

19
82.6%

4
23
17.4% 100.0%

19.0%

5.6%

65.5%

21.1%

13.5%

100
58.5%

71
171
41.5% 100.0%

100.0%

100.0% 100.0%
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Figure 4.8
Type of Atrial Fibrillation and Decisional Conflict

Individuals with paroxysmal atrial fibrillation may have more decisional conflict due to
lack of consistently in the rhythm of atrial fibrillation. This was investigated more by assessing
patient narrative statements of individuals who self-reported having paroxysmal Afib responding
to the question: “If you would like to comment, - Describe any factors that may have influenced
your decision (examples: family support, informational packet, etc.) that may not have been
addressed in the survey.”
Comment 1.
Different providers recommend different things, apparently for different reasons. The
first provider I was sent to was totally unaware of current research and pushed opinions
that proved not true for me.
Comment 2.
I am considering blood thinner. Doctors say all afib patients MUST take them. I would
prefer not to if possible.
Comment 3.
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I am strongly opposed to taking blood thinners because of the side effects
Comment 4.
I feel there are mixed facts concerning stroke prevention in afib.
Comment 5.
I had 2 small strokes at one time last year after I stopped my supplements for a week did not take meds after. A few months ago, had 3 TIA's and decided it was time to take a
blood thinner.
Comment 6.
I was very leery of blood thinners in particular (most "big drugs" worry me, and I've
luckily not had to take many for most of my life), and I was willing to accept a 2% stroke
risk (given my risk factors as they were explained to me--age and gender) --despite dire
warnings about the possible stroke consequences. I consulted every medical friend I had
(and generally got the same message) and then struggled to find alternative treatments,
such as acupuncture and herbal therapies. My (excellent) cardiologist basically said he
was OK with such treatments but come back when the afib recurs. I yearn for someone
who can help me negotiate Western medicine (with all its positives) and alternative
treatments (with fewer side effects). What I most resented in this process was being
"categorized": you have afib and thus you are statistically "obliged" to follow this
medicinal protocol--before anyone really looked at my whole health history and
preferences.
Comment 7.
My AFIB episodes are of short duration and while scary, it is difficult to conceive that a
blood clot can be formed in less than an hour. We need more research on this variable.
Big Pharma has undue influence over cardiologists to overly prescribe anti-coagulants.
Comment 8.
My type of Afib is well controlled by Flecainide and I only go out of rhythm for an hour or
2 every several years so is out of the norm to analyze. So, I tend to disagree with
Cardiologist recommending blood thinners.
The previous statement may give support to reports of greater decisional conflict in the
paroxysmal afib respondents as major themes taken from these comments include uncertainty,
individual preferences, fear of risks and temporal nature of paroxysmal atrial fibrillation.
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Type of Atrial Fibrillation and Control Preference in Medical Decision-Making (CPS)
A chi-square test for independence indicated no statistically significant association
between type of atrial fibrillation (three category) and control preference (active, collaborativeshared and passive) as measured by Control Preference Scale, χ² (4, n = 164) =6.156, p = .188.
Participants reporting paroxysmal and permanent preferred collaborative/shared role (47.7%,
47.6% respectively) and participants reporting persistent preferred an active role (50%). The
least preferred role for all three types of Afib was passive, with those individuals with permanent
atrial fibrillation reporting the most frequently (23.8%) compared to persistent (23.5%) and
paroxysmal (14.7%) (Table 4.20).
Table 4.20
Type of Afib and Control Preference (CPS)

Type of Afib

Total

Paroxysmal N
% within TypeAfib
% within CPS
Persistent N
% within TypeAfib
% within CPS
Permanent N
% within TypeAfib
% within CPS
N
% within TypeAfib
% within CPS

Role Preference
CollaborativePassive
Shared
16
52
14.7%
47.7%
55.2%
73.2%
8
9
23.5%
26.5%
27.6%
12.7%
5
10
23.8%
47.6%
17.2%
14.1%
29
71
17.7%
43.3%
100.0%
100.0%

Active
41
37.6%
64.1%
17
50.0%
26.6%
6
28.6%
9.4%
64
39.0%
100.0%

Total
109
100.0%
66.5%
34
100.0%
20.7%
21
100.0%
12.8%
164
100.0%
100.0%

Type of Atrial Fibrillation and participation in Shared Decision-making (SDMQ9)
A one-way between-group analysis of variance was conducted to explore the relationship
of type of atrial fibrillation and participation in shared decision-making as measured by the
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SDMQ9. There was statistically significant difference at the p < .05 level in shared decisionmaking scores (SDMQ9) and type of atrial fibrillation F (2,156) =3.075, p = .049. The effect size
calculated using eta squared is .038. A post hoc analysis using the Tukey HSD test indicated that
the mean score for Paroxysmal (M = 58.22, SD = 23.971) was significantly different from
Permanent (M = 73.09, SD = 20.365). Persistent (M = 58.52, SD = 24.967) did not differ
significantly from either paroxysmal or permanent (Table 4.21) (Figure 4.9).
Table 4.21
Type of Atrial Fibrillation and Shared Decision-Making Scores (SDMQ9)
95% Confidence Interval for
Mean
Std.
N
Mean
Deviation
Std. Error Lower Bound Upper Bound
Paroxysmal
105
58.22
23.971
2.339
53.58
62.86
Persistent
33
58.52
24.967
4.346
49.67
67.37
Permanent
18
73.09
20.365
4.800
62.96
83.21
Total
156
60.00
24.129
1.932
56.18
63.82
Figure 4.9
Type of Atrial Fibrillation and Participation in SDM-Q-9
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Research Question 5. What is the relationship between the CHA2DS2-Vasc Score and
participation in SDM-Q-9 in a sample of individuals with Afib?
CHA2DS2-Vasc scores are calculated from data extracted from the frail scale (heart
failure, hypertension, diabetes, and stroke), age, gender, and additional questions on the presence
of vascular disease. For calculation purposes, CHA2DS2-Vasc scores ranged from 0 to 9, but in
this sample, scores ranged from 0 to 7 and most of the sample reported CHA2DS-VASc between
1 and 5 (Table 4.22). CHA2DS2-Vasc scores can be used for stroke risk assessment with
individuals with Afib and may therefore influence factors that pertain to an individual’s medical
decision making for stroke prevention. The relationship between CHA2DS2-Vasc score
(continuous scale 0-7) and participation in shared decision making (as measured by the SDM-Q9; n = 181) was investigated using Pearson product-moment correlation coefficient. There was a
positive correlation between the two variables (r = .164, n = 181, p = .027), with higher
CHA2DS2-VASc scores associated with higher participation in shared decision making. There
was a small to medium effect size noted as the coefficient of the determinant was calculated
at .027. For the purposes of analysis, further review revealed few cases with scores of five and
greater on the CHA2DS2-Vasc. Therefore, scores of 5 (n = 11), 6 (n = 3), and 7 (n = 2) were
combined. A determination to collapse the ordinal values into two categories: scores of 1-2 and
scores of 3 and greater (Table 4.23) was performed. Individuals with a score of 0 (n = 8) were
excluded from the analysis because a CHA2DS2-VASc score of >/=1 should be considered for
stroke prevention, which is essentially treatment with oral anticoagulation (Lane & Lip, 2012).
Therefore, participants’ with CHA2DS2-VASc scores of 0 may not have been offered a “choice”
for treatment with oral anticoagulation.
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Table 4.22
CHA2DS2-VASc Scores in this sample (n = 181)
Frequency
%
Valid
0
8
4.4
1
29
16.0
2
62
34.3
3
39
21.5
4
27
14.9
5
11
6.1
6
3
1.7
7
2
1.1
Total
181
100.0

Valid %
4.4
16.0
34.3
21.5
14.9
6.1
1.7
1.1
100.0

Cumulative %
4.4
20.4
54.7
76.2
91.2
97.2
98.9
100.0

A one-way between-group analysis of variance was conducted to explore the relationship
between dichotomous CHA2DS2-Vasc score (Group 1 scores of 1-2 [n = 91] and Group 2 [n =
82] scores of 3 or greater) and participation in shared decision making as measured by the SDMQ-9. There is a statistically significant difference at the p < .05 level in shared decision-making
scores (SDM-Q-9) and CHA2DS2-VASc dichotomous category (1-2 and 3-7) F(1,173) = 4.169,
p = .043. The effect size calculated using eta squared is .024. Individuals with a CHA2DS2-Vasc
score of 3-7 (M = 64.23, SD = 21.138) scored higher on the SDM-Q-9 than individuals with
scores between 1 and 2 (M = 56.75, SD = 26.390; Table 4.23; Figure 4.10).
Table 4.23
CHA2DS2-VASc score and Participation in Shared Decision-Making (SDM-Q-9)
95% Confidence Interval for
CHA2DS2Mean
VASc
score
N
M
SD
SE
Lower Bound Upper Bound
1-2
91
56.75
26.390
2.766
51.26
62.25
3-7
82
64.23
21.138
2.334
59.58
68.87
Total
173
60.30
24.266
1.845
56.65
63.94
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Figure 4.10
Dichotomous CHA2DS2-VASc and reported SDM-Q-9 Scores

Research Question 6. What is the relationship of receiving an education packet and/or
decisional aid from a healthcare provider and participation in shared decision making and
decision conflict in a sample of individuals with Afib?
The ODSF supports the use of decisional aids to assist individuals in decision making.
This researcher was interested in exploring the use of hand-out materials provided by health care
providers and relationship with participating in SDM. The question incorporated into the survey
was, “Did your health care provider share with your materials such as educational material,
brochure or decisional aid to assist you in your decision making for stroke prevention?” A oneway between-group analysis of variance was conducted to explore the relationship of receiving
educational material, brochure, or DA and participation in SDM as measured by the SDM-Q-9.
There was a statistically significant difference at the p < .05 level in SDM scores (SDM-Q-9) and
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response to educational materials/DA, F (1, 179) = 31.951, p < .001. The effect size calculated
using eta squared was .15, representing a large effect size. Recipients of educational materials or
DAs reported higher levels of participation in shared decision making (SDM-Q-9; M = 70.08,
SD = 20.412, n = 86) than respondents who did not receive an education packet or DA (n = 95,
M = 51.23, SD = 24.064; see Table 4.24).
Table 4.24
Use of Education Packet/Decisional Aid and Shared Decision-Making (SDM-Q-9)
95% Confidence Interval
for Mean
Received a
Lower
Upper
Packet or Aid
N
M
SD
SE
Bound
Bound
Yes
86
70.08
20.412
2.201
65.70
74.45
No
95
51.23
24.064
2.469
46.33
56.13
Total
181
60.18
24.254
1.803
56.63
63.74
The use of an educational packet or DA was explored to see if there was a relationship
between the use of the educational material/DA and decisional conflict as measured by the SURE
test. A chi-square test of independence (with Yates’ Continuity Correction) indicated a
statistically significant association between the use of educational materials/DAs and decisional
conflict (as measured by the SURE test), χ² (1, n = 201) = 10.132, p = .001, phi = .235. Overall
decisional conflict was reported in 39.3% of cases (n = 79). Participants who reported not
receiving educational materials or DAs reported higher decisional conflict (50.5%, n = 52) than
participants who received the materials (27.6%, n = 27; Table 4.25, Figure 4.11).
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Table 4.25
Receiving an Education Packet/Decisional Aid and Decisional Conflict (SURE test)
Decisional Conflict
Absence
Present
Educational/DAs
Yes Count
71
27
Provided by HCP
% within
72.4%
27.6%
Educational/DAs
% within SURE_test
58.2%
34.2%
No
Count
51
52
% within
49.5%
50.5%
Educational/DAs
% within SURE_test
41.8%
65.8%
Total
Count
122
79
% within
60.7%
39.3%
Educational/DAs
% within SURE_test
100.0%
100.0%

Total
98
100.0%
48.8%
103
100.0%
51.2%
201
100.0%
100.0%

Figure 4.11
Received and Education Packet/Decision Aid from Healthcare Provider and Decisional Conflict
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Research Question 7. What is the relationship between time since decision and decisional
conflict?
The ODSF includes “decision timing” as part of the decisional needs’ assessment.
Therefore, timing since decision and decisional conflict was investigated to identify changes
over time. Time since decision was categorized as follows: currently continue to contemplate
decision (n = 42), decided within one month (n = 21), two months ago (n = 26), and three
months ago (n = 103). A chi-square test of independence (n = 192) indicated a statistically
significant association between the time since decision and decisional conflict (as measured by
the SURE test), χ²(3, n = 192) = 33.208, p < .001, Cramer’s V = .416. Overall decisional conflict
was reported in 38.5% (n = 74) of individuals from this sample. Those currently contemplating a
decision reported 76.2% (n = 32) presence of decisional conflict. Interestingly, 30.1% (n = 31)
of individuals who decided three months ago reported decisional conflict, with lower reported
rates at 1 month (n = 6, 28.6%) and two months after their decision (n = 5, 19.2%; Table 4.26).
This may give evidence that individuals continue to have decisional conflict after a decision has
been made and initial acceptance may occur, but over time, an individual may reconsider the
decision. Although there are different participants in each cohort, there may be a trend in
individuals who have decisional conflict prior to decision and its reoccurring months after the
decision (Figure 4.12), where individuals who do not report decisional conflict may adapt and
accept their decision.
Table 4.26
Time Since Decision and Decisional Conflict (SURE test)

Time Since
Decision

Currently
Deciding

n
% within Time

Decisional Conflict
(SURE test)
Absence Present
Total
10
32
42
23.8%
76.2% 100.0%
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Within one
month
2 months

3 months

Total

% within
SURE test
n
% within Time
% within SURE_test
n
% within Time
% within SURE_test
n
% within Time
% within SURE_test
n
% within Time
% within SURE_test

8.5%

43.2%

21.9%

15
71.4%
12.7%
21
80.8%
17.8%
72
69.9%
61.0%
118
61.5%
100.0%

6
28.6%
8.1%
5
19.2%
6.8%
31
30.1%
41.9%
74
38.5%
100.0%

21
100.0%
10.9%
26
100.0%
13.5%
103
100.0%
53.6%
192
100.0%
100.0%

Figure 4.12
Time Since Decision and Decisional Conflict. Representing separate cohorts in each category.
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Research Question 8. What is the relationship between decisional self-efficacy and
participation in shared decision-making in an Afib sample?
The relationship between reported decisional self-efficacy (as measured by the DSES)
and SDM (as measured by the SDM-Q-9) was investigated using the Pearson product-moment
correlation coefficient. There is a strong, positive correlation between the two variables, r = .536,
n = 177, p < .001, with high levels of decisional self-efficacy associated with higher levels of
participation in SDM-Q-9 (Table 4.27 and Figure 4.13), where decisional self-efficacy explains
28.7% of the variance in respondents’ scores. The results may be reflective of ceiling effects, as
both instruments are self-reported.
Table 4.27
Correlations Decisional Self-Efficacy Scores and SDM-Q-9

Pearson Correlation

Sig. (2-tailed)

N

SDM-Q-9 Score
Decisional Self-Efficacy
Score
SDM-Q-9 Score
Decisional Self-Efficacy
Score
SDM-Q-9 Score
Decisional Self-Efficacy
Score

Decisional SelfSDM-Q-9 Score Efficacy Score
1.000
.536
.536
1.000
.
.000

.000
.

181
177

177
201
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Figure 4.13
Scatterplot of Decisional Self-Efficacy Scores and Participation in Shared Decision-Making
Scores

Research Question 9. What is the relationship between decisional conflict and participation
in shared decision making in an Afib sample?
In this sample (n = 181), 58% of participants (n = 105) reported no decisional conflict
and 42% of participants (n = 76) reported the presence of decisional conflict. A one-way
between-group analysis of variance was conducted to explore the impact of decisional conflict as
measured by SURE test and participation in SDM as measured by SDM-Q-9. There was a
statistically significant difference at the p < .05 level in SDM-Q-9 scores between those who
reported decisional conflict (n = 76, M = 51.52) and those reporting no decisional conflict (n =
105, M = 66.46) as measured by the SURE test: F (1, 179) = 18.326, p < .001. The effect size,
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calculated using eta squared, was .09 (representing a medium to large effect). Participants
reporting decisional conflict (as measured by SURE test) had lower scores in on the SDM-Q-9,
therefore participated less in SDM for stroke prevention (Table 4.28, Figure 4.14).
Table 4.28
Decisional Conflict (SURE test) and Participation in Shared Decision-Making (SDM-Q-9)
95% Confidence
Interval for Mean
Lower
Upper
Decisional Conflict (SURE
test)
N
M
SD
SE
Bound
Bound
Absence
105 66.46
22.732
2.218
62.06
70.85
Present
76 51.52
23.751
2.724
46.09
56.95
Total
181 60.18
24.254
1.803
56.63
63.74
Figure 4.14
Decisional Conflict (SURE test) and Shared Decision-Making Scores (SDMQ9)
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Research Question 10. What is the relationship between control preferences style in
decision making for stroke prevention and participation in shared decision making in an
Afib sample?
In this sample (n = 180), 36.7% of participants (n = 66) responded as Active participants
(M = 56.60, SD = 24.994), 45.5% (n = 82) responded as Collaborative/Shared Control in
decision making (M = 60.14, SD = 22.374), and 17.8% (n = 32) responded as having a Passive
role (M = 67.85, SD = 26.631). A one-way between-group analysis of variance was conducted to
explore the relationship of control preference in the stroke prevention decision as measured by
CPS and participation in SDM as measured by SDM-Q-9. There was no statistically significant
difference at the p < .05 level in DSM-9-Q scores between active, collaborative/shared, or
passive control preferences in decision making. F (2, 177) = 2.340, p = .099. Although this was
not statistically significant, participants who considered themselves “passive” (n = 32) in the
decision-making process in stroke prevention reported higher scores on the SDM-Q-9
questionnaire (M = 67.85) than those reporting collaborative/shared (n = 82, M = 60.14) and
active roles (n = 66, M = 56.6) in SDM for stroke prevention (Table 4.29 and Figure 4.15).
Table 4.29
Control Preference (CPS) and Shared Decision-Making Scores (SDM-Q-9)
95% Confidence Interval for
Mean

Control/Role
Passive
Collaborative/Shared
Active
Total

N

32
82
66
180

M

67.85
60.14
56.60
60.21

SD

26.631
22.374
24.994
24.319

SE

4.708
2.471
3.077
1.813

Lower Bound Upper Bound

58.25
55.22
50.46
56.63

77.45
65.05
62.74
63.79
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Figure 4.15
Control Preference and Shared Decision-Making Scores

Research Question 11. What is the relationship between frailty status and participation in
shared decision-making in an Afib sample?
The FRAIL scale has been used as both a continuous ranging from 0 to 5 (Gardiner et al.,
2015) and as a three categorical scale, where scores of 0 indicate robust health, 1-2 indicate a
pre-frail state, and 3-5 indicate a frail state (Gleason et al., 2017; Morley et al., 2012). While
examining the dispersion of participants, the decision was made to use a three categorical scale,
as there were only four participants scoring 4 and one scoring a 5 (Table 4.30). Therefore, scores
of 0 are robust, scores of 1-2 are combined as pre-frail, and scores of 3 and greater are
considered frail. Overall, in this sample (n = 176), 12.5% of participants (n = 22) reported a frail
status (M = 62.53, SD = 24.296), 46.6% (n = 82) reported as pre-frail (M = 60.08, SD =
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24.663), and 40.9% (n = 72) reported as robust (M = 59.66, SD = 24.553), based on the FRAIL
3-Categorical Scale (Table 4.31). A one-way between-group analysis of variance was conducted
to explore the relationship between frailty status measured by the FRAIL Scale (categorical) and
participation in SDM as measured by SDM-Q-9. There was no statistically significant difference
at the p < .05 level in DSM-9-Q scores between Robust, Pre-Frail and Frail status decisionmaking, F(2, 173) = .117, p = .890. Although not reaching statistical significance, individuals
reporting Frail status reported higher scores on the SDM-Q-9 than pre-frail and robust. These
findings suggest that the frail status of an individual should not bias clinicians into assuming frail
or that pre-frail individuals prefer not to participate in SDM regarding stroke prevention.
Table 4.30
Descriptives: FRAIL Scores (n = 176)
Frequency
Valid
0
72
1
55
2
27
3
17
4
4
5
1
Total
176

%

Valid %
39.8
30.4
14.9
9.4
2.2
.6
97.2

40.9
31.3
15.3
9.7
2.3
.6
100.0

Cumulative %
40.9
72.2
87.5
97.2
99.4
100.0

Table 4.31
FRAIL-3 Categories and Participation in Shared Decision Making (SDM-Q-9)

N
Robust
Pre-Frail
Frail
Total

72
82
22
176

M
59.66
60.08
62.53
60.21

SD
24.553
24.663
24.298
24.449

SE
2.894
2.724
5.180
1.843

95% Confidence Interval for
Mean
Lower Bound Upper Bound
53.89
65.43
54.66
65.50
51.75
73.30
56.58
63.85
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Research Question 12. What is the relationship between participation in shared decision
making and satisfaction with decision for stroke prevention in atrial fibrillation in a sample
of individuals with Afib?
The relationship between perceived participation in SDM (as measured by SDM-Q-9)
and SWD on a continuous scale of 6 to 30 was investigated using the Pearson product-moment
correlation coefficient (n = 129). There was a positive correlation between the two variables (r
= .431, n = 129, p < .01), with high levels of participation in SDM associated with higher levels
of SWD (Figure 4.16), with an 18.5% shared variance between SDM and SWD in this sample.
Figure 4.16
Shared Decision-Making Scores (SDMQ9) and Satisfaction with Decision Scores (SWD)
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Research Question 13. What is the relationship between consequence (event) of decision
and satisfaction with decision in a sample of individuals with Afib?
To examine SWD further, participants were asked if there was a consequence to their
decision: “After making this decision on stroke prevention, did you have an event requiring a
visit to a health care provider, emergency room or hospital related to your decision?” A one-way
between-group analysis of variance was conducted to explore the relationship between the
consequences of decision and SWD measured by the SWD scale. There was no statistically
significant difference at the p < .05 level in SWD and reporting yes or no to consequence as a
result of their decision F (1,131) = 2.893, p = .091. However, SWD scores were greater in
participants who responded “no” to having a consequence after making the decision (M = 26.20,
SD = 26.20) than participants responding “yes” (M = 24.93, SD = 24.93) (Table 4.32). The SWD
scale was designed not to assume a good health outcome but to measure satisfaction with a
health care decision (Holmes-Rovner et al., 1996).
Table 4.32
Satisfaction with Decision Scores and Experiencing a Consequence After the Decision

Consequence
Yes
No
Total

N
30
103
133

M
24.93
26.20
25.92

SD
4.323
3.368
3.627

95% Confidence Interval for
Mean
SE
Lower Bound Upper Bound
.789
23.32
26.55
.332
25.55
26.86
.314
25.30
26.54
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Predictive Models for Shared Decision-Making and Decisional Conflict
Predictors Model- Participation in Shared Decision-Making
Findings from this study identified significant relationships between concepts and
participation in SDM for stroke prevention, therefore a direct logistic regression was performed
to assess the impact of several factors on the likelihood of participation in SDM. A mean value of
60 on the SDM-Q-9 was used as the cut-off value to distinguish an individual participating in
SDM. The value of 60 reflects the mean and median scores on the SDM-Q-9 in this sample (n =
181), where scores below 60 were designated as a low level of participation and scores 60 or
greater were designated as a higher level of participation in SDM. Therefore, low scores (< 60)
are transformed to 0 and scores 60 or greater (=/> 60) are transformed to 1. The model contained
six independent variables (type of Afib, CHA2DS2-Vasc [2 categorical], gender, age [3
categories], decisional conflict status, educational pamphlet/DA use, and continuous decisional
self-efficacy score). Using Tabachnick and Fidell’s formula where N > 50 + 8m (where m =
number of independent variables), a sample size of 180 (50 + (8*7[variables]) would be
sufficient to detect a relationship (Bujang, Sa’at, & Tg Abu Bakar Sidik, 2017; Pallant, 2016, p.
151). The full model containing all predictors was statistically significant, χ² (7, N = 145) =
50.741, p < .001, indicating that the model was able to distinguish between respondents who
reported and did not report scores of 60 or greater on the SDM-Q-9. The model explained
between 29.57% (Cox and Snell R squared) and 39.5% (Nagelkerke R squared) of the variance in
scores of 60 or greater on the SDM-Q-9 and correctly classified 69% of cases. Two variables
made a statistically unique and significant contribution to the model (receiving an education
packet/DA and greater scores on the DSES; Table 4.33). The strongest predictor of reporting
scores of 60 or greater on the SDM-Q-9 was scores on the DSES, recording an odds ratio of
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1.060. This indicated that for each point on the DSES (p < .01), respondents were 1.060 more
likely to report a score of 60 or greater in participating in SDM on the SDM-Q-9. Individuals
who received an educational packet/DA (p < = .029) were 2.471 times more likely to report
participating in SDM based on score of 60 or greater on the SDM-Q-9. This model has a positive
predictive value of 69.3%, with a sensitivity of 77.2% and specificity of 59.1%.
Table 4.33
Variables in the Equation Logistic Regression Participation in SDM (quantified as scores of 60
or greater on the SDM-Q-9)
95% C.I. for
EXP(B)
B

Step
1a

Male Gender
Permanent Afib
=/> 75 years
Received an
Education/Decisio
nal Aid
No Decisional
Conflict
CHA2DS2-VASc
3-9
Decisional SelfEfficacy Score
SelfConstant

SE

Wald

df

Sig.

Exp(B)

Lower

Upper

.260
1.859
.464
.905

.430
1.023
.526
.415

.365
3.305
.777
4.754

1
1
1
1

.546
.069
.378
.029

1.297
6.418
1.590
2.471

.558 3.010
.865 47.642
.567 4.461
1.096 5.574

.078

.447

.031

1

.861

1.081

.451

2.595

.045

.431

.011

1

.917

1.046

.449

2.436

.059

.016 14.065

1

.000

1.060

1.028

1.093

-5.646

1.321 18.270

1

.000

.004

a. Variable(s) entered on step 1: Male Gender, Permanent Afib, Age =/> 75 years, Received an
Education Packet/Decisional Aid, Reports no Decisional Conflict (SURE test), CHA2DS2-VASc scores
of 3 or greater, Decisional Self-Efficacy Score

Predictors of Decisional Conflict
Current research focuses on the concept of decisional conflict in medical SDM; therefore,
a direct logistic regression was performed to assess the impact of several factors on the
likelihood that respondents would report the presence of decisional conflict. The model
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contained four independent variables (Gender [female], Non-Partnered, Paroxysmal Afib, and
not receiving an Educational Packet/DA). The model was statistically significant, x² (4, N = 155)
=16.229, p = .003, indicating that the model can distinguish between respondents who did not
report and those who reported decisional conflict as quantified by the SURE test. The model
explained between 9.9% (Cox and Snell R square) and 13.3% (Nagelkerke R squared) of the
variance of independent variables and correctly classified 66.5% of cases. Only two of the
variables made a unique and statistically significant contribution to the model (non-partnered [p
= .019] and individuals who had not received an education packet/DA [p = .022]). Nonpartnered participants reported an odds ratio of 2.688, indicting they are 2.688 more times likely
to report decisional conflict than partnered individuals, and individuals who had not received an
educational packet/DA are 2.225 times more likely to report decisional conflict than participants
who had received such items (Table 4.34). This model has a positive predictive value of 65.8%
with a sensitivity of 51.5% and specificity of 78.2%.
Table 4.34
Variables in the Equation Logistic Regression Predicting Decisional Conflict
95% C.I. for
EXP(B)
B
Step 1

a

SE

Wald

df

Sig.

Exp(B)

Lower

Upper

Female Gender-1

.299

.357

.703

1

.402

1.349

.670

2.716

Non-Partnered-1

.989

.422

5.483

1

.019

2.688

1.175

6.150

Paroxysmal Afib

.477

.381

1.565

1

.211

1.611

.763

3.401

No Education
Packet/Decisional
Aid

.800

.350

5.227

1

.022

2.225

1.121

4.417

.389 13.094

1

.000

.245

Constant

-1.408

a. Variable(s) entered on step 1: Female Gender, Non-Partnered, Paroxysmal Afib, No Educational
Packet/Decisional Aid Received
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Conclusion
In this chapter, a comprehensive decisional needs assessment based on the ODSF was
investigated to explore relationships between individual characteristics and participation in SDM
for thromboembolic stroke prevention in an Afib sample. The embedded theories of decisional
self-efficacy and decisional conflict in ODSF supported much of the findings. In this chapter,
data were organized and described. Analysis in this study included Chi-square, ANOVA,
Pearson’s product-moment correlations and logistic regression. Participants were predominantly
White (97.5%), female (53.7%), between 65-74 years old (47.8%), married or partnered (75.6%),
college educated (72.2%), with most reporting paroxysmal Afib (56.7%). Reliability testing
demonstrated instruments valid for use in this sample, as reporting Cronbach’s alpha: DSES
= .952, SDM-Q-9 = .930, and SWD = .915 and Spearman-Brown half-split reliability for: SURE
test = .808, Control Preference = .669 and FRAIL Scale (3 item) = .743.
Statistical significant results regarding participation for stroke prevention in this sample
of individuals with Afib demonstrated the following: greater participation in SDM reported in
participants: 75 years or older (p = .023), men (p = .002), participants reporting permanent Afib
(p = .049), CHA2DS2-VASc score of 3-7 (p = .043), individuals receiving an educational packet
or DA from healthcare provider (p < .01), greater decisional self-efficacy scores (p < .01), and
participants reporting less decisional conflict (p < .01). Men reported higher decisional selfefficacy scores (p = .011), while women (p = .041), non-partnered participants (p = .014),
participants reporting paroxysmal Afib (p = .028), and individuals who did not received an
educational packet/DA from their clinician (p < .01) were associated with greater decisional
conflict. Overall, 76.2% (n = 32) of individual currently considering treatment decision
compared to those who made a decision within 1 month (28.6%, n = 6), 2 months (19.2%, n =
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5), and 3 months ago (30.1%, n = 31) reported decisional conflict (p < .01). Non-college
participants reported a greater passive role than college graduates (30% versus 14.1%
respectively; p = .024).
Participation in SDM was strongly correlated with SWD (p < .01). From these findings,
the prediction models identified the following: greater decisional self-efficacy scores (p < .01)
and receiving a DA or education packet from healthcare provider (p = .029) were the most
predictive variables for participating in SDM for stroke prevention (p < .01). On the other hand,
non-partnered individuals (p = .019) and those participants not receiving a DA or education
packet from a healthcare provider (p = .022) were the most predictive of decisional conflict (p
< .01). In this sample, frailty status (p = .099) and control preference were not reported as
statistically significant (p = .890) regarding participation in SDM.

201
CHAPTER FIVE: DISCUSSION AND RECOMMENDATIONS
SDM for stroke prevention in the Afib population is recommended and embedded within
professional organizational guidelines. Supporting individuals with Afib through the decisionmaking process is considered an important function of nursing practice. Therefore, nursing
practice should include the assessment of “decisional needs,” identifying individualized barriers
and facilitators of SDM, along with educating and preparing individuals to participate in SDM.
Using an online survey, this study described, compared, and correlated individualized
characteristics and participation in SDM for thromboembolic stroke prevention in Afib.
This study determined that in this sample (n = 201), increased SDM was associated with
individuals 75 years and older, male gender, individuals with permanent Afib, CHA2DS2-Vasc
scores of 3 or greater, individuals with greater decisional self-efficacy scores, individuals
reporting “no decisional conflict”, and those receiving educational material or DAs. Educational
attainment, relationship status (partnered vs. non-partnered), control preference (measured by
CPS), and frailty status (measured by the FRAIL scale) did not demonstrate statistical
significance in participation in SDM for stroke prevention in this sample. SDM and satisfaction
with the decision for stroke prevention demonstrated a positive linear correlation, where greater
reporting of SWD was associated with higher scores on participation in SDM-Q-9 for stroke
prevention. The purpose of this research study was to determine factors associated with
individual characteristics in an Afib sample and participation in SDM for stroke prevention. This
chapter explains the findings and associated previous findings. Several findings were examined
in greater depth to explain the outcomes. This chapter also identifies strengths and limitations of
the study along with describing implications of the findings to nursing education, practice, and
future research. This study’s major findings can be found in Appendix O.
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Subject Characteristics
The majority of patients who participated in this trial were overwhelmingly between the
ages of 65-74 (47.8%), female (53.7%), White (97.5%), married or partnered (75.6%), and
college graduates (72.2%). Consistent with some prior studies on Afib and SDM studies, this
sample was overwhelmingly older than 65, predominantly White, married or partnered, with
CHA2DS2-VASc scores 1 or greater. For a comparison of demographics from prior studies in
SDM and Afib, see Table 5.1 (Fraenkel et al., 2012; Man-Son-Hing et al., 1999; McAlister et al.,
2005; Thomson et al., 2007).
Table 5.1
Demographic comparing this study (Afib: DMSP) to previous studies on SDM and Afib
Study

Fraenkel et
al., 2012

Man-SonHing et
al., 1999

Thomson
et al., 2007

McAlister
et al., 2005

Sample Size
Age M
Age
<65
65-74 yrs.
=/> 75
Female
Non-Hispanic
White

135
NA

287
M = 66

109
M = 73

434
M = 72

This
Study
Afib:
DMSP
201
NA

22.2%
21.5%
56.3%
0.5%
ND
94%

NA
NA
NA
24%
ND
ND

NA
NA
NA
44%
ND
ND

ND
NA
NA
38.9%
ND
ND

28.8%
47.8%
23.4%
53.7%
98.5%
97.5%

Married
CHA2DS2-Vasc
0
1-2
3+

60%

ND

ND

ND

76.4%a

ND
ND
ND

ND
ND
ND

ND
ND
ND

4.35%
50.0%
45.65%

Paroxysmal Afib

3.7%
65.9%
30.4%
(max 5)
ND

ND

ND

38.3%

56.7%

College Graduate

ND

ND

ND

ND

72.2%

Note. NA = not applicable, ND = no data, a married/partnered
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The guidelines for the treatment of stroke prevention in Afib recommended that in
patients with Afib, therapy should be individualized on the basis of SDM after discussing the
absolute risks and relative risk of stroke and bleeding, as well as incorporating individual values
and preferences (January et al., 2019). Based on scores from the SDM-Q-9 (n = 181), 32.6% (n
= 59) of participants scored 75 or greater (M = 60.18, Mdn = 60.00) when participating in
decision making for stroke prevention. Although a ceiling effect may be an influential factor,
when asked to self-report on a scale of 0 to 100 (n = 185, M = 76.77, Mdn = 87.0), scores were
greater than measured on the SDM-Q-9 (Table 5.2). Based on the findings of this study overall,
more individuals participate in SDM than those who do not. To this researcher’s knowledge,
there are no previous studies in the Afib population using the SDM-Q-9 scale to assess for
participation in SDM. Cronbach’s alpha coefficient of .930 for this 9-item instrument (n = 181)
demonstrated acceptable reliability in this sample and therefore may be suitable to use in the
Afib population for future studies, although further reliability testing in an alternative Afib
sample is recommended.
Table 5.2
Statistics Comparing SDM-Q-9 and Self Reports of Shared Decision Making
SDM-Q-9 Score
Self-Report SDM (0-100)
N
Valid
181
185
Mean
60.18
76.77
Median
60.00
87.00
Mode
80
100
Minimum
0
0
Maximum
100
100
Percentiles
25
45.56
68.00
50
60.00
87.00
75
80.00
99.50
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Individual Characteristics and SDM
Age
Decision making becomes more complex for older people with multiple health and care
needs as the capacity to self-manage is affected by cumulative effects of long-term complications
(Bunn et al., 2018). Prior literature notes that clinicians may apply less SDM in practice with the
elderly (Meijers et al., 2019), and older and younger age has been identified as a barrier to
facilitating SDM (Joseph-Williams, Elwyn et al., 2014). One prior study examining self-efficacy
and participation in cancer trials indicated that enhancing self-efficacy may be the key factor in
facilitating decisions (Miller et al., 2013).
When investigating differences in age cohorts and DSES total scores, there were no
statistical differences (p = .446). However, as individuals’ cohort ages increased, so did selfefficacy scores. Based on Bandura’s self-efficacy theory, one would expect to find statistical
significance, but this did not emerge. Therefore, for further investigation, each item was
examined on the 11-item DSES for further review. Interestingly, item # 10 (“Let the clinic team
know what’s best for me”) was significant (p = .006) in individuals less than 65 years (M = 3.05,
n = 58), 65-74 years (M = 3.45, n = 96), and participants 75 years and older (M = 3.47, n = 47;
Table 5.3). Based on the mean scores, this finding suggests that younger individuals are less
likely to let the clinic team know what’s best for them. For all groups combined, although item
#10 was not the lowest scored item on the DSES (M = 3.34, n = 206; Table 5.4), reviewing all
age groups combined item #1 (“Get the facts about the medication choices,” M = 3.32), item #2
(“Get the facts about the benefits of each choice,” M = 3.25), item #3 (“Get the facts about the
risks and side effects of each choice,” M = 3.15), and item #8 (“Figure out the choice that best
suits me” M = 3.31) were the lowest scoring items for all age groups combined (Table 5.4). This
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may suggest that discussion within the clinical encounter may not be focusing on clinical
information such as risks and benefits or that patients are not receptive to listening to risks and
benefits.
Table 5.3
Age Cohort Groups and Decision Self-Efficacy, Item #10 “Let the health care team know what’s
best for me”
95% Confidence
Interval for Mean
Lower
Upper
N
M
SD
SE
Bound
Bound
DSES10 <65
58
3.05
1.083
.142
2.77
3.34
65-74
96
3.45
.694
.071
3.31
3.59
=/>75
47
3.47
.747
.109
3.25
3.69
Total
201
3.34
.851
.060
3.22
3.46

Table 5.4
Mean Decisional Self Efficacy (DSE) Scale All Items- All Ages

Mean

DSE1 DSE2 DSE3 DSE4 DSE5 DSE6 DSE7 DSE8 DSE9 DSE10 DSE11
3.32 3.25 3.15 3.42 3.45 3.42 3.38 3.31 3.43 3.34
3.39

There were no statistical differences between age cohorts and decisional conflict scores
(p = .211). However, older individuals reported less decisional conflict than their younger
cohorts where decisional conflict was reported in 43.9% in participants < 65 years, 41.8% in
participants 65-74 years, and 28.3% in individuals 75 years and older. This is inconsistent with
prior findings in an Afib cohort where younger age was associated with lower overall decision
conflict scores (using the 16 item DCS; p < .04; Man-Son-Hing et al., 1999).
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In this study, there was a statistically significant difference (p = .023) between three age
cohorts and SDM scores (SDM-Q-9) with the greatest difference seen between ages < 65 years
(M = 54.93, n = 50) and those 75 years and older (M = 68.67, n = 41; Table 5.5).
Table 5.5
Age Cohorts and SDM-Q-9 Scores

N
< 65
65-74
=/> 75
Total

50
90
41
181

M
54.93
59.23
68.67
60.18

SD
27.375
22.969
21.092
24.254

95% Confidence Interval for Mean
Lower Bound
Upper Bound
47.15
62.71
54.42
64.05
62.01
75.33
56.63
63.74

Previous studies have used the CPS in evaluating SDM, and contrasts are made in this study
(Afib: DMSP). In this study (Afib: DMSP), there was no statistical difference between age
cohorts and control preference (p = .088). Overall, 44.3% (n=85) preferred a
collaborative/shared role, 37.5% (n=72) preferred an active role and 18.2% (n=35) preferred a
passive role. The findings in this study are consistent with a previous study in multimorbid
individuals and decision making, where 82.7% of individuals 75-84 years old and 71.8% of
individuals 85 years and older preferred an active role (Chi et al., 2017). Chi and colleagues
categorized the sample with two categories (active or passive). In this study (Afib: DMSP), the
use of the CPS with three distinct categories (Active, Collaborative/Shared, and Passive)
revealed that 53.1% of individuals 65-74 years reported preferring a collaborative/shared role
and 34.4% preferred an active role. In contrast, Chi, and colleagues (2017) reported that
combining both collaborative/shared and active would produce similar results. Additionally,
there were consistent findings among individuals with coronary artery disease, where there was
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no statistical difference in age and control preference using the CPS. However, inconsistent with
this study’s (Afib: DMSP) findings, 7% preferred an active role, 33% preferred a
collaborative/shared role, and 60% preferred a passive role (Burton et al., 2010). Among
participants 75 years and older, 31.8% preferred a collaborative/shared role and 40.9% preferred
an active role. Furthermore, participants 75 years and older reported the greatest percentage of
passive role (27.3%) compared to those 65-74 (12.5%) and under 65 (21.2%; Table 5.6). This is
similar to other non-Afib cohort studies (Chi et al., 2017; De las Cuevas & Peñate, 2016;
Lechner et al., 2016); where older individuals reported a more passive role than younger cohort
groups.
Table 5.6
Age and Control Preference Scale (CPS)
<65
CPS

Passive
CollaborativeShared
Active

Total

n
% within Age
n
% within Age
n
% within Age
n
% within Age

11
21.2%
20
38.5%
21
40.4%
52
100.0%

Age3
65-74
12
12.5%
51
53.1%
33
34.4%
96
100.0%

=/>75
12
27.3%
14
31.8%
18
40.9%
44
100.0%

Total
35
18.2%
85
44.3%
72
37.5%
192
100.0%

Overall, although some statistical test may not reach significance, older participants
reported; higher decisional self-efficacy scores (p = .446), lower reports of decisional conflict (p
= .211), preference for a collaborative/shared or active role (p = .088) and higher scores on the
participation in SDM-Q-9 (p = .023). According to Bandura, mastery is the most influential
source of efficacy, as it is described as the most authentic evidence of whether one can do
whatever it takes to succeed and is an indicator of capability (Bandura, 1997, p. 80). In this
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study, although the elderly reported a greater passive role than cohorts, they still perceived
participating in SDM more so than younger cohorts based on the SDM-Q-9 scores. Health care
providers through bias or historical context may assume that older individuals do not want to
participate in decision making. However, when considering Bandura’s self-efficacy concept
within the ODSF, the concept of mastery through potentially more frequent exposure to health
care interactions and experiences as one gets older may influence decisional self-efficacy. Selfefficacy can therefore influence desire or actual participation in health care decisions regarding
stroke prevention in Afib.
Gender
In this study, males reported greater participation in SDM (p = .002) than females and
statistically significant higher scores on the DSES (p = .011). To explain the differences in the
self-efficacy finding between the genders, a further analysis of each item on the DSES were
investigated according to gender responses. On the DSES, women scored statistically
significantly lower on questions with a social context (Table 5.7), such as item #5,6,7,9 and 10:
“Ask questions without feeling dumb” ( p = .046), “Express my concerns about each choice” (p
= .017), “Ask for advice” (p = .010), “Handle unwanted pressure from others in making my
choice” (p = .014), and “Let the clinic team know what’s best for me” (p = .006; Table 5.7 &
5.8). This may be explained by historically social structured system that have suppressed
women’s voices, which has the potential to marginalize and silence them (Wittmann-Price,
2004). This is an important finding as women have a higher burden of stroke risk factors than
men (Covel, 2014). Item number nine on the DSES, - “figure out the choice that best suits me”
may reflect the overall scores on the DSES and gender differences in this sample as women
scored lower on overall DSES. Implications to consider include women may lack self-efficacy
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and therefore may require education and skills to increase their self-efficacy in a social setting,
including a SDM process. Gender differences manifest in decision making where men
demonstrate heightened levels of reward drive and are likely to take more risks than women
(Zhang, Xiao, & Gu, 2017). The findings in this study (Afib: DMSP) may suggest that women
carefully consider options and risks more than men, and according to decisional conflict within
the ODSF, women may vacillate when it comes to health care decisions. Miller and colleagues
(2013) recommended enhancing self-efficacy related to decision making may be the key factor in
facilitation decisions and recommend further exploration of interventions to prepare and assist
individuals in making effective choices to reduce conflicts surrounding decisions (Miller et al.,
2013).
Table 5.7
ANOVA- Gender and Decisional Self-Efficacy Scale (Items 5-10)
Sum of
Squares
df
Mean Square
DSES5
Between Groups
3.553
1
3.553
Within Groups
179.248
204
.879
Total
182.801
205
DSES6
Between Groups
4.830
1
4.830
Within Groups
170.729
204
.837
Total
175.558
205
DSES7
Between Groups
6.388
1
6.388
Within Groups
191.708
205
.935
Total
198.097
206
DSES8
Between Groups
4.775
1
4.775
Within Groups
157.749
204
.773
Total
162.524
205
DSES9
Between Groups
6.136
1
6.136
Within Groups
155.422
204
.762
Total
161.558
205
DSES10 Between Groups
5.410
1
5.410
Within Groups
144.144
204
.707
Total
149.553
205

F
4.044

Sig.
.046

5.771

.017

6.831

.010

6.175

.014

8.054

.005

7.656

.006
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Table 5.8
Gender differences in Item 5-10 Scores on the Decisional Self-Efficacy Scale

N
DSES5

DSES6

DSES7

DSES8

DSES9

DSES10

Male
Female
Total
Male
Female
Total
Male
Female
Total
Male
Female
Total
Male
Female
Total
Male
Female
Total

94
112
206
95
111
206
95
112
207
94
112
206
95
111
206
95
111
206

M
3.59
3.32
3.44
3.57
3.26
3.40
3.56
3.21
3.37
3.46
3.15
3.29
3.59
3.24
3.40
3.51
3.18
3.33

SD
.860
.997
.944
.753
1.033
.925
.834
1.067
.981
.812
.932
.890
.644
1.029
.888
.742
.916
.854

SE
.089
.094
.066
.077
.098
.064
.086
.101
.068
.084
.088
.062
.066
.098
.062
.076
.087
.060

95% Confidence Interval
for Mean
Lower
Upper
Bound
Bound
3.41
3.76
3.13
3.51
3.31
3.57
3.42
3.72
3.07
3.46
3.28
3.53
3.39
3.73
3.01
3.41
3.23
3.50
3.29
3.62
2.98
3.33
3.17
3.41
3.46
3.72
3.05
3.44
3.28
3.52
3.35
3.66
3.01
3.35
3.21
3.45

In this study, men reported statistically significant less decisional conflict than women (p
= .041), which is consistent with a previous study in Afib, where being male was an independent
predictor of lower overall decision conflict scores on the 16-item DCS (p = .04) ( Man-Son-Hing
et al., 1999). Although in this study (Afib: DMSP) there was statistical significance in men
reporting higher scores in participating in SDM-Q-9 (M = 66.27, n = 83, p = .002), there was no
statistical significance in control preferences (Active/Shared-Collaborative/Passive; p = .155)
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between genders. However, men did report 24.1% (n = 21) passive role compared to 13.3% of
women (n = 14). Previous literature support these findings as men taking a greater passive role
than women (Chi et al., 2017; Lechner et al., 2016; Singh et al., 2010).
Decisional aids have been used as a strategy to mitigate decisional conflict (Stacey et al.,
2017). To examine a rationale why women reported more decisional conflict, an investigation
into the use of DAs in gender ensued. In this study (Afib: DMSP), women reported not receiving
an educational packet/DA 54% of the time versus men responding 50%. Women who did not
receive a DA reported lower SDM-Q-9 scores (M = 46.92) than their male cohorts (M = 56.67;
Table 5.9).
Table 5.9
Gender Reporting Not receiving an Education Packet/Decisional Aid and SDM-Q-9 Scores
Gender
SDM-Q-9
receiving no
EP/DA
N
Mean
Male
42
56.67
Female
53
46.92
Total
95
51.23
EP/DA=Education Packet/Decisional Aid

95% Confidence Interval for Mean
Lower Bound
49.11
40.51
46.33

Upper Bound
64.22
53.33
56.13

Additionally, when examining gender, CPS, and SDM-Q-9 scores, men who perceived a
passive role reported the highest scores on the SDM-Q-9 (M = 77.78, n = 19) than any other
groups (based on gender and control preference; Table 5.10). In this sample, this gives doubt to
the societal concept of shared and active decision making based on control preferences.
Individuals who prefer a passive role may in fact perceive they have participated in a SDM
method. Taking a passive role may historically be accepted by individuals ingrained social norms
of patients assuming a “good patient” role.
Table 5.10
Comparing Gender/Role Preference/Shared Decision-Making Scores (SDM-Q-9)
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SDM-Q-9
Gender CPS
N
Mean
Male
Passive
19
77.78
C/S
34
66.14
Active
30
59.11
Total
83
66.27
Female Passive
13
53.33
C/S
48
55.88
Active
36
54.51
Total
97
55.03
C/S= Collaborative/Shared Role

SD
23.260
22.880
24.396
24.277
25.223
21.226
25.633
23.249

SE
5.336
3.924
4.454
2.665
6.996
3.064
4.272
2.361

95% Confidence
Interval for Mean
Lower
Upper
Bound
Bound
66.57
88.99
58.16
74.13
50.00
68.22
60.96
71.57
38.09
68.58
49.72
62.04
45.83
63.18
50.34
59.71

Differences in gender and concepts of SDM were investigated in this study (Afib:
DMSP) study. Overall, men scored higher on in decisional self-efficacy (p = .011), less reporting
of decisional conflict (p = .041), and increased SDM-Q-9 (p = .002). When examining the
relationship between gender and control preference, there was no statistical significance (p
= .155). However, men reported greater passive role (24.1%) than women (13.3%) and yet
reported the highest scores on the SDMQ. These findings suggest that control preference and the
concept of SDM should not be used synonymously to interpret and quantify health care shared
decision-making, and regardless of what role an individual performs (Active/CollaborativeShared/Passive), SDM may occur based on an individual’s perceptions. The concept of
concordance in SDM is encouraged and refers to consistency in approaching SDM based on a
patient-preferred role of involvement. According to the ODSF, assessing individuals for a
preferred role in decision making and congruency in clinician approach can provide decision
support to increase the patient’s desire to participate in decision making (O'Connor et al., 2015).
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Educational attainment (non-college vs. college graduates)
Lower levels of education have been identified as a barrier to patient involvement in
SDM (Joseph-Williams, Elwyn et al., 2014). In this study, there was no statistical significance
between educational attainment described as non-college graduates versus college graduates and
participation in SDM-Q-9 (p = .470) for stroke prevention. Additionally, there was no statistical
difference in educational attainment with decisional self-efficacy (5-category, p = .173 and 2category, p = .632) and reported decisional conflict (p = .083). Expected findings revealed
college graduates reported higher scores on the DSES (M = 84.17, n = 145) than non-college
graduates (M = 82.75, n = 56). However, unexpected findings were that college graduates
reported greater decisional conflict (42.6%, n = 64) than non-college participants (27.8%, n =
15). In a previous study in prostate cancer, more education (post-elementary) education was
associated with less decisional conflict (p < .05; Chien et al., 2014). In this study, greater degree
of decisional conflict in college graduates may be explained by college graduates perhaps
analyzing the information to a greater degree than non-college graduates. Overall, the groups
demonstrated a 38.5% decisional conflict.
Individual control preferences demonstrated non-college graduates reported a more active
role (38%, n = 19) in decision making and college graduates preferring a collaborative role
(48.6%, n = 69, p = .024). In both groups, 18.2% (n = 35) reported a passive role preference, but
non-college educated reported higher rates of passive role 30% (n = 15) than their college
counterparts, 14.1% (n = 20). These findings are consistent with previous research as lower
education levels have been identified as a barrier to decision-making interactions and individuals
may prefer a more passive role (De las Cuevas & Peñate, 2016; Joseph-Williams, Elwyn &
Edwards, 2014; Mah et al., 2016). However, in a study with individuals with coronary artery
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disease, there were no statistical differences in control preference using the CPS and educational
attainment (Burton et al., 2010). Although considering the non-college graduates greater report
for an active 38% (n = 19) one may hypothesize the process of SDM potentially having a “power
challenge” between patient and provider. SDM is a balance between the physician as the clinical
knowledge expert and patient as the expert in what matters to them. Based on the CPS statement,
the “active” role takes the clinicians input to a less degree than collaborative/shared roles.
Therefore, based on SDM models, a shared or collaborative role should be the goal to promote
interaction between experts. To explain participant choosing the active versus the shared role, the
growth of patient involvement in health care deliberation may give historically marginalized
populations a voice in health care decision making and potentially narrow the power disparity
(O'Shea et al., 2019).
Although no statistical significance was found (p = .470), non-college graduates reported
higher scores in SDM-Q-9, reporting greater participation in SDM (M = 62.36 versus M =
59.40). Expectations may have been higher scores on the SDM-Q-9 in the college education
cohort. Although the SDM-Q-9 is a unidimensional instrument, further analysis into the 9 item
SDMQ instrument revealed interesting findings. In question #2, 3, and 6, college graduates
reported higher scores (Table 5.11): item #2, “My doctor wanted to know exactly how I wanted
to be involved in making the decision,” item #3, “My doctor told me that there are different
options for treating my medical condition,” and item #6, “My doctor asked me which treatment
option I prefer.” Non-college graduates reported higher scores on items 1, 4, 5, 7, 8, and 9. Item
#1, “My doctor made clear that a decision needs to be made,” item #4, “My doctor precisely
explained the advantages and disadvantages of the treatment options,” item #5, “My doctor
helped me understand all the information,” item #7, “My doctor and I thoroughly weighed the
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different treatment options,” item #8, “My doctor and I selected the treatment option together,”
and item #9, “My doctor and I reached an agreement on how to proceed.” When examining each
item, college graduates responded with higher scores may be perceived as items (questions)
specific to ‘expected’ autonomous engagement where a clinician may see the college participants
as expected to understand. Whereas in non-college graduates the questions appear to be
questions of engagement where both the clinician and individual work for and seek engagement
between each other.
Table 5.11
Educational Attainment and Shared Decision-Making Scores (SDM-Q-9) item 1-9
95% Confidence Interval
for Mean
Lower
Upper
N
M
SD
Bound
Bound
SDM-9- Non-College
49
3.43
1.720
2.93
3.92
Q1
Graduate
College Graduate
132
3.28
1.432
3.03
3.53
Total
181
3.32
1.512
3.10
3.54
SDM-9- Non-College
49
2.78
1.662
2.30
3.25
Q2
Graduate
College Graduate
132
2.95
1.523
2.69
3.22
Total
181
2.91
1.559
2.68
3.13
SDM-9- Non-College
49
3.12
1.654
2.65
3.60
Q3
Graduate
College Graduate
132
3.24
1.539
2.98
3.51
Total
181
3.21
1.567
2.98
3.44
SDM-9- Non-College
49
3.10
1.686
2.62
3.59
Q4
Graduate
College Graduate
132
3.00
1.523
2.74
3.26
Total
181
3.03
1.565
2.80
3.26
SDM-9- Non-College
49
3.18
1.523
2.75
3.62
Q5
Graduate
College Graduate
131
3.16
1.391
2.92
3.40
Total
180
3.17
1.424
2.96
3.38
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SDM-9Q6

SDM-9Q7

SDM-9Q8

SDM-9Q9

Non-College
Graduate
College Graduate
Total
Non-College
Graduate
College Graduate
Total
Non-College
Graduate
College Graduate
Total
Non-College
Graduate
College Graduate
Total

49

2.65

1.575

2.20

3.11

131
180
49

2.86
2.81
2.98

1.592
1.586
1.639

2.59
2.57
2.51

3.14
3.04
3.45

132
181
49

2.70
2.78
2.92

1.567
1.587
1.631

2.43
2.55
2.45

2.97
3.01
3.39

131
180
48

2.72
2.77
3.40

1.427
1.483
1.484

2.47
2.55
2.96

2.96
2.99
3.83

132
180

3.34
3.36

1.375
1.401

3.10
3.15

3.58
3.56

When examining the relationship between educational attainment, there was no statistical
differences: decisional self-efficacy scores (p = .632), decisional conflict (p = .083), and SDM (p
= .470). However non-college graduates reported lower scores on decisional self-efficacy (M =
82.75 versus M = 84.17). Statistical significance was attained on the CPS (p = .024), where noncollege graduates reported a greater passive role than college graduates (30%, versus 14.1%,
respectively).
Relationship Status (partnered vs. non-partnered)
In this study, there was no statistical difference between partnered status and participation
in SDM (p = .100), decisional self-efficacy scores (p = .275), and control preference (p = .514).
However, partnered individuals reported higher scores on the SDM-Q-9, indicating more
participation in SDM (Table 5.12). Non-partnered individuals reported statistically significant
presence of decisional conflict (p = .014) compared to partnered individuals. Although this
study (Afib: DMSP) did not report on individuals “living alone”, Thompson-Leduc and
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colleagues (2016) noted a greater prevalence of decisional conflict in individuals who live alone
(Thompson-Leduc et al., 2016).
Table 5.12
Partnership Status and Shared Decision-Making Scores
95% Confidence
Interval for Mean
N
Not Partnered
Married/Partnered
Total

43
137
180

M
55.04
62.01
60.35

SD

SE

25.498
23.661
24.224

3.888
2.021
1.806

Lower
Bound
47.19
58.01
56.78

Upper
Bound
62.89
66.01
63.91

A previous study is consistent with these reports of no statistical differences in
relationship status and control preference (Chi et al., 2017; Janz et al., 2004). Surprisingly,
20.3% (n = 29) of partnered individuals reported a passive role compared to 12.8% (n = 6) of
non-partnered individuals, as this may reflect a small sample in the non-partnered passive
category (n = 6). In a previous study by Chi et al. (2017), they found that when an informal
caregiver was present at a medical visit, participants reported a greater passive role (p < .01, CI
1.78 [1.40-2.25]). There were no questions in this study examining the presence of “other”
individual during a healthcare consultation.
Type of Afib
To this researcher’s knowledge, this is the first study investigating decisional needs based
on the ODSF in an Afib sample without the use of DA investigation. A novel feature of this study
is examining self-reported type of atrial fibrillation and relation to concept within “decisional
needs”; therefore, these findings are unique. Prior research had demonstrated, when Afib is
difficult to predict, individuals felt a constant readiness for it to reappear (Ekblad et al., 2013).
Findings from this study reported statistically significant results regarding the type of Afib (e.g.,
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paroxysmal, persistent, and permanent) and participation in SDM-Q-9 (p = .049). Where,
participants with paroxysmal Afib reported lower scores (M = 58.22) in SDM than participants
with permanent Afib (M = 73.09; Table 5.13). There were no statistical differences in the type of
Afib and decisional-self-efficacy (p = .814). Permanent Afib reported greater scores on the
DSES (M = 86.05) than persistent (M = 84.87) and paroxysmal (M = 83.47). Based on selfefficacy theory, this finding was expected where individuals with permanent afib may have had
more exposure to clinical decision making and have “mastered” the experiences based on the
Bandura’s theory.
Table 5.13
Type of Atrial Fibrillation and Participation in Shared Decision-Making
95% Confidence Interval for
Mean
N
M
SD
SE
Lower Bound Upper Bound
Paroxysmal
105
58.22
23.971
2.339
53.58
62.86
Persistent
33
58.52
24.967
4.346
49.67
67.37
Permanent
18
73.09
20.365
4.800
62.96
83.21
Total
156
60.00
24.129
1.932
56.18
63.82
Participants with paroxysmal Afib reported a greater presence of decisional conflict (p
= .028, n = 171). Participants with paroxysmal reported 47.3% (n = 53) presence of decisional
conflict versus 38.9 % (n = 14) of persistent and 17.4% (n = 4) of permanent Afib. Based on
self-efficacy theory, this would be expected, as individuals with paroxysmal Afib may not have
had the chronic exposure to the arrhythmia and therefore may report greater decisional conflict.
This was further explored through narrative statements from individuals who self-reported as
having paroxysmal Afib. Narrative themes examined from individuals with self-reported
paroxysmal afib identified: themes of uncertainty, individual preferences, consideration of risks,
and the temporal nature of paroxysmal. These suggest greater uncertainty, which is the main
tenet within the ODSF incorporating Janis and Mann’s decisional conflict theory.
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Although there was no statistical difference between type of Afib and control preference
(p = .188, n = 164), 23.8% (n = 5) of individuals with permanent reported a passive role,
compared to 23.5% (n = 5) of participants reporting persistent and 14.7% (n = 16) reporting
paroxysmal Afib. Overall, 17.7% of respondents (n = 29) reported a passive role (Table 5.14).
Table 5.14
Type of Atrial Fibrillation and Control Preference

Type Afib

Total

Passive
Paroxysm n
16
al
% within Type Afib 14.7%
Persistent n
8
% within Type of
23.5%
Afib
Permanent n
5
% within Type of
23.8%
Afib
n
29
% within Type of
17.7%
Afib

Collaborati
ve/Shared Active Total
52
41
109
47.7% 37.6% 100.0%
9
17
34
26.5% 50.0% 100.0%
10
47.6%

6
21
28.6% 100.0%

71
43.3%

64
164
39.0% 100.0%

When examining the findings of this study (Afib: DMSP), it is important to consider that
SDM should take into consideration the patients’ perceptions, as discussed, those individuals
with permanent Afib reported greater scores on the SDM-Q-9 (M=73.09, n = 18; Table 5.13),
although reported a greater percent of passive compared to their counterparts.
Findings in this study Afib: DMSP demonstrate the type of Afib having a statistical
significance with decisional conflict (p = .028) and SDM (p = .049). No statistical significance
was found in decisional self-efficacy (p = .814) and control preference (p = .188). Although
individuals with permanent Afib reported a preferred collaborative/shared role, they also reported
a greater ‘passive’ role than other cohort, while reporting higher scores in DSES and SDM-Q-9.
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Individuals with paroxysmal Afib reported the greatest decisional conflict. This was explored
with narratives that indicated themes such as uncertainty, consideration of risk, individual
preference, and temporal nature of paroxysmal type of Afib. These findings suggest that selfefficacy may be an important component in decisional conflict.
CHA2DS2-Vasc Score and participation in SDM-Q-9
The CHA2DS2-VASc score is a screening tool for stroke risk in individuals with Afib.
This study examined categorical CHA2DS2-VASc scores as a categorical scale of scores of 1-2
and 3-7. The CHA2DS2-VASc scale reports from 0-9, but guidelines recommend prescribing an
oral anticoagulant to reduce thromboembolic stroke may be considered with a CHA2DS2-VASc
score of 1 in men and 2 in women (January et al., 2019). Therefore, the score of 0 was removed
and the highest score reported in this sample was 7. Two groups were compared in Group 1
scores of 1-2 (lower risk for stroke) and 3-7 (greater risk for stroke). Individuals with a
CHA2DS2-Vasc score of 3-7 (M = 64.23, SD = 21.138, n = 82) scored significantly higher in
SDM-Q-9 than individuals with scores between 1-2 (M = 56.75, SD = 26.390, n = 91, p = .043).
Multiple exposures to health care experiences allow individuals to increase mastery within the
context of health care visits, which may explain these findings.
Use of Educational Material, Pamphlets or DAs
This study demonstrated statistically significance in individuals who were given an
educational packet or DA and their reported participation in SDM (p < .001) and decisional
conflict (p < .01). The use of DAs has been the focus of SDM studies and has been extensively
investigated. Studies in DAs and decisional conflict have become of emerging interest since the
concept of SDM has become mandates in certain therapeutic options in Afib management.
Previous studies have been inconsistent in the use of all items of the 16-item DCS, where studies
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have used specific subscales of the DCS instrument (Fraenkel et al., 2012). One study using DA’s
demonstrated statistical significance in decreasing decisional conflict, however at a 3-month
follow–up, statistical significance was no longer evident (Thomson et al., 2007). Another study
used the 16-item DCS where outcomes demonstrated overall improvement in overall decisional
conflict using the 16 item DCS (p = .05). However, no statistical differences were seen in the
subscales of “feeling supported” and “ineffective decision making” and where the “usual care”
group reported less uncertainty (McAlister et al., 2005). To this researcher’s knowledge, the
SURE test has not been used in the Afib population. Due to the brevity of this study, the SURE
test was used instead of the 16-item DCS. Based on participants’ responses, this study supports
the use of educational material or DAs in Afib.
Time since decision and decisional conflict
Overall, decisional conflict was reported in 38.5% of individuals (n = 74) from this
sample (n = 192). Those currently contemplating a decision reported a 76.2% (n = 32) presence
of decisional conflict. Interestingly, 30.1% (n = 31) reported decisional conflict in those
individuals who decided three months ago, with lower reported rates at 1 month (28.6%, n = 6)
and two months after their decision (19.2%, n = 5). Although this study (Afib: DMSP) was not
longitudinal to evaluate changes over time in same cohort groups, a previous study in consistent
cohorts demonstrated similar findings. Chien and colleagues (2014) reported similar findings in a
longitudinal study in prostate cancer, where decisional conflict at baseline was reported at 46%,
22% at 1 month and then increasing to 28% at 6 months (Chien et al., 2014). Their finding is
consistent with this study as there was an increase in decisional conflict at three months.
Although this study represents different cohort groups (individuals currently considering a
decision and those at 1, 2- and 3-months post decision), decisional conflict continues post
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decision and may increase as time goes on. Another study with individuals with Afib
demonstrated significance in decreasing decisional conflict immediately following the use of a
computerized DA (p = .036) compared to usual care, but at a three-month follow-up, there was
no statistical difference (Thomson et al., 2007). This supports a potential temporal nature of
decisional conflict, where after time, individuals may reconsider their decision, or this increase in
decisional conflict may indicate decisional regret. These finding support the evidence for
screening for decisional conflict both pre- and post-decision.
Decisional Self-Efficacy and Participation in SDM-Q-9
Increased self-efficacy is described as an important facilitator in the SDM process. An
individual’s perceived self-efficacy refers to beliefs in one’s capabilities to organize and execute
the courses of action required to produce given attainment (Bandura, 1997, p. 3). In this sample,
a positive linear relationship was demonstrated in participants reporting greater scores in
decisional self-efficacy also reporting greater scores on the SDM-Q-9 (p = <.001), where
decisional self -efficacy explained 28.8% of the variance in respondents’ scores on the SDM-Q9. These findings were expected based on the ODSF and Bandura’s self-efficacy theory where
efficacious people take opportunity and have the ability to exercise influence over what they do
and have the power to make things happen (Bandura, 1997, p. 3). These findings are consistent
with finding from Miller and colleagues (2013) who suggest that enhancing self-efficacy and
educating individuals related to participation in clinical trials is a key factor in decisions to
participate (Miller et al., 2013). According to Bandura, sources of self-efficacy include mastery
experiences, vicarious experiences, verbal persuasion, and physiological and affective states that
are intrinsically judged (Bandura, 1997, pp. 80-106). Therefore, according to self-efficacy theory,
providing individuals with exposure to SDM methodologies may provide opportunities to
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increase self-efficacy in decision making by mastery or vicarious experiences by observing
health care providers participating, accepting, and engaging patients in SDM as routine practice.
Decisional Conflict and Participation in SDM-Q-9
This study demonstrated a statistically significant relationship between decisional conflict
(absence/presence) and participation in SDM (p < .001), where individuals reporting presence of
decisional conflict reported lower scores in participation in SDM (M = 51.52, n = 76) than
individuals reporting no conflict (M = 66.46, n = 105) (Figure 5.1). Therapeutic management for
Afib includes mitigating risk for stroke. Greater patient involvement in treatment decisions is
associated with less decisional conflict, which can be viewed as a moderator for patient
satisfaction (Doherr et al., 2017).
Figure 5.1
Boxplot-Shared Decision Making Scores and Decisional Conflict (Absence/Presence)

The ODSF incorporates decisional conflict under their decisional needs’ assessment,
which describes a personal uncertainty about the best course of action (O'Connor et al., 2015).
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Providing individuals with an individualized needs assessment, unresolved decisional issues can
be addressed, such as “uncertainty” surrounding a decision. The use of DAs has been used to
facilitate discussion with health care providers and identify unmet needs. Therefore, for further
analysis to review if the use of DA was influencing this finding, a comparison of the scores in
participation in SDM were examined in relation to decisional conflict and the use of educational
packet or DAs. In this sample, scores in participants who reported decisional conflict and did not
receive an education packet were lower on the SDM-Q-9 than other cohorts (M = 46; Table
5.15). Therefore, individuals who reported decisional conflict and did not receive a DA reported
less participating in SDM.
Table 5.15
Comparison of Mean SDMQ9 scores and Decisional Conflict Status and reported receiving an
education packet or decisional aid by healthcare provider
95% Confidence
Interval for Mean
SDMDA/ED
Q-9
Lower
Upper
Decisional-Conflict
N
Mean
SD
SE
Bound
Bound
Yes
Absence
60
73.52
19.751
2.550
68.42
78.62
Present
26
62.14
20.049
3.932
54.04
70.23
Total
86
70.08
20.412
2.201
65.70
74.45
No
Absence
45
57.04
23.230
3.463
50.06
64.02
Present
50
46.00
23.821
3.369
39.23
52.77
Total
95
51.23
24.064
2.469
46.33
56.13
DA/ED= received a decisional aid or Education Packet from Healthcare provider

This study (Afib: DMSP) demonstrated individuals who are contemplating a decision
reported decisional conflict 76.2% (n = 32) of the time (Table 5.16). This is an important finding
as decisional resources may focus on the pre-decision phase. This study supported the use of
educational packet and/or DAs in reducing decisional conflict in the Afib population. However
decisional conflict should be continued to be re-assessed after a decision has been made.
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Table 5.16
Decisional Conflict and Time Since Decision

Decisional
Conflict
(SURE test)
Total

Absence
Present

Time Since Decision
Currently
2
3
Deciding 1 month months months Total
n
10
15
21
72
118
% within Time
23.8% 71.4% 80.8% 69.9% 61.5%
n
32
6
5
31
74
% within Time
76.2% 28.6% 19.2% 30.1% 38.5%
n
42
21
26
103
192
% within Time 100.0% 100.0% 100.0% 100.0% 100.0%

Control Preference and SDM
To this researcher’s knowledge comparisons of control preference with the shared SDMQ-9 have not been performed. The findings in this study demonstrate no statistical significance
between control preference (Active, Collaborative/Shared, and Passive) with participation in
SDM (p = .099, n = 180). Surprisingly, those who reported “passive” (17.78%) control in the
decision reported the greatest participation in SDM (M = 67.85, n = 32; Table 5.17). However,
inconsistent with this study (Afib: DMSP), a previous study of veterans with heart failure
demonstrated less perceived involvement in decision making was associated with a preference
for a more passive decision-making role (p < .01; Rodriguez et al., 2008).
Examining preferred roles from prior research in an Afib is inconsistent with this study
findings, with an overall preferred method of participation as passive (51.67%; McAlister et al.,
2005). In this study (Afib: DMSP), passive was the least preferred (17.8%; Table 5.17). These
differences in the sample’s preferred role may be reflective of social norm changes over a 15year span as McAlister and colleagues’ study was published in 2005. This is an interesting
finding for clinicians to consider as individuals may prefer passive involvement, yet still may
feel that they participated in a SDM. Considering an individual’s preference for role in medical
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decision making may provide for more patient-centered care. Prior research recommends that the
level of involvement in decision making should be consistent with an individual’s preferences
(Street et al., 2012). Additionally, SWD does not assume high patient involvement in decision
making, as some prefer a surrogate or alternative decision maker (Holmes-Rovner et al., 1996).
Table 5.17
Participants Control Preference and Shared Decision-Making Scores

Control
Preference
Passive (17.8%)
Collaborative/Shared
(45.7%)
Active (36.6%)
Total

N
32
82

M
67.85
60.14

SD
26.631
22.374

66
180

56.60
60.21

24.994
24.319

95% Confidence Interval
for Mean
Lower
Upper
SE
Bound
Bound
4.708
58.25
77.45
2.471
55.22
65.05
3.077
1.813

50.46
56.63

62.74
63.79

Interestingly, for individuals reporting passivity, they also reported the highest mean
score in participation in SDM-Q-9 (M = 67.85) than their cohort groups. In one previous study,
preferred role was not associated with a patient’s perceived quality of care. However, reports of
treatment decisions that were physician controlled (vs. shared) were associated with lower odds
of excellent patient-reported quality (p < .001). The CPS does not enable an understanding of
what it is about the decision-making process that patients perceived a “shared-decision process”.
One explanation may be differences in conceptual definitions of shared decisions (Shay &
Lafata, 2015). According to the ODSF, clinicians are recommended to ask patients what role they
would like to play in the decision (O'Connor & Jacobsen, 2001).
Frailty and SDM-Q-9
Physical impairment has been identified as a barrier to participation in SDM (JosephWilliams, Elwyn & Edwards, 2014). Previous studies indicate that preference for active
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participation in health care decisions declines with an increasing number of comorbidities among
older adults (Chi et al., 2017). A critical barrier is that physicians’ impression of “elderly” may
infer the elderly may defer decision making to their providers (Bynum et al., 2013). Additionally,
in frail patients, there has been an underreported use of oral anticoagulation (Baczek et al., 2012;
Bahri et al., 2015), which questions the notion that practitioners may not be prescribing based on
their own perceptions of risk for bleeding and perhaps not engaging patients in SDM
methodologies.
Recognizing frailty may enable improved identification of vulnerabilities in individuals
with specific needs who might benefit from SDM (Pilotto et al., 2014). Individuals presenting
with clinical complexity is closely linked to uncertain, which can present difficulties in decision
making (Amblàs-Novellas et al., 2015). Therefore, this study investigated the relationship
between frailty status as reported by the FRAIL scale and participation in SDM-Q-9. This study
demonstrated no significant differences in frailty status and participation in SDM (p = .890).
However, frail individuals reported greater participation in SDM (Table 5.18). This finding is
consistent with the ODSF when considering that frail individuals would have more exposure to
healthcare environment and decision making, potentially increasing their self-efficacy. However,
inconsistent with the Afib:DMSP survey, Chi and colleagues (2017) reported that individuals
with multimorbidity reported less active participation (81.1%) than individuals without
multimorbid conditions (91.1%) using categorical active and passive role preference.
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Table 5.18
FRAIL Categories and Mean Scores on SDMQ9

N
Robust
Pre-Frail
Frail
Total

72
82
22
176

M
59.66
60.08
62.53
60.21

SD
24.553
24.663
24.298
24.449

SE
2.894
2.724
5.180
1.843

95% Confidence Interval for
Mean
Lower Bound Upper Bound
53.89
65.43
54.66
65.50
51.75
73.30
56.58
63.85

Health care providers may have preconceived notions of frailty influences to participate
in SDM and this may be a self-fulfilling prophecy. These findings suggest that the frail status of
an individual should not bias clinicians into assuming that frail or pre-frail individuals prefer not
to participate in SDM regarding stroke prevention.
SDM-Q-9 and SWD
An important feature of a decision is an individual’s satisfaction with the decision. SWD
have previously been studied regarding decisional regret (Khoder et al., 2017). To this
researcher’s knowledge, there is only one study correlating the two scales of SDM-Q-9 and the
SWD. This study was performed in a healthy sample of individuals who had a health care visit
within three months where a linear regression revealed that the total SDM-Q-9 score was a
predictor of SWD (p < .001; Glass et al., 2012).
This study (Afib: DMSP) explored the relationship between perceptions of participation
in SDM and SWD. The SWD was investigated both as a continuous scale (scores of 6-30) and
categorical (scores </= 23 and 24 or greater) scale. Results were statistically significant for
participation in SDM with both continuous (p < .001) and categorical (p < .001) SWD reporting.
Decisional quality is defined as reaching a decision that is based on the best available evidence
and patients’ informed values for outcomes of options (Carroll et al., 2013). This has
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implications where increasing participation in SDM (as defined by the patient) can have the
potential to increase SWD.
To investigate this further, the present study examined individuals who as a result of their
decision required a hospital visit or visit to a health care provider as it would be expected that
individuals who experienced a consequence would report lower SWD scores when asked, “After
making this decision on stroke prevention, did you have an event requiring a visit to a health care
provider, emergency room or hospital related to your decision?” There was no statistical
difference in individuals responding “yes” or “no” (p = .316). However, those who responded
“No” as not having a consequence had higher SWD scores (M = 65.40, n = 105) than those
responding “Yes” to having a consequence (M = 60.48, n = 28). Therefore, although it is not
statistically significant, events or consequences after the decision may impact SWD.
Predictive Models
The unique feature of this study (Afib: DMSP) was obtaining multiple characteristics to
provide a comprehensive framework in this sample where individualized needs assessments may
be demonstrated. The findings from the data allowed predictive models to be explored. Much of
the literature in SDM is concentrated in the concept of decisional conflict, which may be limited
when considering the complexity of decision making. Two predictive models were investigated:
predictors of SDM and predictors of decisional conflict. These predictive models may provide a
framework for screening individuals for decisional needs prior to decisions and/or healthcare
consultations.
Predictor of SDM in Stroke Prevention for Afib
Findings from this study allowed the researcher to explore predictive models for
participation in SDM for stroke prevention in Afib. Statistically significant results in relation to
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SDM-Q-9 were imputed (type of Afib [permanent], CHA2DS2-Vasc categorical [3-9], gender
[male], age [=/> 75], decisional conflict [none reported] and receiving an educational
pamphlet/DA by a health care provider), which demonstrated statistical significance (p < .001).
Two variables made a unique statistically significant contribution to the model: greater decisional
self-efficacy scores and participants provided with educational materials/DA from a health care
provider.
Predictors of Decisional Conflict in Afib Sample regarding stroke prevention
Findings from this study allowed the researcher to explore predictive models for
decisional conflict in this sample. The model contained four independent variables (Gender
[female], Non-Partnered, Paroxysmal Afib, and not receiving an Educational Packet/DA). The
model was statistically significant (p = .003), indicating that the model can distinguish between
respondents who did not report and those who reported decisional conflict as quantified by the
SURE test.
Conclusion and Synthesis of Findings
Statistical analysis including Chi-Square, ANOVA, and Pearson product-moment
coefficient correlation was performed to determine relationships between individual
characteristics and concepts in SDM for thromboembolic stroke prevention in Afib. Logistic
regression was used to determine predictors for participation in SDM and decisional conflict. In
total, 201 participants were available for analysis. Participants were predominantly White
(97.5%), female (53.7%), between 65-74 years old (47.8%), married or partnered (75.6%),
college educated (72.2%), with most reporting paroxysmal Afib (56.9%). Reliability testing
demonstrated instruments valid for use in this sample with reporting Cronbach’s alpha: DSES
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= .952, 9-item SDM-Q = .930, and SWD = .915 and Spearman-Brown half-split reliability for
SURE test = .808, Control Preference = .669, and FRAIL Scale (3 item) = .743.
Statistical significant results regarding participation for stroke prevention in this sample
of individuals with Afib demonstrated greater participation in SDM reported in participation for
individuals 75 years or older (p = .023), men (p = .002), reporting permanent Afib (p = .049),
higher CHA2DS2-VASc score (p = .043), individuals receiving an educational packet or DA
from healthcare provider (p < .01), higher decisional self-efficacy scores (p < .01), and
individuals reporting less decisional conflict (p < .01). Men reported higher decisional selfefficacy scores (p = .011) while women (p = .041), non-partnered participants (p = .014) and
participants reporting paroxysmal Afib (p = .028) were associated with greater decisional
conflict. Overall, 76.2% (n = 32) of individual considering treatment decision compared to those
who made a decision within 1 month (28.6%, n = 6), 2 months (19.2%, n = 5), and 3 months ago
(30.1%, n = 31) reported decisional conflict (p < .01). Non-college participants reported a
greater passive role than college graduates (30% versus 14.1%; p = .024). Although partnered
individuals reported preferred a collaborative/shared role, they also reported a greater passive
role (20.3%, n = 29) than non-partnered individuals (12.8%, n = 6, p = .024). In this sample,
frailty status (p = .099) and control preference were not reported as statistically significant (p
= .890) regarding participation in SDM. Participation in SDM was strongly correlated with SWD
(p < .01). From these findings, prediction models identified that greater decisional self-efficacy
scores (p < .01) and receiving a DA or education packet from a healthcare provider (p = .029)
were the most predictive variables for participating in SDM for stroke prevention (p < .01).
However, non-partnered individuals (p = .019) and those participants not receiving a DA or an
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education packet from a healthcare provider (p = .022) were the most predictive of decisional
conflict (p < .01).
Strengths and Limitations
Striving for decisional quality should be imperative for clinicians as the result of a
process that includes both supporting clinical evidence and incorporating an individual’s
preferences (Wittmann-Price & Fisher, 2009). One of the major strengths of this study is
providing the first comprehensive assessment of individual characteristic within the ODSF
“needs assessment” to explore relationships with participation in SDM for thromboembolic
stroke prevention in individuals with Afib. Clinician awareness of characteristics that promote or
impede participation in SDM is imperative in individuals with Afib. Currently, many studies
focus on the use of DAs, but understanding an individual’s characteristics is important to tailor
decisional support. Findings such as the impact of age, gender, clinical factors, educational
packet/DA, decisional self-efficacy, and decisional conflict on participation in SDM emphasizes
the need to individualize SDM methods consistent with the “need.” Findings from this study can
alert clinicians to the overwhelming prevalence reporting of 76.2% of individuals responding as
having decisional conflict prior to a decision. Although decisional conflict decreased over time,
there was an increase at three months, perhaps suggesting decisional regret or continuing to
question their treatment choice. This study provides evidence for continued screening for
decisional conflict after a decision is made.
Although the literature suggests that patients should participate in SDM, this study
demonstrated greater mean scores of SDM in men who prefer to take a passive role. Studies have
previously used the CPS in measuring SDM. This study suggests that control preference and
SDM are two separate constructs, where role should be defined by the patient. These findings
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suggest that clinicians should provide concordant shared-decision methods of engagement to
promote individual preferences.
This study is unique as it asked about consequences to the decision, if a decision had
been made. There were no statistical differences in SWD in patients who had suffered a
consequence of their decision (e.g., event requiring a visit to a healthcare provider, emergency
room, or hospital). Although the Afib: DMSP survey did not ask about the type of consequences,
this is important as it raises the questions of clinicians (more than the individual patient) placing
a greater value on risks associated with the therapeutic management for stroke prevention.
Although this was not a qualitative study, the narrative statements provided by participants
assisted in the analysis and supported self-efficacy theory within the decisional needs’
framework of ODSF.
Potential limitations to the Afib: DMSP study include demographics, small sample size
for larger group comparisons, convenience sample, self-reporting questionnaires, online format,
and survey length. The convenience sample consisted of participants from both an online
advocacy group (StopAfib.org) and individuals from a large hospital network in the New York
Metro Area. They were overwhelmingly White, therefore racial comparisons could not be made,
college-educated individuals with the largest cohort age between 64 and 75 years old. Since the
sample lacks diversity, generalizability to a larger population is limited.
For eligibility to participate, individuals were required to be English literate, have access
to a computer, and have computer literacy skills. Although recognizing “vested interest” could be
both a strength and limitation, participants had a vested interest in this study as they were aware
that the results of this study were to assist clinicians in better understanding decisional needs,
which could bias participants by responding in a socially desirable manner. Social desirability is
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a bias in self-report instruments created because participants tend to misrepresent their opinions
in the direction of answers consistent with prevailing social norms (Polit & Beck, 2008).
Multiple comparisons within the study were evaluated. A sample size of 201 with
pairwise deletion limited the number of available comparisons. A priori power analysis revealed
a sample size of 145-196 (depending on the group size and statistical test). Comparison group
sizes were limited in some analysis, although collapsing groups increased the number of patients
for each factor. Therefore, it is acknowledged there might be a type II error.
Most perceived involvement instruments show strong ceiling effects, and there is a high
risk of bias in rating as some as these tools can be based more on self-concept than on what has
really taken place (Scholl et al., 2011). In this study (Afib: DMSP), ceiling effect may be seen
with mean scores on the Decisional Self-Efficacy Scale (M = 83.77, scores range 0-100) and the
SWD Instrument (M = 25.92, scores range 0-30). The SDM-Q-9 (M = 60.18, scores range 0100) had a mode reporting of 80.
This study examined associations between some but not all decisional needs identified in
the ODSF (e.g., values, knowledge, expectation, emotions, cognition, and health literacy). Also,
the study did not include the measurement of the complex relationship between any of these
variables and actual behavior. This may limit our understanding of this population of patients
within the SDM context. This study was not attempting to establish causality, but rather, it was
designed to provide an initial description of the associations among the decisional need variables
and to explore how such variables affect participation in SDM.
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Implications for Nursing
Practice
Nursing practice incorporates both the physical and psychosocial domains of assessment.
Nursing has been at the forefront of assessing individuals for specific needs. An awareness of a
patient’s decisional needs is important for nursing practice. The intent of this study was to
provide a framework for needs assessment for individuals with Afib who are contemplating a
decision. The primary goal for patients is to make decisions that are consistent with their values,
preferences, and ultimate health goals. A primary role in nursing is supporting patients through
decision making. One of the primary roles a nurse can assume is one of decisional coaching
described by the ODSF. Decisional coaching providing decisional support, which aims to
develop the patient’s skills in thinking about the options, prepare for discussing the decision in a
consultation, and implement the choice. Decisional coaching strategies include clarifying
decision and monitoring needs, facilitating access to evidence-based information, verifying
understanding, clarifying personal values, enhancing skills in deliberation and communication,
and monitoring decisional quality (O'Connor et al., 2015). One of the key concepts within this
study was enhancing decisional self-efficacy, which is embedded in the decisional coach role.
According to self-efficacy theory, providing individuals with opportunities to participate in
SDM, vicarious exposure, modeling behavior, and social persuasion will increase self-efficacy in
decision making. The key to promoting self-efficacy is to help patients learn new behaviors
(Zulkosky, 2009). Nurses have a role in educating individuals on their new conceived role as
“expert.” At the individual level, the accumulated effects of repeated exposure to collaboration
and deliberation through an SDM methodology would modify relationships with the health care
delivery system and lead to new social norms (Elwyn et al., 2016).
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Decisional support involves preparing the patient and practitioners for decision making.
The main objective is to improve the quality of the decision-making process by modifying
determinants of decisions that are sub-optimal with high uncertainty, inadequate knowledge of
options, unrealistic expectations of benefits and risks, unclear values for benefits and risks of
options, unwanted pressure, and inadequate support (Cranney et al., 2002).
In this sample, vulnerable characteristics that may impede SDM include younger age,
female gender, paroxysmal Afib, low CHA2DS-Vasc score, presence of decisional conflict, and
inadequate decisional self-efficacy. Although the findings are not generalizable, one can consider
these characteristics and create screening tools for their specific populations. One important
feature of this study was decisional conflict and the importance for clinicians to screen for preand post-decision. Given their emphasis on holistic care, patient autonomy, and empowerment,
nurses are well positioned to provide patients with the support needed to make informed
decisions consistent with their individual values and preferences (Pierce & Hicks, 2001).
Education
Some decisions in therapeutic treatment for Afib mandates SDM methodologies for
reimbursement. As an ethical imperative and now a mandate, clinicians are incentivized to
participate in SDM. Education is imperative to inform and facilitate SDM in both patients and
clinicians. With the focus on value-based outcomes and patient experiences, there is opportunity
for nursing faculty and staff development to incorporate a curriculum in SDM training.
Curriculum should include increasing self-efficacy in both patients and clinicians as well as
raising awareness to clinicians by referring to online training opportunities provided by the
Ottawa Hospital Research Institute to facilitate SDM behavior. Education is expected to be
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provided to the patients to assume an unfamiliar role or raise awareness that they have a voice in
verbalizing their preferred role.
Nurses have the opportunity to educate clinicians in decisional conflict. The ODSF
considers decisional conflict to be important for needs assessment evaluation. Clinicians should
be aware of the signs and symptoms, such as vacillating over or postponing decisions. This study
demonstrated the importance of being aware of this concept, as it relates to participation in SDM.
Research
Nurses have been at the forefront of decisional research (e.g., Annette O’Connor, PhD;
Dawn Stacey, PhD; Lesley Degner, PhD) and have developed some of the instruments used in
this study. The Ottawa Decision Support Framework emphasized decision preparation using a
framework that separates the effects of each decision support method (Carroll et al., 2013). The
framework has three major elements: decisional needs, decision support, and decision quality.
The focus of this study was on decision needs in an Afib sample. Finding from this study can
assist in the refinement of SDM constructs within the Afib population and raise awareness in
clinicians on biases and preconceived notions regarding engagement. This study recommends
replicating the study in a larger and less homogenous sample because the reproduction of this
study in settings with greater variation in an Afib population is warranted.
Decisional quality is embedded within the Ottawa Framework. To this researcher’s
knowledge, specific outcomes such as the SWD process, clinical and patient-focused outcomes
in the Afib population have not been studies in regard to the implementation of SDM
methodologies in clinical practice. Recommendations in the literature suggest that research
should identify how to encourage clinicians to achieve meaningful SDM rather than merely
checking a box (Elwyn et al., 2017).

238
The focus of decisional research in Afib has focused on decisional conflict. In this study,
there was a strong relationship between presence of decisional conflict and lower scores in
participation in SDM (p < .01, eta .09). Future research should focus on self-efficacy science and
decisional conflict education curriculum for clinicians to develop skills and examine outcomes.
Important concepts that were not examined in this study and are important in considering
decisional needs include cognitive function and health literacy effects in participating in SDM,
where such findings can enhance a needs assessment framework.
Conclusion
Decisional needs include the assessment of decisional conflict, personal and clinical
characteristics, values assessment, expectations and preference clarifications, support, and
resources. Unmet decisional needs can affect decisional quality, which can affect behavior, which
can in turn lead to negative outcomes (Pluye et al., 2017). Investigation into how individual
characteristics influence perceived participation in SDM is essential to understanding preferences
and abilities, including the role an individual wants to play in decision making (Elwyn et al.,
2017). The implementation and evaluation of SDM in Afib is both ethically sound and a concept
endorsed and recommended by professional organizations. This study (Afib: DMSP) investigated
constructs within the decisional need’s assessment within the ODSF. Major constructs within the
framework are decisional self-efficacy and decisional conflict. In this study, both these constructs
had statistically significant effects on SDM. Most findings could be explained based on selfefficacy theory and decisional conflict theory. Therefore, the ODSF was appropriate for this
study. The findings in this study are intended to educate clinicians on the importance of
decisional needs assessment. For example, including demographics, decisional self-efficacy,
decisional conflict, clinical status, and control preferences can influence perceptions of
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participation in SDM. Findings from this study have the potential to assist clinicians in providing
enhanced patient-centered care.
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APPENDIX F
Letter of Permission for Use of Instruments
•

Decisional Self Efficacy Scale- Although no permission is required, Dr. Annette
O’Connor was informed of the use in an Afib Sample.

Permission to change item #1 and Item #10: March 29, 2019 from Annette O’Connor
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•

SURE-Decisional Conflict – Dr. France Légaré approved on December 1, 2018
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•

Control Preference Scale/Methodology
Scale- Approved on Sept 25, 2018, by Dr. Tom Hack, College of Nursing Rady
Faculty of Health Sciences, University of Manitoba
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Control Preference updated Image approval on Research Gate on December 26,
2018, by Alessandra Solari (primary Author- “Role preferences of people with
multiple sclerosis: Image-Revised, Computerized Self-Administered Version of
the Control Preference Scale)

Control Preference- Methodological Approach for administration- inquiry to
researchers.

285
1) Dr. David Matlock- University of Colorado- Daniel.Matlock@ucdenver.edu
March 14, 2019
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2) Dr. Nancy Keating- Harvard University- keating@hcp.med.harvard.edu on
January 22 and 23 2019
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•

FRAIL Scale- permission granted from Dr. John Morley on December 26, 2018
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•

Shared Decision Making- SDM-Q-9 (page 1 of 3) original request for permission
to Dr. Levente Kriston, permission granted by Stephen Zen on October 25, 2018
with cc: to Dr. Isabelle Scholl- University Medical Center Hamberg-Eppendorg
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SDM-Q-9- (page 2of 3)- permission for use

290
SDM-Q-9 (page 3 of 3)- permission for use
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•

Satisfaction with Decision – permission granted from developer, Dr. Margaret
Holmes Rovner on Dec. 26, 2018
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APPENDIX G
Socio-Demographic Sheet (Developed For This Survey)
1) Have you been told by your doctor that your atrial fibrillation is related to a “valve”
disorder?
2) What type of atrial fibrillation have you been diagnosed with?
3) How long have you had atrial fibrillation?
4) How long ago did you make your decision for stroke prevention related to atrial
fibrillation?
5) What treatment options are you currently considering or have made within the last 3
months regarding stroke prevention in atrial fibrillation? Choose all that apply.
6) How many prescription pills do you take a day?
7) Birth Sex
8) Ethnicity
9) Race
10) What is your age?
11) What is your education level?
12) Relationship status
13) Did another individual other than your physician support you during your decision? If
so, please identify other individual(s). Choose all that apply.
14) Did your health care provider share with you materials such as a decisional aid packet
or brochures to assist you in your decision making for stroke prevention?
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APPENDIX H- DECISIONAL SELF EFFICACY SCALE
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APPENDIX I
Sure Test-Decisional Conflict Scale
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APPENDIX J
Control Preference Statement and Images
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APPENDIX K
Frail Scale
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APPENDIX L
9 Item Shared Decision-Making Questionnaire (SDM-Q-9)

298
APPENDIX M
Satisfaction with Decision Instrument
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APPENDIX N
SurveyMonkey Privacy Policy
•

SurveyMonkey March 23, 2019
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APPENDIX O
Results of the Afib: DMSP
Instrument Reliability in the Afib Sample
Outcomes

Statistical
Findings

Sample

Test

DSES

.952

201

Cronbach’s Alpha

SDM-Q-9

.930

181

Cronbach’s Alpha

SWD Scale

.915

133

Cronbach’s Alpha

SURE test

.808

201

Spearman-Brown Split Half
Reliability

CPS

.661

192

.669

192

Cronbach’s Alpha/Kuder
Richardson 20
Spearman Brown

.743

185

FRAIL

Spearman-Brown Split Half
Reliability

Age and Outcomes
Findings

Sample

Test

Findings

Age
DSE

.446

201

ANOVA

Older adults had ^
DSES>75 M = 85.98

SURE test

.211

201

Chisquare

39.3% in sample
reported DC.
(=/>75 28.3%, 65-74
41.8%, <65 43.9%)

CPS

.088

192

Chisquare

Older individuals =/> 75
reported a passive role
(27.3%), <65 = 21.2%,
65-74 = 12.5%

301

SDM

Findings

Sample

Test

Findings

.023
Effect .042

178

ANOVA

>/= 75 had higher scores
on SDM, M = 68.67, 6474 = M 59.23, <65, M =
54.98

Note. DSE = decisional self-efficacy; SURE test evaluates decisional conflict; CPS = Control
Preference Scale; SDM = Shared Decision-Making
Gender and Outcomes

Gender
DSE

SURE test

Statistical

Sample

Test

Findings

.011
Effect .032

201

ANOVA

Men had higher scores
on DSES (women scored
lower on social context
scores M= 87.39,
women M=80.666

.041
Phi .154

201

Chisquare

Women reported greater
decisional conflict than
men (15.1% difference)
Women M= 46.3%, Men
M= 31.2%

192

Chisquare

Men preferred a more
passive role than women
(24.1% vs 13.3%) (both
preferred a
collaborative/shared role

ANOVA

Men have higher scores
on SDM-Q-9 M = 66.27,
women M= 55.03

CPS
.155

SDM

.002
Effect .054

181
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Educational Attainment and Outcomes
Outcome Variable

Statistical
Findings

Sample

Test

DSES

.632

201

ANOVA College graduates had higher scores M
= 84.17, non-college M = 82.75

SURE
test

.083

195

Chisquare

College graduates had greater
decisional conflict (42.6% versus
27.8%)

CPS

.024
192
Cramer’s
V .197

Chisquare

Non-college graduates reported more
passive role (30% versus 14.1%).
College grads prefer a Collab/Shared
role 48%, Non-college grads preferred
an Active role 38%)

SDM

.470

ANOVA Non-college graduates had higher
scores on the SDM-Q-9 (M = 62.36
versus M = 59.40)

181

Findings

Partnership Status and Outcomes
Outcome Variable

Statistical Sample
Findings

Test

DSE

.275

199

ANOVA Non-partnered had lower M scores
(81.33 versus 84.72)

SURE
test

.014
Phi .186

199

Chisquare

Non-Partnered individuals reported
more decisional conflict (55.1% versus
34.0%). Overall decisional conflict
39.2%

190

Chisquare

Partnered individuals preferred a more
passive role (20.3% versus 12.8%).

CPS
.514

Findings
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Outcome Variable

Statistical Sample
Findings

Test

Findings
Both cohorts prefer collab/shared role
(Partnered=42.7%, vs. Non-partnered
46.8%)

SDM

.100

180

ANOVA Non partnered individuals have lower
scores on the SDMQ (55.04 versus
62.01)

Outcome Variable

Statistical
Findings

Sample

Test

DSES

.814

178

ANOVA Permanent Afib had higher Mean
DSES scores (86.05, persistent 84.87,
paroxysmal 83.47)

SURE
test

.028
171
Cramer’s
V .205

Chisquare

Paroxysmal reported greater decisional
conflict (47.3%, persistent 38.9%,
permanent 17.4%)

CPS

.188

164

Chisquare

Permanent Afib reported more passive
role (23.8%, persistent 23.5%,
paroxysmal 14.7%). Small sample size
in Permanent n = 4

SDM

.049
Eta .039

156

ANOVA Permanent Afib reported greater Mean
SDM-Q-9 scores (73.09, persistent
58.52, paroxysmal 58.22)

Type of Afib
Findings
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CHA2DS2-VASc scores and Participation in Shared Decision Making
Relationship

Statistical Sample Test
Findings

Continuous
CHA2DS2-VASC
(1-7) and SDMQ-9

.027
26.8%
variance

181

Pearson’s Greater CHA2DS2-VASc
Product
scores were associated with
higher scores on SDM-Q-9

.043
Eta .024

173

ANOVA

Categorical
CHA2DS2-VASc
(1-2, 3-7) and
SDM-Q-9

Findings

CHA2DS2-VASc score of 3-7
had higher Mean scores on the
SDM-Q-9 than scores of 1-2
(64.23, 56.75)

Received an Educational Packet or Decisional Aid from Health care Provider
Outcome
Variable
SDMQ-9

Statistical Sample Test
Findings
Findings
<.01
181
ANOVA Received an Educational Packet/Decisional
Effect .15
Aid reported higher Mean scores on the
SDM-Q-9 (70.08, 51.23)

SURE
test

<.01
Phi .235

201

Chisquare

Received an Educational Packet/Decisional
Aid reported less decisional conflict (27.6%
versus 50.5%)

Time Since Decision
Outcome Variable
SURE
test

Statistical Sample
Findings

Test

Findings

<.01

Chi
Square

Participants currently considering a
decision reported 76.2% decisional

192
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Outcome Variable

Statistical Sample
Findings
Cramer
V .416

Test

Findings
conflict (1 month-28.6%, 2 month17.8%, 3 month- 30.1%)

Event occurring (Yes/No) and Satisfaction with Decision (Consequence of a decision)
Outcome Variable
SWD

Statistical Sample
Findings

Test

Findings

.091

ANOVA

Individuals reporting no event had
higher scores on the SWD (M = 26.20)
while those responding ye to having an
event occur after decision (M = 24.20)

133

Variables and Participation in Shared Decision Making
Variable

Statistical Sample
Findings

Test

DSE

<.01
28.7%
variance

Pearson’s
Strong positive relationship (.536)
Correlation DSE scores explaining 28.7% of
variance

SURE
test

<.01
181
Effect .09

ANOVA

Participants reporting decisional
conflict reported lower Mean scores
on the SDM-Q-9 (51.52 versus 66.46)

CPS

.099

ANOVA

Participants reporting a passive role
reported greater Mean scores on

177

180

Findings
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Variable

Statistical Sample
Findings

Test

Findings
SDM-Q-9 (67.85,
Collaborative/Shared 60.14, Active
56.60)

FRAIL

.890

176

ANOVA

Participants reporting Frail Status
reported greater Mean scores on the
SDM-Q-9 (62.53, Pre-Frail 60.08,
Robust 59.66)
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Correlation and Prediction Models
Outcomes
SDM-Q-9 scores and
Self-Report SharedDecision Making

Statistical Sample Test
Findings

Findings

Pearson’s
Mean scores on SDM-Q-9 =
Correlation 60.18 (n = 181), Means Scores on
Self-Report (0-100) M = 76.77 (n
= 185)

<.001
30.9%

177

<.01

129

Shared DecisionMaking

<.01

181

Logistic
Regression

Model: type of Afib [permanent],
CHA2DS2-Vasc categorical [3-9],
gender [male], age [=/>75],
decisional conflict [none reported]
and receiving an educational
pamphlet/decisional aid by health
care provider). Greater Self
Efficacy Scores and Receiving an
Education Packet/Decisional Aid
most predictive.

Decisional
Conflict

.003

155

Logistic
Regression

Model: (Female, Non-Partnered,
Paroxysmal Afib, and not
receiving an Educational
Packet/Decisional Aid. Nonpartnered (.022) and not receiving
an educational packet/decisional
aid (.019)

Participation in SDM
and Satisfaction with
Decision

Pearson’s
Strong positive relationship (.431)
Correlation SDM-Q-9 scores and SWD scores
explaining 18.5%

Predication Model
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